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Scaffold-based regenerative heart valve therapy represents a promising and innovative approach 
to address the unmet clinical need in treating valvular heart diseases. However, current tissue-
engineered heart valve scaffolds often suffer from issues such as architectural and mechanical 
mismatch to native valve leaflet, thrombogenicity, and calcification tendency. Our overall goal is 
to provide effective strategies to improve the design of regenerative heart valve therapies by 
alleviating these common issues. This dissertation summarizes our efforts to develop micro-
/nanotechnology-based strategies in mimicking the fibrous architecture and mechanical 
properties of the native valves while improving the biocompatibility of tissue-engineered 
scaffolds.  
We first synthesized a novel series of polyethylene glycol (PEG) functionalized 
biodegradable elastomers. With different molar ratios and molecular weights of PEG in the 
polymer backbone, these biodegradable and biocompatible elastomers possessed widely tunable 
mechanical properties and desirable degradation mechanism.  
We then fabricated PEGylated biodegradable elastomers into fibrous scaffolds by 
electrospinning. The introduction of PEG into the polymer backbone led to reduced 
thrombogenicity of the fibrous scaffolds. Moreover, the uniaxial and cyclic mechanical 
properties of fibrous scaffolds could be tuned to mimic those of the native valve leaflets.  
The electrospinning process was further modified to fabricate anisotropic fibrous 
scaffolds. By modulating polymer formulation, fibrous scaffolds were produced to possess 
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anisotropic biaxial mechanical properties. The anisotropic nature of scaffold also guided the 
alignment of human valvular interstitial cells (hVICs) seeded on the scaffolds.  
To address the calcification tendency of heart valve substitutes, we developed shape-
specific cerium oxide nanoparticles (CNPs), which have unique properties to mitigate oxidative 
stress. We demonstrated that the oxidative stress exacerbated the calcification in hVICs. We then 
demonstrated the effectiveness of CNPs in alleviating oxidative stress and preventing 
calcification in hVICs. 
Finally, we combined antioxidant CNPs with anisotropic fibrous scaffolds to obtain 
nanocomposite scaffolds. These scaffolds possessed antioxidant properties and supported hVIC 
attachment and proliferation. In an oxidative stress-induced calcification model, hVICs cultured 
on CNP encapsulated scaffolds displayed reduced calcification tendency.  
Collectively, using micro-/nanotechnology-based strategies, we developed novel tissue-
engineered heart valve scaffolds with anisotropic mechanical properties and the potential to 
mitigate the thrombogenicity and calcification frequently observed in current valve replacement 
therapies. 
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1.0  INTRODUCTION 
[Xue Y, Sant V, Phillippi JA, and Sant S. (2017) Acta Biomaterialia 48. 2–19.] 
1.1 VALVULAR HEART DISEASES AND CURRENT TREATMENTS 
1.1.1 Current issues in treating valvular heart diseases  
Valvular heart diseases represent a major public health issue affecting more than 5 million adults 
in the US alone [1]. Valvular heart diseases remain a serious concern and economic burden, 
particularly in pediatric patients with the incidence of 1–2 cardiac valve defects in 1000 births in 
the US, and 8 in 1000 births globally [2, 3]. Each year, more than 25,000 deaths in the US and 
3% of sudden deaths in the European Union are caused by cardiac valve defects [4]. In addition, 
recent epidemiology has forecasted a dramatic increase in the prevalence of valvular heart 
disease in the next 50 years due to the increasing aging population [5]. Despite the tremendous 
interdisciplinary efforts in understanding heart valve pathology, drug/therapy development and 
clinical healthcare over the past few decades, a substantial unmet clinical need in treating 
valvular heart diseases remains.  
Currently, there is a lack of effective pharmacological treatment specifically for valvular 
heart diseases while valve repair and replacement stand as the only clinically available treatment 
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options. Strikingly, almost 70% of the diseased valves are beyond the capability of valve repair 
and therefore, must be replaced [6]. Indeed, heart valve replacement surgery remains the second 
most performed procedures among all cardiovascular related surgeries with a total of 300,000 
valve replacement performed annually worldwide and a total of 14 billion US dollars in medical 
costs in the US alone [7]. Currently, the mainstay in valve replacement are mechanical and 
bioprosthetic valves, both of which suffer from several major drawbacks. Valve replacement by 
a bioprosthetic valve often lead to rapid ectopic calcification in vivo and its tendency towards 
mechanical failure further shortens its durability [8]. On the other hand, mechanical valve 
replacements demand long-term anticoagulant therapy and may be subjected to life-threatening 
hemodynamic failure [9, 10]. More importantly, both valve replacements are not viable and 
cannot grow with patients [11]. As a result, these valve replacements are likely to require re-
operation, often multiple re-operations, especially for pediatric patients [12]. Therefore, there is a 
pressing and imminent need for developing new treatment options that can mitigate or overcome 
the problems associated with the current treatments. 
1.1.2 Scaffold-based heart valve regenerative therapy  
To overcome the drawbacks of current therapies, heart valve tissue engineering (HVTE) has 
been proposed as a promising strategy for regenerating and/or repairing diseased valve tissue 
[13-16]. Tissue engineering can enhance the limited self-healing capacity of damaged, 
malformed, or diseased tissue by guided reconstruction of native extracellular matrix (ECM)-
mimetic microenvironment with adequate biomechanical integrity and by providing the 
necessary biomimetic physical and biological cues [17]. HVTE is of special significance and 
potential because valvular heart diseases often result in substantial loss of healthy cells as well as 
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disruption of normal tissue microenvironment that are beyond the repair capacity of native 
valves [18]. Therefore, biomimetic tissue-engineered heart valve constructs that can deliver cells 
while providing mechanical support and biological cues to promote valve regeneration are in 
critical need [19, 20]. Among different components of HVTE, scaffold plays a critical role in 
directing and guiding the cellular activities towards regeneration. Ideally, a suitable scaffold 
would mimic the complex hierarchical and anisotropic structure of valve leaflet ECM and 
withstand the dynamic mechanical environment in vivo. Here, we are particularly interested in 
scaffolds prepared from synthetic elastomers. These scaffolds have been well established and 
recognized as one of the promising tools to engineer microenvironments mimicking native heart 
valve ECM [21]. In HVTE, scaffolds made from biodegradable synthetic elastomer offer a 
wealth of benefits including 1) more controllable material composition and structure than natural 
materials, thus minimizing the variance between batches [22]; 2) high mechanical compliance 
and elastic behavior, which enables them to endure the high demand of cyclic stretch and 
relaxation processes experienced by native valve tissue in vivo [23]; 3) low immunogenicity and 
toxicity because the degradation products are mostly endogenous metabolic molecules [24]; 4) 
tunable degradation rates that will balance evolving mechanical properties due to gradually 
degrading matrix and new ECM synthesized by the regenerating tissue [25, 26]; and 5) ease of 
processability by common material fabrication methods such as molding, spraying, spinning and 
stereolithography [22]. Therefore, synthetic biodegradable elastomers are especially suitable 
material candidates for HVTE scaffolds. 
In spite of the exponential growth in HVTE research, a mature tissue-engineered heart 
valve construct made from synthetic biodegradable elastomers has yet to be developed for 
clinical use [4]. Such slow progress towards clinical translation can be attributed to several 
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challenges in the field. One important feature responsible for valve function is the complex 
multiscale hierarchical architecture and tri-layer structure of native valve leaflets. This consists 
of anisotropic fibrous layers of ventricularis and fibrosa which are instrumental for closing and 
opening of the leaflets. In addition, middle proteoglycan-rich spongiosa provides shock-
absorbing properties. Recapitulation of such intricate structure in synthetic elastomers is still 
challenging. Many researchers in the materials science as well as tissue engineering field are 
working towards developing functional heart valves, yet lack of materials with tunable 
degradation rates and processability to capture fibrous structure with mechanical compliance 
along with shock-absorbing properties of the middle spongiosa layer are some of the many 
hurdles to the progress in the field. Inadequacies in creating such a biomimetic construct might 
contribute to lack of efficacy of tissue-engineered valves. Moreover, the optimal morphological, 
physical, mechanical and degradation properties of an ideal HVTE construct are not yet 
understood [27]. This may be due, in part, to the lack of long term in vivo efficacy and safety 
data on the currently available HVTE constructs [27].  
Previously, several reviews have summarized the synthesis and properties of 
biodegradable elastomers used for tissue engineering [22, 23, 28] and their application towards 
HVTE using different approaches [29-31]. However, how the multiscale hierarchical 
architecture, mechanical anisotropy, scaffold degradability and biocompatibility of synthetic 
elastomeric scaffold-based HVTE approaches are associated with HVTE outcome have not been 
thoroughly reviewed. Hence, based on the most recent studies on synthetic biodegradable 
elastomers used for HVTE from 2000 to 2016, we emphasize on the discussion of native heart 
valve microenvironments and various up-and-coming approaches to engineer synthetic 
elastomers to recreate key features in the heart valve microenvironment such as anisotropic and 
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hierarchical tri-layered architecture, mechanical anisotropy, biodegradability, and 
biocompatibility. 
1.2 SYNTHETIC BIODEGRADABLE ELASTOMERS  
This section introduces and summarizes different types of synthetic biodegradable elastomers 
that have been explored for HVTE to date. Table 1–4 summarize existing studies on 
polyurethane (PU)-based elastomers, poly (hydroxyalkanoate) (PHA)-based elastomers, poly (e-
caprolactone) (PCL)-based elastomers and poly(glycerol sebacate) (PGS)-based (thermoset) 
elastomers for HVTE, respectively. 
1.2.1 Thermoplastic elastomers  
Thermoplastic elastomers, or physically crosslinked elastomers, refer to a category of elastomers 
whose individual polymer chains are linked to each other by weak inter/intramolecular 
interactions such as hydrogen bonds and dipole-dipole interactions. The majority of 
thermoplastic elastomers consist of a rigid domain providing the structural integrity and an 
amorphous domain, which renders the flexibility. Such elastomers can be melted and remodeled 
and are therefore widely exploited for tissue-engineered constructs. 
a. Polyurethane (PU)-based elastomers 
PU polymers include a large class of elastomers with varying chemical structures, physical 
properties and degradation profiles. Due to their wide property spectrum and facile fabrication 
methods, PUs are one of the most widely used synthetic polymers for biomedical applications 
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[32]. PUs share the common polymer backbone structure, which includes an aliphatic or 
aromatic units coming from the isocyanate monomers and a more complex moiety derived from 
polyether or polyester monomers. PUs often undergo microphase separation forming a soft 
segment created by polyester or polyether and a hard segment formed by diisocyanates and chain 
extenders [26]. Conventionally, PUs have been developed to resist degradation for long term 
implantation [33]. However, more recently, chemical modifications of PUs have been explored 
to accelerate their biodegradability so that they can be suitable for applications which require the 
fast degrading materials. Currently, PU, polycarbonaturethane (PCU) and poly (ester urethane) 
urea (PEUU) have been used alone or in combination with other materials for HVTE (Table 1). 
Table 1. PU-based elastomers used for HVTE studies 
Type of PU 
elastomers 
Year 
(Ref) 
Fabrication 
Method Scaffold Description Significant Findings 
PCU 2003[34] molding 
Bi-leaflet structure 
designed for the mitral 
valve 
Scaffold showed excellent 
hemodynamic performance and 
durability with mild 
calcification in calf model. (in 
vivo study) 
PEUU 2006[35] 
Electrospinning 
on rotating 
stainless steel 
mandrel 
Fibers with different 
diameter, porosity and 
anisotropy 
High velocity spun scaffolds 
exhibited highly anisotropic 
mechanical properties closely 
resembling the native 
pulmonary valve leaflet. 
POSS-PCU 2009[36] Solvent casting 
100, 150 and 200 µm 
thick films; can be 
fabricated into valve 
shape design 
POSS–PCU possessed excellent 
mechanical strength, good 
surface properties and 
resistance to platelet adhesion. 
PU (not 
specified) 
2012
[37] 
PU spraying 
technique 
Randomly oriented PU 
fiber sheet with a 
thickness of 0.3 mm; 
sutured to a Teflon 
fixation unit 
Conditioning of scaffolds in a 
pulsatile bioreactor may 
improve the tolerance of cells to 
shear stress. 
PEUU with 
PEO or PCL 
2012
[38] 
Electrospinning 
on rotating 
stainless steel 
mandrel 
Electrospun scaffold 
with various fiber 
densities and mechanical 
properties 
The scaffold morphology and 
mechanical properties can be 
tuned by secondary fiber 
populations and processing 
parameters. 
PEUU 2013[39] 
Electrospinning 
on rotating 
stainless steel 
Isotropic and anisotropic 
electrospun scaffold 
Based on FE simulation, 
curvilinear fiber trajectories for 
tissue-engineered semilunar 
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mandrel valves leaflet resulted in more 
uniform strain field under 
physiologic loading. 
PU (not 
specified) 
2013
[40] PU spraying 
Randomly oriented PU 
fiber sheet with a 
thickness of 0.3 mm; 
Sutured to a Teflon 
fixation unit 
The biocompatibility of the 
synthetic scaffold was good. 
Conditioning in the newly 
developed bioreactor improved 
cell adaption to shear stress. 
PEUU 2015[41] 
Electrospinning 
on conical 
mandrels of 
varying 
pitch angles 
The angle of fiber 
alignment varied linearly 
over scaffold length. 
The electrospun constructs 
exhibited a curvilinear fiber 
structure and local mechanical 
properties similar to the native 
leaflet. 
PU: polyurethane; PCU: polycarbonaturethane; PEUU: poly(ester urethane) urea; POSS: 
polyhedral oligomeric silsesquioxane; PEO: poly(ethylene) oxide; PCL: poly(ɛ-caprolactone); 
FE: finite element. 
 
b. Poly(hydroxyalkanoate) (PHA)-based elastomers  
PHAs are a class of polyesters formed by hydroxyl-alkanoic acid which share the same structure 
of HO-R-COOH where R represents alkyl units [42]. In the field of biomaterials, PHAs are one 
of the oldest elastomers ever discovered and usually refer to those derived from bacterial 
fermentation under limiting nutrients and excess carbon environment [42, 43]. PHAs are 
naturally occurring polyesters synthesized by a variety of microorganisms and then isolated for 
further use. This class of elastomers is generally stronger than PUs and more suitable for work 
under dynamic conditions such as cardiovascular tissue engineering [28]. Currently, PHA, poly-
4-hydroxybutyrate (P4HB), poly-3-hydroxybutyrate (P3HB), polyhydroxyoctanoate (PHOH), 
poly (3-hydroxybutyrate-co4-hydroxybutyrate) (P3HB-co-4HB) and poly (3-hydroxybutyrate-
co-3-hydroxyhexanoate) (PHBHHx) have been used solely or in combination with other 
materials for HVTE (Table 2).  
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Table 2. PHA-based elastomers used for HVTE studies 
Type of PHA 
elastomers 
Year 
(Ref) 
Fabrication 
Method 
Scaffold 
Description Significant Findings 
PGA, PHA and 
P4HB 
2000
[44] Salt leaching 
Tri-leaflet heart 
valve scaffolds; 
nonwoven mesh of 
fibers (pore size: 
100–300 μm; 
porosity: 95%). 
PHA and P4HB could be 
molded into the shape of a tri-
leaflet heart valve scaffold and 
showed a considerable amount 
of cell attachment and ECM 
formation. 
PHA 2000[45] Salt leaching 
Porous scaffold 
(pore size: 80–180 
µm) 
PHAs could be used to fabricate 
a three-dimensional, 
biodegradable heart valve 
scaffold. 
PHA 2000[46] Salt leaching 
Porous scaffold 
(pore size: 180–240 
µm) 
PHA scaffold could maintain 
valve function for 120 days in 
lambs. (in vivo study) 
P4HB/PGA 
composite 
2000
[47] 
Heat-application 
welding 
P4HB coated PGA 
mesh 
Scaffolds conditioned in 
biomimetic environment in vitro 
could function satisfactorily in 
vivo up to 5 months. (in vivo 
study) 
P4HB/PGA 
composite 
2002
[48] 
Heat-application 
welding 
P4HB coated PGA 
mesh 
Scaffold showed good 
biocompatibility with marrow 
stromal cells and constructs 
showed similar morphological 
and mechanical properties of 
native heart valve. 
P4HB and 
PHOH 
2002
[49] 
Porogen 
leaching 
Porous scaffold 
porosity: 60–80%; 
pore size: 80–200 
μm 
Scaffold opened and closed 
synchronously under sub-
physiological and supra-
physiological flow conditions. 
P4HB-PGA 
and  P4HB-
PGA/PLLA 
composite 
2003
[50] 
P4HB dip 
coating 
Non-woven 
PGA/PLLA mesh 
coated with P4HB 
Mechanical stimulation of 
scaffolds by dynamic flexure 
resulted in reduced stiffness and 
induced anisotropic mechanical 
properties. 
P3HB, P4HB 
and P3HB-co-
4HB + 
Decellularized 
valve 
2004
[51] 
Dip-coating of 
polymer on 
ECM 
Similar surface 
morphology, 
texture and 
microporosity of 
decellularized 
Matrix/polymer hybrid tissue 
valves had better biological and 
biomechanical characteristics 
than decellularized ECM. (in 
vivo study) 
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matrix 
P3HB, P4HB 
and P3HB-co-
4HB + 
decellularized 
valve 
2004
[52] 
Dip coating/ 
impregnation of 
lyophilized 
decellularized 
matrices 
Porous scaffold 
coated with thin 
polymer layer 
Hybrid scaffolds showed 
excellent biomechanical, 
hemodynamic, and structural 
characteristics under systemic 
load conditions. 
P4HB 2006[53] 
Three-
dimensional 
stereolithographi
c modeling 
Porosity of 
approximately 80% 
(pore size: 200 to 
400 µm) 
Seeding of cryopreserved human 
umbilical cord cells showed 
excellent growth potential and in 
vitro tissue formation. 
P4HB/PGA 
composite 
2006
[54] 
P4HB dip 
coating 
Non-woven PGA 
mesh coated with 
P4HB; thickness: 
1.0 mm 
Prenatal fetal progenitors could 
be used as new cell source for 
the engineering of living heart 
valve leaflets. 
P4HB/PGA 
composite 
2006
[55] 
P4HB dip 
coating 
Non-woven PGA 
mesh coated with 
P4HB; thickness: 
1.0 mm 
The heart valve leaflet 
fabrication from prenatal 
umbilical cord–derived 
progenitor cells was feasible. 
PHBHHx 
coated 
decellularized 
valve 
2007
[56] 
PHBHHx 
coating 
Porous surface with 
thin polymer layer 
coating 
PHBHHx coating improved 
mechanical properties, reduced 
calcification and promoted the 
repopulation of hybrid valve. 
P4HB coated 
decellularized 
valve 
2008
[57] Electrospinning 
Ultrathin P4HB 
fibers have 
magnitude 
similarity to the 
fibrils in ECM 
The feasibility and improved 
biomechanical characteristics of 
a novel hybrid heart valve leaflet 
scaffold was demonstrated. 
Decellularized 
leaflet coated 
chitosan/ P4HB 
2009
[58] Electrospinning 
Fibers of 
chitosan/P4HB 
randomly deposited 
on the surface of 
decellularized 
leaflets. 
bFGF loaded hybrid valve 
leaflets showed increased 
mechanical properties and good 
cytocompatibility. 
P4HB 2009[59] 
Stereolithogra-
phic modeling 
Scaffold with 
length and inner 
diameter compared 
with the homograft 
This technique allowed 
fabricating custom-made, 
patient-specific polymeric 
cardiovascular tissue 
engineering scaffolds. 
P4HB/PGA 
composite 
2009
[60] 
P4HB dip 
coating 
Non-woven PGA 
mesh coated with 
A real-time and non-invasive 
functionality check of tissue-
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P4HB engineered valves could be used 
to monitor mechanical 
properties during tissue culture. 
P4HB 2010[61] 
Three-
dimensional 
stereolithogra-
phic modeling 
Porous scaffolds 
with porosity of  
80% (pore size 200 
to 400 µm) 
Generation of viable tissue-
engineered heart valves based on 
CD133+ cells derived from 
umbilical cord blood and P4HB 
scaffold was successful. 
P4HB/PGA 
composite 
2010
[62] 
P4HB dip 
coating 
Non-woven PGA 
mesh coated with 
P4HB 
In vitro mechanical conditioning 
induced the development of 
native-like tissue architecture. 
P4HB/PGA 
composite 
2010
[63] 
2011
[64] 
2012
[65] 
P4HB dip 
coating 
Non-woven PGA 
mesh coated with 
P4HB 
Proof-of-concept study in 
combining tissue-engineered 
scaffold with minimally-
invasive valve replacement 
technology. (in vivo study) 
P4HB/PGA 
composite 
2012
[66] 
P4HB dip 
coating 
Non-woven PGA 
mesh coated with 
P4HB 
Prenatal in-vitro fabrication and 
fetal implantation of amniotic 
fluid stem cell-based heart 
valves in the ovine fetal model.  
(in vivo study) 
PGA: polyglycolide; PHA: polyhydroxyalkanoate; P4HB: poly-4-hydroxybutyrate; PHOH: 
polyhydroxyoctanoate; PLLA: poly-L-lactide; ECM: extracellular matrix; P3HB: poly-3-
hydroxybutyrate; P3HB-co-4HB: poly (3-hydroxybutyrate-co4-hydroxybutyrate); PHBHHx:  
poly (3-hydroxybutyrate-co-3-hydroxyhexanoate); bFGF: basic fibroblast growth factor 
 
c. Poly(ɛ-caprolactone) (PCL)-based thermoplastic elastomers  
PCL based thermoplastics are also a family of polymers that have been widely applied in 
biomedical fields [14]. This class of polymers includes PCL, poly(glycolic acid)  (PGA), 
poly(lactic  acid)  (PLA) and their copolymers. Generally, they have excellent biocompatibility 
and controlled biodegradation profile, which enable them to be used for the applications in 
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sutures and drug delivery systems that have been approved by FDA [28]. The synthesis of PCL-
based thermoplastics is often accomplished by the ring-opening polymerization of the 
corresponding acid monomer in the presence of an initiator. Currently, PCL, PGA and PLA have 
been used alone or in combination with other materials for HVTE (Table 3). 
Table 3. PCL-based elastomers used for HVTE studies 
Type of PCL 
based 
elastomers 
Year 
(Ref) 
Fabrication 
Method Scaffold Description Significant Findings 
PGA 2000[67] N/A 
Non-woven scaffold 
with fiber diameter of 
12–15 mm 
Pre-coating of polymeric 
scaffold with autologous 
human ECM could improve 
cell attachment. 
PCL 2006[68] 
Electrospinning/
Knitting 
Electrospun scaffold: 
fiber diameter: 5–
10μm; pore size: 15–
20μm; Knitted 
scaffold: rectangular 
patch with three 
leaflets knitted on 
semilunar pocket 
An optimal scaffold could be 
a combination of the 
strength of the knitted 
structure and the cell-
filtering ability of the spun 
structure. 
PCL 2006[69] Knitting 
Knitted patch sutured 
into a tube and 
covered with fibrin 
This scaffold was 
mechanically reliable and 
biocompatible. 
PGA/PLLA 
blend 
2006
[70] N/A 
Non-woven 50:50 
blend of PGA and 
PLLA fibers with 
diameter of 0.012–
0.015 mm 
Cyclic flexure and laminar 
flow could synergistically 
accelerate tissue formation. 
PCL 2007[71] Electrospinning 
Random fibers without 
beads defect; porosity: 
89.13± 2.5%; fiber  
diameter: 3.11 ± 0.43 
µm. 
PCL electrospun leaflets 
showed a correct co-aptation 
in the diastolic phase during 
pulse duplicator testing. 
PCL 2008[72] Electrospinning 
Tri-leaflet valve shape 
fiber; fiber diameter: 4 
µm 
Leaflets were able to open 
and close under 
mechanical/hydraulic 
conditions. 
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PGA/PLLA 
composite 
2010
[73] 
Manual and 
machine needle 
punch 
Non-woven fiber sheet 
MSCs seeded on the scaffold 
functioned well at the time 
of implantation in sheep 
model, but suffered 
regurgitation after 6 weeks. 
(in vivo study) 
PGA/PLLA 
blend 
2010
[74] N/A 
Non-woven fibrous 
scaffolds in a 
functional tri-leaflet 
valve 
Preconditioning of scaffolds 
in organ level bioreactor 
resulted in higher tissue 
formation rate. 
PCL 2013[75] Electrospinning 
Conventional 
electrospun scaffold 
PCL scaffolds were with 
minimal compaction and 
without compromising tissue 
composition and properties. 
PEG/PCL 
composite 
2014
[76] 
Electrospinning/
molding 
Anisotropic PCL 
scaffold embedded in 
PEG hydrogel 
PCL as an analog to the 
fibrosa could improve 
strength and introduce 
anisotropic mechanical 
behavior. 
PEGDMA-PLA 2014[77] Electrospinning 
Morphologically 
similar to native 
leaflets 
Scaffold showed 
biomechanical properties 
that resembled the native 
valve matrix. 
PCL 2014[78] Jet-spraying 
Aligned nanofibers 
(600 nm); >90% 
porosity 
Scaffolds had anisotropic 
mechanical properties, 
which induce cell orientation 
along with fiber alignment. 
PCL/Chitosan 
composite+ 
decellularized 
ECM 
2015
[79] Electrospinning 
Nanofibers but with 
beaded morphology 
Scaffolds had superior 
mechanical properties and 
enhanced cyto- and 
haemocompatibility. 
PCL 2015[80] Electrospinning 
Biomimetic 
circumferentially 
oriented nanofibers 
VICs aligned along the 
scaffold and showed 
fibroblast phenotype. 
PGA-P4HB or 
PCL 
2016
[81] Electrospinning 
Conventional 
electrospun scaffold 
Slow degrading scaffold 
were favored over fast-
degrading materials in terms 
of maintaining of their 
shape, promoting cell 
proliferation and ECM 
secretion. 
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PGA: polyglycolide; PCL: poly(ɛ-caprolactone); MSCs: mesenchymal stem cells; PLLA: poly-
L-lactide; PEG: poly(ethylene glycol); PEGDMA: poly(ethylene glycol) dimethacrylate; VICs: 
valvular interstitial cells; ECM: extracellular matrix. 
1.2.2 Thermoset elastomers   
Thermoset elastomers, or chemically crosslinked elastomers, refer to a class of elastomers whose 
individual polymer chain is linked to others by covalent bonds. The formation of the thermoset 
elastomers requires at least one of the monomers to have at least three functional groups that can 
react with other monomers so that polymer chain can grow linearly and also form a network 
structure. Usually, the synthesis of thermoset elastomers is accomplished in two steps. The first 
step involves the synthesis of a linear chain pre-polymer with little crosslinking. The second step 
is the curing process, which results in the crosslinked polymer network structure. Such 
crosslinking processes are either achieved thermally or via radiation. Once cured, the elastomers 
cannot be melted and remodeled and will only undergo degradation. 
a. Poly(glycerol sebacate) (PGS) 
PGS has been the most widely studied thermoset elastomer. PGS was first synthesized in 2002 
by the polycondensation reaction of glycerol and sebacic acid [82]. Since then, PGS has been 
well characterized in terms of its degradation, mechanical and biological properties. Meanwhile, 
PGS is amenable to multiple fabrication methods and have been proposed for different tissue 
engineering applications by numerous studies [83]. Table 4 summarizes the studies involving the 
use of PGS for HVTE. 
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Table 4. PGS-based elastomers used for HVTE studies 
Type of PGS 
elastomers 
Year 
(Ref) 
Fabrication 
Method 
Scaffold 
Description Significant Findings 
Protein 
coated PGS 
2007
[84] Salt fusion 
Pore size 75 to 150 
µm, porosity 90%, 
thickness 1.0 mm 
Scaffold pre-coating with ECM 
proteins could allow the tuning of 
cellular behavior by altering ECM 
production and cell phenotype. 
PGS 2013[85] Laser ablation 
Diamond-shaped 
pores 
Scaffold matched the anisotropy and 
peak tangent moduli of native bovine 
aortic heart valve leaflets. 
PGS 2013[86] 
Machining-based 
micromolding 
Diamond-shaped 
pores  
 
Scaffolds with anisotropic stiffness 
resembling those of native valvular 
tissues in the low stress–strain 
ranges. 
PGS/PCL 2013[87] Electrospinning 
Porous electrospun 
scaffold 
VICs were able to remodel the 
synthetic scaffolds by depositing 
new matrix proteins and maintaining 
scaffolds mechanical properties. 
PGS/PCL 
+ 
Hyaluronic 
acid & 
Gelatin 
2014
[88] 
Electrospinning 
/hydrogel 
embedding 
 
Fiber-reinforced 
hydrogel 
PGS–PCL scaffolds preserved 
mechanical properties while 
hydrogel improved the three-
dimensional distribution of VIC. 
PGS-PCL 2014[89] Electrospinning 
Electrospun aligned 
fibers 
Scaffold mechanical property could 
be tuned to mimic the native heart 
valve. 
PGS-PCL 2014[90] 
Micromolding/ 
electrospinning/
Layer by layer 
assembly 
 
 
Tri-layered 
structure resembled 
valve leaflet 
Scaffold had tunable anisotropic 
mechanical properties similar to 
native heart valves. Scaffolds opened 
and closed properly in ex vivo model. 
PGS/PCL 2015[91] 
Electrospinning 
/hydrogel 
Fiber-reinforced 
hydrogel 
COLLAGEN 1 and ELASTIN genes 
expression were higher in fiber-
hydrogel composite scaffolds than 
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+ 
Hyaluronic 
acid & 
Gelatin 
embedding 
 
those of fiber-only and hydrogel-
only scaffolds. 
PGS: poly(glycerol sebacate); PCL: poly(ɛ-caprolactone); VICs: valvular interstitial cells; ECM: 
extracellular matrix 
1.2.3 Summary   
In summary, tunable biodegradability and excellent mechanical compliance of synthetic 
biodegradable elastomers have attracted them as materials of choice for soft tissue engineering 
such as HVTE. Both thermoplastic and thermoset biodegradable elastomers listed above have 
their own pros and cons. Most of the thermoplastic elastomers are non-toxic with good 
processability [28]. However, they do suffer from heterogeneous degradation profile, which may 
lead to unpredictable loss of mechanical integrity during degradation [92]. On the other hand, 
thermoset elastomers have more controllable degradation kinetics and predicable mechanical 
stability during degradation [22]. However, they have poor processability compared to 
thermoplastic elastomers despite some recent efforts on the creation of functional thermoset 
elastomeric scaffolds by rapid prototyping, micromolding, microablation and electrospinning 
[83]. In addition, since both classes of elastomers are synthetic materials, they are often 
considered to have potential foreign body response after implantation [28]. The following 
sections discuss applications of both classes of elastomers in HVTE and biomimetic strategies to 
improve their tissue engineering outcomes.  
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1.3 IMPORTANT SCAFFOLD DESIGN CRITERIA FOR TISSUE-ENGINEERED 
HEART VALVES 
The development of biomimetic tissue-engineered construct has been recognized as one of the 
central themes in the field of tissue engineering [17, 93]. The principle of ‘‘Form follows 
Function” has been actively practiced [94, 95]. In particular, for HVTE, it has been 
acknowledged that cellular activities are instructed by biophysical factors such as anisotropy and 
multiscale hierarchy in ECM architecture [95-97]. Valve ECM-mimetic scaffolds have shown 
promising results in multiple in vitro and preliminary in vivo studies implying that a tissue-
engineered heart valve scaffold, which can recapitulate the native valve structure has huge 
promise to become a functional construct. Here, we identify several key design criteria for the 
functional biomaterial-based heart valve constructs such as anisotropic architecture, mechanical 
anisotropy, and biocompatibility. 
1.3.1 Scaffold architecture  
Scaffold architecture provides the structural support and cues to the cells cultured on it. 
Moreover, the scaffold architecture can also affect its mechanical properties and degradability. 
Native valve leaflet ECM has its own macroscopic shape, size and unique fibrillar 
microarchitecture [98]. Therefore, tissue-engineered scaffold recapitulating these morphological 
properties holds great promise in guiding valve tissue regeneration [20]. This section discusses 
how the architecture of biodegradable elastomeric scaffolds has evolved for HVTE application. 
a. Natural heart valve tissue architecture 
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Structurally, adult heart valves consist of three flexible tissue leaflets with a highly complex 
structure. Cross-section of the valve leaflet is characterized by a tri-layered structure that consists 
of fibrosa, spongiosa and ventricularis, each of which have their own ECM protein composition 
and alignment [99]. Fibrosa consists of circumferentially oriented thick collagen bundle structure 
and provides mechanical strength to the leaflet [100]. Spongiosa is made up of randomly 
oriented proteoglycans, which acts as a cushion between the fibrosa and ventricularis layers 
[101]. Ventricularis is composed of radially oriented elastic fibers (mainly elastin), which results 
in high elasticity in radial direction and enables the proper opening and closing of the valve 
[101]. Thus, heart valve leaflets possess multiscale hierarchical organization from micro- to 
macro-scale. Additionally, the circumferentially and radially aligned ECM proteins in fibrosa 
and ventricularis layers confer anisotropic structural and mechanical properties to heart valve 
leaflets. These important features of heart valve leaflets pose substantial challenges in 
recapitulating the valve structural characteristics using conventional tissue engineering scaffolds 
and motivate the development of new generation biomimetic HVTE scaffold. 
b. Mimicry of anisotropic nature of heart valve leaflet 
Early studies on polymeric HVTE constructs used randomly oriented fibers or meshes as heart 
valve prosthesis to match the macroscopic size and shape of valve [44, 45, 47, 48, 67]. These 
studies demonstrated that scaffolds made from biocompatible materials could support the growth 
of multiple cell types (vascular cells, myofibroblasts and endothelial cells) and ECM protein 
secretion with similar inflammatory response level compared to that of human heart valve 
homografts [40]. However, scaffold architecture design was not taken into consideration. 
To match the anisotropic nature of native heart valve leaflets, electrospun poly (ester 
urethane) urea (PEUU) were produced with aligned fiber network by tuning the rotating mandrel 
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velocity [102]. The mechanical properties of highly anisotropic fibers closely resembled those of 
the native pulmonary heart valve leaflet. Based on this elastomeric scaffold leaflet, finite element 
(FE) simulation was applied to explore the optimal shape and architecture for HVTE, which was 
accomplished by comparing the deformed shape from computational modeling and ex vivo 
microCT scan of a native ovine valve leaflet [39]. The curvilinear fiber architecture was 
determined to be the optimal architecture for the valve leaflet with local mechanical properties 
comparable to those of native heart valve leaflet [41]. 
Alternatively, hybrid poly(glycerol sebacate)-poly(ε-caprolactone) (PGS-PCL) scaffolds 
with anisotropic fibrous structure were fabricated by directional electrospinning technique [89]. 
Primary human valvular interstitial cells (VICs) could attach and align according to the fiber 
alignment of PGS-PCL scaffolds and actively expressed smooth muscle actin and heart valve 
ECM proteins such as collagen and vimentin. Similarly, anisotropic nanofibrous PCL scaffold 
was fabricated by jet-spraying technique [78]. Porous scaffolds supported cell invasion, 
proliferation and ECM protein deposition. More importantly, the aligned fiber structure was able 
to instruct cellular alignment and polarization along the fiber orientation [78].  
c. Mimicry of anisotropic nature of heart valve leaflet 
Besides the anisotropic fibrous structure, the recapitulation of tri-layered valve leaflet with 
unique ECM fiber alignment in each layer is another challenge for the design and fabrication of 
elastomeric scaffolds [98]. So far, only a limited number of studies have devised tri-layered 
scaffolds, with the intention to mimic both structural and mechanical anisotropy of the native 
valve leaflets. As an example, anisotropic sandwich-like polyethylene glycol (PEG)-PCL 
hydrogel–fiber composites were developed by embedding PCL fibers within the PEG hydrogel 
[84]. The alignment of VICs cultured on top of sandwich PEG-PCL scaffolds was guided by the 
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anisotropy of underlying electrospun PCL fibers. Although the constructs were believed to 
mimic only fibrosa, this study provided a novel approach of combining hydrogel and fibrous 
scaffold for HVTE. In another study, a diamond-patterned PGS layer was created by 
micromolding, which served as the central layer [98]. Then, unidirectionally aligned PGS-PCL 
fibers were directly electrospun on the PGS layer [98]. These hybrid constructs supported growth 
of VICs and mesenchymal stem cells (MSCs) and guided their alignment. After 4 weeks of 
culture, the mechanical properties (stiffness and tensile strength) of the engineered constructs in 
both circumferential and radial directions were comparable to the native valve tissue and 
correlated well with the de novo ECM protein deposition. To further evaluate the potential of 
these scaffolds for a leaflet replacement, the authors tested the construct in an ex vivo model of 
leaflet replacement in the pulmonary valve position of isolated fresh pig hearts. Tri-layered 
scaffolds had adequate systolic performance and complete diastolic co-aptation, which was better 
than single layered scaffold [98]. 
1.3.2 Mechanical properties of scaffolds  
The mechanical properties of ECM play important roles in determining the cellular behaviors, as 
shown in cell biology [103], disease pathology [104] as well as tissue regeneration [105]. Since 
tissue-engineered scaffolds act as temporary ECM substitutes and provide initial support to the 
seeded/recruited cells, their mechanical properties should ideally be similar to those of the 
targeted native tissues and/or could be tuned to deliver mechanical cues for tissue 
repair/regeneration by activating/deactivating cells.   
a. Native heart valve leaflet mechanics 
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Human heart valves are responsible for controlling the continuous unidirectional blood flow 
into/out from the ventricles. Normally, average human heart beats almost 2 billion times through 
the life span [106]. Hence, heart valves are subject to highly dynamic mechanical loads such as 
high pressure (as high as 12 kPa in adults) and shear stress due to blood flow. Uniaxial 
mechanical testing on porcine leaflet revealed that the valve leaflet had good compliance 
initially, but eventually became rigid at larger strains [7]. Due to its unique ECM (collagen and 
elastin) fiber alignment, valve leaflet demonstrated anisotropic mechanical properties in 
circumferential and radial directions. Uniaxial mechanical testing also revealed that the elastic 
modulus of the initial loading phase varies between 2 and 10 kPa in the radial direction and 20–
100 kPa in the circumferential direction [107]. Biaxial mechanical testing further confirmed that 
the valve leaflet is highly anisotropic (index of anisotropy: 0.247) [108, 109]. Therefore, ideal 
HVTE scaffolds should be elastic and strong enough to withstand the dynamic in vivo 
environment without permanent deformation under the influence of repeated stresses. More 
importantly, HVTE scaffolds should resemble the anisotropic nature of valve leaflet to provide 
the correct biomechanical cues towards functional valve regeneration [110].  
b. Strategies to tune the mechanical properties of HVTE scaffolds 
Early studies on synthetic HVTE scaffolds highlighted the importance of mechanical properties 
to provide tissue support as well as to endure the in vivo mechanical environment and the 
implantation procedure such as suture [44]. However, there is no consensus in the field on the 
optimal mechanical properties of HVTE scaffolds, for both, as-prepared and during in vivo 
degradation of scaffolds and tissue remodeling. Therefore, it is worthwhile to develop methods 
that can widely tune the mechanical properties of HVTE scaffolds so that the optimal mechanical 
properties can be assessed.  
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One of the methods to tune the mechanical properties of elastomeric scaffold is by 
modifying the chemical structure of well-established elastomers. Based on the structure of 
polycarbonate (PCU), Kidane et al. grafted polyhedral oligomeric silsesquioxanes (POSS) 
segment onto polycarbonate and found that PCU-POSS possessed higher tensile strength, 
Young’s modulus and elongation at break than pure PCU [36]. It was hypothesized that 
nanoscale POSS segment could form strong intermolecular forces with neighboring molecules 
and reduce its dipole interaction potential, thus making the polymer stronger. 
Amoroso et al. focused on fine tuning the scaffold stiffness by electrospinning PEUU 
with modified fiber intersection densities [38]. This was achieved by the addition of a secondary 
polymer strain (non-leachable PCL or leachable poly(ethylene) oxide (PEO)) during 
electrospinning. The lower bending moduli were achieved with the higher fiber intersection 
densities within PEUU scaffolds. Interestingly, the incorporation of non-leachable, stiff 
secondary fiber populations (PCL) led to higher bending moduli while the removal of leachable 
secondary fiber populations (PEO) resulted in lower bending moduli.  
Post-manufacturing modifications have also offered new possibilities to further tune the 
mechanical properties of elastomeric scaffolds. Tseng et al. modified electrospun PCL scaffolds 
by protein adsorption, alkali digestion and acrylation, respectively [76]. All three modifications 
changed the physico-chemical properties of the scaffolds and significantly reduced the elastic 
modulus compared to the unmodified scaffolds. Additionally, modification by acrylation and 
protein adsorption also resulted in the change in mechanical anisotropy of electrospun scaffolds.  
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1.3.3 Biocompatibility of scaffolds  
Most current biodegradable scaffolds and their degradation products are non-toxic and can 
support cell proliferation. However, such scaffolds are still considered as foreign materials to the 
body. Therefore, synthetic tissue engineering scaffold may suffer from low cell attachment, 
inflammation and thrombogenicity in vivo. Many studies have shown that the physico-chemical 
properties such as hydrophilicity, surface charge and roughness are crucial for the cell 
attachment and protein adsorption in vivo, which eventually determine the cytocompatibility, 
level of inflammatory reaction and hemocompatibility [111]. 
Emerging trend in the tissue engineering field is the departure from the ‘‘bio-inert” 
scaffolds towards “bio-responsive” and “bio-instructive” scaffolds [112]. In the context of tissue 
engineering, bio-responsive and bio-instructive materials refer to those, which can respond to the 
in vivo biological environment and provide proper cues towards the tissue regeneration [113]. 
Various strategies that have been proposed to improve the biocompatibility of elastomeric 
scaffolds are summarized in this section. 
a. Use of decellularized tissue matrix and natural ECM proteins to improve cell attachment and 
regulate cell behavior 
Native derived tissue-engineered constructs such as decellularized tissue matrix have been 
extensively studied in growing animal model [114], long-term in vivo performance [115] and 
clinical study [116]. Indeed, one of the greatest advantages of using decellularized tissue 
scaffolds is that they are derived from materials already present inside body and do not usually 
pose the toxicity problems. Also, they are bioactive with specific protein binding sites and other 
biochemical signals that may assist in a range of cellular activities including cell attachment and 
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cell-cell communication [117]. Therefore, it is valuable to incorporate the advantages offered by 
natural biomaterial into the design of HVTE scaffold.  
Surface coating or functionalization of biodegradable elastomers with natural ECM 
proteins can promote cell attachment onto the hybrid scaffolds and can also regulate de novo 
synthesis of ECM proteins, remodeling, and the inflammatory response [118]. In an effort to 
engineer cellular behaviors such as de novo ECM production and functional cellular phenotypes 
on tissue-engineered heart valves constructs, porous PGS scaffolds were pre-coated with 
laminin, fibronectin, fibrin, collagen types I/III, or elastin, respectively [84]. The hybrid scaffolds 
significantly increased cellularity of the scaffolds and regulated cellular behaviors such as ECM 
protein production. 
b. Reduce thrombogenicity of HVTE scaffold 
One common reason of the material failure in vivo, especially in artificial heart valves is their 
high thrombogenicity, which is a serious issue for all constructs in direct contact with the blood 
[119]. Hence, significant efforts are needed in the field of HVTE to reduce scaffold 
thrombogenicity. One such chemical modification is the incorporation of a polyethylene glycol 
(PEG) motif into the chemical structure of elastomers [120, 121]. The fabrication of 
nanocomposite scaffolds made of elastomers and nanomaterials may also reduce 
thrombogenicity. For example, Kannan et al. demonstrated that POSS-PCU nanocomposites 
have lower thrombogenicity than polytetrafluoroethylene (PTFE) and PCU due to the remarkable 
ability of nanocomposite surface to repel both proteins and platelet offering greater thrombo-
resistance [122]. In addition, nanocomposites made of elastomers and carbon nanotubes have 
also been shown to have antithrombotic property [123, 124]. It was speculated that the improved 
electrostatic properties, nanostructured topography as well as pure carbon composition could 
 24 
have contributed to the reduced thrombogenicity [123, 124]. We envision the use of synthetic 
elastomers will provide new antithrombotic strategy since the chemical structure of synthetic 
elastomers can be easily modified to obtain novel materials with lower thrombogenicity. The 
issue of thrombogenicity may also be tackled by the delivery of antithrombotic agents. Heparin–
VEGF polyelectrolyte multilayer films have been shown to significantly reduce platelet adhesion 
on the decellularized heart valves [125]. Although there is no study using synthetic elastomers as 
drug carriers to reduce thrombogenicity so far, the chemical structure of synthetic elastomers can 
be tailored for the controlled release of bioactive molecules [126]. 
c. Towards the development of bio-responsive and bio-instructive HVTE scaffolds 
The required function of tissue-engineered scaffolds has evolved towards being cell-instructive 
materials to promote tissue regeneration [127]. As the most abundant cell type in valves, the VIC 
population is diverse and plastic, which can switch from quiescent (fibroblast-like) phenotype to 
activated (myofibroblast-like) or diseased (osteoblastic) phenotype [128]. It is important to 
regulate the VIC phenotypes because the transition between different VIC phenotypes is known 
to be involved in both, valvular disease progression towards calcification as well as the valve 
regeneration [129-131]. Therefore, tissue-engineered scaffolds, which can instruct VIC activities 
and phenotypic changes to promote healthy valve regeneration, are of great interest. VIC 
phenotypes and activities such as cellular adhesion, alignment, morphology, de novo protein 
synthesis and activation state have been shown to be influenced by soluble factors [132], matrix 
composition [133], matrix architecture [76], bioactive peptides [76], matrix stiffness [134] and 
material surface chemistry [135]. Although it has not been explored yet, synthetic biodegradable 
elastomeric scaffolds have the potential to encapsulate and release VIC-responsive biomolecules 
in a predictable manner [126]. Moreover, scaffold mechanical properties and surface chemistry 
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can be tuned by modifying the chemical structural of elastomers, which is a notable advantage of 
synthetic biodegradable elastomer over natural polymers. Therefore, we envision that 
biodegradable synthetic elastomer-based scaffolds will be useful to investigate and regulate VIC 
cellular activities. 
1.4 CLINICAL TRANSLATION OF SCAFFOLDS FOR HVTE 
The success of in vitro research on biodegradable synthetic elastomeric scaffolds for HVTE led 
to multiple in vivo animal studies (in calf [34], sheep [46, 47, 64, 136] and non-human primate 
models [64]). These studies have revealed the feasibility of scaffold implantation by different 
methods including minimally invasive and trans-catheter implantation. Moreover, the implanted 
scaffolds exhibited adequate functionality with suitable valve integrity, mobility and also 
supported valve ECM remodeling processes. However, such encouraging results in animal 
models are still far from clinical translation. Here, we identify several major reasons/challenges 
that may be responsible for this limited success. The first hurdle is the lack of long term safety 
and efficacy study of implanted tissue-engineered scaffolds. As for the studies reviewed here, the 
vast majority of them are done in the in vitro setting (Table 1–4). Among the few in vivo studies, 
most of them reported the follow-up of the implanted valve functionality for less than 20 weeks. 
Extended follow-up study will elucidate the fate of tissue-engineered heart valves as well as the 
underlying tissue remodeling mechanisms in vivo [64]. The long-term in vivo study can also 
determine the toxicity and/or adverse effect of degradation products in vivo [27], which is critical 
for the administrative approval to move forward into clinical setting. The second major challenge 
is the in vivo calcification of the scaffolds [137]. Calcification has been one critical drawback 
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and leading cause of failure of heart valves, especially bio-prosthetic valve. Although synthetic 
elastomers seem to have less calcification problems than bioprosthesis in vivo [34, 52], the 
concern of potential calcification still exists because most of the studies were performed in sheep 
model, which is a less thrombogenic model than human. The concern of calcification can be 
alleviated by surface modification of the elastomeric scaffold or by the encapsulation of anti-
thrombotic therapeutics. The third challenge for most of the current tissue-engineered heart 
valves is the leaflet contraction. Tissue-engineered constructs made from either synthetic 
polymers (such as PGA/PLLA [73]) or natural polymers (such as fibrin [138]) have been shown 
to suffer from the shortening of the tissue over the period of time after implantation in sheep 
model. The transplanted cells (often in activated state which exhibit contractile phenotype) have 
been identified to induce the valve contraction [139]. Therefore, elastomeric scaffolds that can 
control cellular activation and contractility will have tremendous impact on the successful 
translation of HVTE. Lastly, although research in HVTE has come a long way since its 
conception (pioneered by R. Langer, JP. Vacanti and JE. Meyer in 1995 [140]), the development 
of a functional TEHV construct ready for clinical translation is time-consuming like any other 
tissue engineering endeavors. For example, Hoerstrup group has been focused on non-woven 
PGA mesh coated with P4HB scaffold for more than fifteen years. Only after the completion of a 
series of in vitro biomechanical and biocompatibility characterizations [35,56,57,62,63], the 
preliminary in vivo animal studies were performed [71–74]. It also highlighted the importance of 
focusing on certain promising scaffolds to keep optimizing their properties (scaffold architecture, 
biomechanics, biodegradability) and processing techniques (fast production rate, uniformity 
between batches, accuracy in micro- to nano-meter level structure) before the successful clinical 
translation of the tissue-engineered constructs. 
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1.5 SUMMARY AND FUTURE PROSPECTS 
Recent literature suggests that the scaffold architecture including multi-scale (nano-, micro- to 
macro-scale) hierarchy and anisotropy, mechanical properties, degradation profile and 
biocompatibility are the key factors that will determine the success of functional tissue 
engineering strategies to repair, restore or replace the damaged heart valves. For mechanical 
properties, biodegradable elastomers are specifically suitable for HVTE, where the mechanically 
dynamic in vivo microenvironment demands recreation of compliant and elastic tissue-
engineered constructs. Researchers now appreciate the importance of multiple mechanical testing 
at different scales and aspects in determining the fate of tissue-engineered scaffolds. Another 
challenge in the field is limited data and lack of consensus on the most appropriate degradation 
profile of tissue-engineered scaffold. Therefore, tissue-engineered constructs should be tested 
empirically in specific in vivo settings. Elastomers with wide range of tunable degradation 
profiles are usually favored to provide flexibility in controlling the degradation rates. Current 
research has broadened the definition of biocompatibility beyond cytotoxicity and inertness. Any 
immune response or thrombogenicity events might cause systematic adverse effects and can even 
be life-threatening. Furthermore, the state-of-the-art tissue engineering has already shifted from 
developing bio-inert and safe materials towards bioactive materials, which can instruct cellular 
behavior and tissue regeneration while mitigating the biocompatibility concerns simultaneously. 
Overall, the future research directions in HVTE scaffolds are to rationally design biodegradable, 
biomimetic and bioactive heart valves by taking these aspects into consideration. Long-term 
safety and efficacy study of promising tissue-engineered constructs made of promising 
elastomers is needed to ultimately move the potential scaffolds forward to the clinical setting. 
More importantly, multidisciplinary approaches with scientists in materials science, tissue 
 28 
engineering, valve biology, and valve mechanics working side by side will be instrumental to 
realize the true clinical translation and huge potential of tissue-engineered heart valves. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
2.1 BACKGROUND 
 
The huge challenges and unmet needs in managing valvular heart diseases motivate us to 
innovate heart valve tissue engineering strategy. In this dissertation, I aim to apply micro- and 
nanotechnology-based strategies to directly address several prominent yet unsolved issues in the 
design of tissue engineered heart valve such as architectural and mechanical mismatch, 
thrombogenicity, and calcification.  
Micro- and nanotechnology refer to an array of techniques used for the fabrication of 
materials with micron and nanoscale features, respectively [141]. The past decades have 
witnessed the exponential growth in micro- and nanotechnologies as promising tools to address 
the challenges in tissue engineering and drug delivery [142]. Fine control over the micro- and 
nanoscale structural features of biomaterials can be used to resemble the microenvironment of 
native tissues and modulate their bioactivity [143]. In this dissertation, I aim to engineer 
biocompatible nanocomposite scaffolds made from synthetic biodegradable elastomers and 
bioactive cerium oxide nanoparticles (CNPs) to mimic the anisotropic architecture and 
mechanical properties of the native valves as well as mitigate the thrombogenicity and 
calcification tendency of the current valve substitutes.  
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2.1.1 ECM-mimetic micro-/nanofibrous scaffolds    
Every tissue in the body is composed of fibrous extracellular matrix (ECM) made of proteins and 
glycoproteins that act as substrate to host the cells and signaling molecules [144]. Therefore, 
micro-/nanofibrous scaffolds have gained increasing attention because of their unique properties 
to interface with cells at the same scale as native ECM [145]. The smaller size of the fibers 
results in the high surface area and porosity, which support and facilitate cell attachment and 
spreading, and transport of nutrients and waste [142].  
Micro-/nanofibrous scaffolds can be engineered to mimic one or multiple structural and 
functional roles of the ECM by different fabrication methods including self-assembly, phase 
separation, and fiber spinning [144]. Among all, electrospinning has gained immense interests 
due to its facile setup and operation, versatility, and controllability. So far, electrospinning is one 
of the most common micro-/nanofiber fabrication methods and has been used with a wide variety 
of synthetic polymers and biopolymers [146].  
Generally, a basic electrospinning setup consists of a polymer source (or sources), a high 
voltage supply, and a grounded collector. The solution is loaded in a reservoir where high 
voltage is applied. If the electric potential is high enough to overcome the surface tension, a jet 
of solution will be pulled out towards the collector. During this process, the solvent is being 
evaporated and whipping instability produces the accumulation of fiber meshes [147]. Overall, 
the fiber diameter can be engineered ranging from 50-2000 nm, with pore size from 2-465 μm, 
and porosity up to 90% [148]. These structural features can be fine-tuned by the optimization of 
an array of electrospinning parameters such as solvent composition, the concentration of polymer 
solution, the collector, applied voltage, spinneret-to-collector distance, and polymer flow rate 
[146].  
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Although standard electrospinning often yields random-oriented fibers, electrospinning 
process also allows control over fiber alignment/orientation resulting in properties that are 
direction-dependent (anisotropy). These scaffolds are of greater interest in soft tissue engineering 
because many native tissues such as valve leaflets have anisotropic ECM structure. One method 
to induce fiber alignment in electrospun scaffolds is by a rotating drum collector. The fiber 
anisotropy can be controlled by rotating speed of the collector [102, 149, 150]. Alternatively, 
fiber alignment could be controlled using a system with differentially grounded pairs of 
electrodes [151-153]. In this way, different rosette patterns of fibers were generated in a layer-
by-layer manner by varying the state of the electrodes (grounded or not).  
In this dissertation, I will design and test a valve leaflet-inspired electrospinning collector 
to obtain anisotropic fibrous scaffolds. In addition, I propose to electrospin a novel series of 
polyethylene glycol (PEG) functionalized (PEGylated) biodegradable elastomers to serve two 
goals: 1) to tune the elastomeric mechanical properties to mimic those of the native valves, and 
2) to incorporate PEG moiety in polymer backbone to mitigate thrombogenicity.  
2.1.2 CNPs as a potential therapy to mitigate valve calcification  
Valve calcification remains a major healthcare burden in developed countries, resulting in 
~17,000 deaths per year in the United States and currently affecting a quarter of the senior 
population older than 65 [1]. Calcification of the aortic valve, if not treated properly, can impair 
the normal valve movement and eventually lead to valve stenosis and heart failure. Of the 
different mechanisms of valve calcification, oxidative stress has been recognized as a key 
upstream driving force in the early stages of the disease [154] . Increased reactive oxygen species 
(ROS) such as superoxide and hydrogen peroxide (H2O2) levels were found in the calcified 
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regions of human stenotic valve tissues [155]. Moreover, instead of being merely a consequence 
of valve calcification progression, ROS production was found to precede the valve calcification 
in a mice model [156]. However, the benefits of antioxidant therapies, which directly target 
oxidative stress to treat valve calcification, are yet to be studied.  
Nanomedicine is a promising strategy to improve physiochemical properties, enhance 
therapeutic efficacy and reduce systemic toxicity of carriers and payloads. Because of their small 
size, nanoparticles can enter the cells and are considered as valuable biomedical tools for 
different therapeutic applications [157]. However, to the best of our knowledge, there is no 
nanoparticle-based therapy reported for treating valvular heart diseases. Here, I focus on CNPs, 
which have shown multiple therapeutic applications such as treating neurodegenerative diseases 
[158], diabetes [159], ocular diseases [160], and other oxidative stress-related diseases [161]. 
CNPs also possess good safety profiles as demonstrated in multiple animal models [162, 163]. 
 CNPs have been historically utilized in corrosion protection coatings for metal alloys 
[164] and fuel cell oxidation catalysis [165]. In the bulk state, cerium oxide can exist as pure 
CeO2 (Ce4+) or Ce2O3 (Ce3+), whereas at the nanoscale, cerium oxide crystal structure comprises 
both Ce3+ and Ce4+ oxidation states [162]. Oxygen vacancies are developed as a result of the 
presence of Ce3+ ions in the crystal lattice as the particle size of cerium oxide is reduced. These 
oxygen vacancies are responsible for the important catalytic activity of CNPs, allowing them to 
switch between Ce3+ and Ce4+ oxidation states. This activity enables the self-regenerative 
properties of CNPs. Recently, the biomedical field has focused on utilizing the unique catalytic 
activities of CNPs for mimicking the antioxidant properties of enzymes such as superoxide 
dismutase (SOD) and catalase (CAT) [166, 167]. CNPs are also effective scavengers for 
hydroxyl radical, nitric oxide radical, and peroxynitrite, making them broad spectrum 
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antioxidants. Since oxidative stress is one of the main inducers and driving factors of valve 
calcification, I propose that CNP encapsulation in the nanocomposite scaffolds as a strategy to 
mitigate valve calcification.  
It is well known that nanoparticle shapes and sizes can have significant effects on their 
biological activities, such as cellular uptake, intracellular localization, and therapeutic activity 
[168, 169]. However, most of the studies that use CNPs as antioxidants have been carried out 
without specifying nanoparticle shape. I will investigate the effect of CNPs shape on mitigating 
oxidative stress in this dissertation since this has not been well elucidated before. 
2.2 CENTRAL HYPOTHESIS & SPECIFIC AIMS 
The central hypothesis of this dissertation is: a nanocomposite fibrous scaffold combining 
PEGylated elastomers and CNPs will recreate a suitable microenvironment to recapitulate the 
anisotropic mechanical properties of the heart valve with reduced thrombogenicity and 
calcification tendency.  
 To test this hypothesis, three specific aims are proposed:  
Aim 1 will develop fibrous scaffolds of PEGylated elastomers, which mimic the 
anisotropic mechanical properties of the heart valve and possess less thrombogenicity. This aim 
is further divided into three sub-aims:  
Sub-aim 1.1: Synthesis and characterization of a novel series of biodegradable PEGylated 
elastomers (reported in chapter 3 of this dissertation).  
Sub-aim 1.2: Fabrication and characterization of the fibrous scaffolds of PEGylated 
elastomers (reported in chapter 4).  
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Sub-aim 1.3: Fabrication and biaxial mechanical characterization of anisotropic fibrous 
scaffolds (as reported in chapter 5).  
Aim 2 will develop shape-specific CNPs to inhibit calcification of human valvular 
interstitial cells (hVICs), as reported in chapter 6. Two sub-aims are further proposed: 
Sub-aim 2.1: Development and characterization of oxidative stress-mediated VIC 
calcification model.  
Sub-aim 2.2: Evaluation of efficacy of antioxidant CNPs in inhibiting oxidative stress-
induced VIC calcification in vitro. 
Aim 3 will develop PEGylated elastomer-CNPs nanocomposite fibrous scaffolds with 
reduced calcification tendency, as reported in chapter 7.  
The successful completion of these studies will not only create technologies that can be 
interfaced to mitigate the current challenges of mechanical mismatch, thrombogenicity and 
calcification in the valve replacement therapies, but also offer an opportunity to fine tune the 
physico-chemical, mechanical, and biological properties of a variety of tissue engineered 
scaffolds.  
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3.0  SYNTHESIS AND CHARACTERIZATION OF A NOVEL SERIES OF 
BIODEGRADABLE PEGYLATED ELASTOMERS 
[Xue Y, Patel A, Sant V, and Sant S. (2015) European Polymer Journal 72. 163–179.] 
3.1 BACKGROUND 
There is a growing interest in developing novel biocompatible and biodegradable materials for 
multiple biomedical applications such as tissue engineering and drug delivery [22, 28, 145]. For 
successful regeneration of soft and mechanically demanding tissues like heart valves and 
myocardium, it is important that tissue engineered scaffolds 1) are biodegradable and promote 
cell growth and tissue regeneration; 2) have tunable mechanical and degradation properties to 
match the regeneration/healing rate of the target tissue; and 3) endure the dynamic in vivo 
microenvironment and mechanically mimic the native extracellular matrix (ECM) to maintain 
tissue integrity. Biodegradable synthetic elastomers stand out as one of the most promising 
materials for soft tissue engineering because of their tunable mechanical compliance, 
biodegradation rates and excellent biocompatibility [23, 170]. Previous research has focused on 
thermoplastic polymer/elastomers such as polyurethanes (PU), poly (lactic acid) (PLA), poly 
(glycolic acid) (PGA), poly (ε-caprolactone) (PCL) and their block copolymers [171, 172]. 
Although crystalline segments in the structures of these thermoplastic elastomers provide 
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mechanical strength, they resist degradation [28, 173]. Therefore, these materials suffer from 
heterogeneous degradation profiles and demonstrate non-linear loss of mechanical strength 
during degradation [174]. Such degradation profile is usually not preferred in tissue engineering 
applications because it may lead to sudden mechanical failure of the scaffold before substantial 
degradation and tissue regeneration [174]. 
Recent years witnessed significant advances in the development of biodegradable 
thermoset elastomers. Poly (glycerol sebacate) (PGS) is a benchmark polymer in this class and 
has been extensively studied for its synthesis and fabrication [82, 175, 176], biocompatibility 
[83, 177], degradation [178], and tissue engineering applications [87, 88, 179-181]. Rapid in vivo 
degradation rates of PGS limits its potential use for applications in regeneration of tissues that 
regenerate slowly. To circumvent this limitation, poly (1,3-diamino-2-hydroxypropane-co-polyol 
sebacate) (APS) elastomers were synthesized by incorporating amide bonds in the PGS backbone 
to reduce the in vivo degradation rate [182, 183]. APS elastomers possess tunable degradability 
and mechanical properties, as well as excellent in vitro and in vivo biocompatibility [182, 183]. 
Airway stents made from APS via microfabrication method have shown good biocompatibility 
[184]. However, due to their poor solubility in common organic/aqueous solvents, APS 
elastomers are amenable only to few fabrication methods, such as thermally cured films or 
microfabrication. Moreover, the poor solubility of APS pre-polymer restricts further chemical 
modification to fine-tune the physicochemical properties. Importantly, altering the selection of 
polyols, monomer ratio, and curing conditions of APS elastomers has provided a relatively 
narrow range of elastic modulus (0.56-4.34 MPa) and tensile strength (0.24-1.69 MPa) [183]. 
Thus, it is worthwhile to broaden the spectrum of physicochemical, mechanical, and degradation 
properties of APS by chemical modification. 
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Polyethylene glycol (PEG) is a biocompatible, hydrophilic polyether that has been widely 
applied in drug delivery [185]. A wide range of thermoplastics including PLA, PCL, and 
poly(lactic-co-glycolic acid) (PLGA) have been copolymerized with PEG to tune their physical 
properties [186], drug loading capacity [187], drug release kinetics [188, 189], and improve their 
biocompatibility [190, 191]. Of note, thermoset PGS elastomers have recently been 
copolymerized with PEG to obtain PGS-co-PEG polymers to improve hydration and enhance the 
utility for biomedical applications [192].  
  We hypothesize that incorporation of PEG into the APS structure will yield poly (1,3-
diamino-2-hydroxypropane-co-glycerol sebacate)-co-poly (ethylene glycol) (APS-co-PEG) 
copolymers with tunable physicochemical, mechanical, and degradation properties. This will 
expand the repertoire and property spectrum of currently available elastomers for biomedical 
applications. Here, we report the synthesis and characterization of a series of APS-co-PEG 
polymers with varying PEG mole % ranging from 10-40% of sebacic acid (SA) and PEG 
molecular weight ranging from 400Da to 4kDa. 
3.2 METHODS 
3.2.1 Polymer synthesis 
Sebacic acid (SA), glycerol (G) and 1,3-diamino-2-hydroxy-propane (DAHP) were purchased 
from Sigma-Aldrich. The APS pre-polymer was synthesized according to the previously 
published method of the polycondensation reaction of DAHP, G and SA [175]. Briefly, a round 
bottom flask was charged with a molar ratio of 2:1:3 of DAHP: G: SA monomer mixture. The 
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reactants were heated under argon atmosphere at 120 °C for 3 h. Approximately 300 mTorr 
vacuum was applied to the reaction system and the reaction continued for another 9 h at 120°C to 
obtain APS pre-polymer. The pre-polymer samples were characterized for their chemical 
composition. 
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Figure 1. The synthesis scheme of APS-co-PEG elastomers.  
Nomenclature of APS-co-PEG: APS-xPEGy, where “x” represents the PEG/Sebacic acid molar 
ratios (15%, 25%, 40%) and y represents the PEG molecular weight (400, 1000, 2000, 4000). 
The molar ratio between glycerol and DAHP is constantly 0.5.  
 
The synthesis of APS-co-PEG is shown in Fig. 1. Briefly, APS-co-PEG pre-polymers 
were synthesized via a one-pot two-step condensation polymerization. The first step is the 
polycondensation between SA and PEG. The mixture was heated in a round bottom flask at 
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130°C under Argon atmosphere for 2 h and the reaction was continued at 120°C under reduced 
pressure of 300 mTorr for 24, 48 or 72 h to optimize the time of the first reaction. In the second 
step, specific amounts of G and DAHP (Table 5 and 6) were added into the round bottom flask 
and mixed thoroughly with the reactants. The reaction was stirred at 120°C under Argon 
atmosphere for 30 min and continued at 120°C under the reduced pressure of 300 mTorr for 12 
or 48 h to obtain APS-co-PEG pre-polymers. The pre-polymers obtained were subjected to 
chemical and thermal characterization.  
 
Table 5. Effect of PEG molar ratio on the molecular weight of APS-co-PEG pre-polymers 
 
 
Table 6. Effect of PEG molecular weight on the molecular weight of APS-co-PEG pre-
polymers. 
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The effect of first and second step reaction time and monomer feeding ratio on the 
molecular weight and polydispersity of APS-40PEG1K pre-polymer were explored to optimize 
the reaction conditions. The optimized reaction time and monomer feeding ratio were then used 
to synthesize a library of APS-co-PEG pre-polymers by varying mole percentage of PEG to SA 
(15%, 25% or 40%) and molecular weights of PEG (400Da, 1kDa, 2kDa, 4kDa). The pre-
polymers were denoted as APS-xPEGy, where x represents the PEG to SA mole percentage and 
y represents the PEG molecular weight. The detailed molar ratios of the reactants in various pre-
polymers can be found in Table 5 and 6. Product yield: 61.4-72.6%.  
3.2.2 Polymer film fabrication by thermal crosslinking 
APS pre-polymer was uniformly spread on a Teflon dish and thermally cured at 170°C for 72 h 
in a vacuum oven to fabricate the APS polymer film. The thickness of the film was around 
1.5mm. Similarly, the APS-co-PEG pre-polymer was spread on a Teflon dish and thermally 
cured at 170°C for 24, 48 or 72 h in a vacuum oven. The thickness of films was kept constant 
around 1.5mm. 
3.2.3 Proton nuclear magnetic resonance (1H-NMR) 
The synthesized APS-co-PEG pre-polymers were analyzed using nuclear magnetic resonance 
(1H-NMR) spectroscopy (Bruker 400). SA and PEG were dissolved in DMSO-d6 and the pre-
polymer samples were dissolved in CDCl3 and the spectra were recorded at 400 MHz. 1H-NMR 
(400 MHz, CDCl3, δ/ppm): 1.30 (m,-CH2-), 1.62 (m,-CH2CH2O(CO)-), 2.35 (m,-CH2O(CO)-), 
3.64 (m,-OCH2CH2O-), 3.72 (m,-NCH2CHOHCH2N-), 4.22 (m,-OCH2CHOHCH2O-). The 
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peak assignments in the 1H-NMR spectra for APS-co-PEG pre-polymers are also denoted in Fig. 
2a. To calculate the PEG:SA ratio, peaks of methylene hydrogen within PEG (3.65 ppm) and SA 
(the combination of 1.30, 1.62, and 2.35 ppm) in 1H-NMR spectra were integrated using 
TopSpin software.  
3.2.4 Fourier-transform infrared spectroscopy (FTIR) 
Chemical composition of the pre-polymers was studied using Fourier Transform Infrared (FTIR) 
spectroscopy with attenuated total reflection (ATR-FTIR). The FTIR spectra were recorded in 
absorption mode with a resolution of 4 cm-1 using Bruker Vertex 70 FTIR spectrometer. The 
results are presented as an average of 256 scans. Ester, amide I and amide II peaks intensity were 
integrated for semi-quantitative analysis using Origin8 software. 
3.2.5 Differential scanning calorimetry (DSC) analysis 
Differential Scanning Calorimeter (DSC, Mettler Toledo) was utilized to study the thermal 
properties of APS-co-PEG pre-polymers. Sample (approx. 5 mg) was sealed in an aluminum pan 
and first heated from room temperature to 150°C (1st cycle), then cooled to −70°C (2nd cycle), 
and finally reheated to 150°C (3rd cycle) at a heating/cooling rate of 10°C/min. All the processes 
were carried out under nitrogen atmosphere. Crystallization temperature (Tc) and enthalpy (∆Hc) 
were obtained from the cooling cycle (150°C to -70°C, 2nd cycle) whereas glass transition 
temperature (Tg), melting temperature (Tm) and enthalpy (∆Hm) were obtained from the heating 
cycle (-70°C to 150°C, 3rd cycle). DSC data was analyzed using STARe software. 
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3.2.6 Uniaxial tensile testing 
The mechanical properties of APS and APS-co-PEG polymer films were evaluated using 
uniaxial tensile testing with ADMET MTEST Quattro mechanical testing system (n=4). 
Thermally crosslinked polymer films were cut into rectangular shape (10 mm* 7 mm). Samples 
were stretched until failure at a constant jogging speed of 10 mm/min. The stress (MPa) was 
obtained by dividing the applied force (N) with cross-section area (mm2) and % elongation 
(strain) was obtained from the displacement using ((L-L0)/L0*100), where L0 was initial gauge 
length and L was instantaneous gauge length. Ultimate tensile strength (UTS) was recorded as 
the maximum stress at sample failure. Elastic modulus was calculated from the linear stress-
strain curve between 5 and 15% strain. 
3.2.7 Hydration and degradation study 
The hydrophilicity of thermally crosslinked polymer films was determined by contact angle 
measurements and hydration study. The contact angles of polymer films were measured using 
VCA 2000 video contact angle goniometer (AST products, n=4). A droplet of de-ionized water 
was deposited on the sample film using a 21-gauge needle and high-resolution image of the 
droplet was captured. The contact angles were determined using the VCA software.  
For hydration and degradation study, samples were cut into rectangular shape (around 
15mm*7mm) and immersed in Dulbecco’s phosphate buffer saline (DPBS, Corning) at 37 °C in 
a dry bath shaker (50 RPM) after recording their initial weight (W0) and thickness (t0) (n=3). 
Samples were taken out from the DPBS solution at regular time intervals, wiped with kimwipes 
to remove excess surface water, and vacuum dried for 10 mins. The weights (Wt) and thickness 
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(tt) of samples at time t as well as at equilibrium (Weq and teq) were recorded. The hydration of 
the polymer films was determined by Eq. (1). The degradation study was carried out for 14 days 
in DPBS at 37°C after the equilibrium hydration was achieved. The mass loss of polymer films 
during degradation was determined by Eq. (2). The decrease in thickness of the films was 
determined by Eq. (3). Degraded samples were dried in desiccator and examined by FTIR to 
study the changes in their chemical structure. Morphology of degraded films was studied by 
scanning electron microscope (SEM) imaging (JEOL 6335F Field Emission SEM). Dried films 
before and after degradation were sputter-coated with 5nm of gold-palladium using Cressington 
108 auto sputter-coater and images were obtained using accelerated voltage of 3kV and a 
working distance of 8 mm. 
Equilibrium hydration (%) = (Weq- W0)/ W0×100   Eq. (1) 
Mass loss (%) = (Weq- Wt)/ Weq×100    Eq. (2) 
Decrease in thickness (%)= (teq- tt)/ teq×100    Eq. (3) 
3.2.8 In vitro biocompatibility by alamarBlue® assay 
The mouse myoblast cells (C2C12) ATCC (CRL-1772™) were obtained from Dr. Adam 
Feinberg’s lab (Carnegie Mellon University, Pittsburgh, PA). The cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Corning Cellgro) supplemented with 10% Fetal 
Bovine Serum (FBS, Hyclone, Thermofisher Scientific) and 1% Penicillin/Streptomycin 
(Corning Cellgro).  Cells in passage 2-7 were used. The films (0.5 cm x 0.5 cm) were sterilized 
by exposing to 70% isopropanol under UV light for 30 min, washed with DPBS thrice and 
seeded with C2C12 cells using a seeding density of 50,000 cells/scaffold. Cells were allowed to 
adhere for 40 min and then 500µL of medium was added. After 24 hours, all films were 
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transferred to new wells and the proliferation rate of adhered cells on day 1 and 3 was assessed 
using an alamarBlue® assay (Invitrogen) following the standard protocol. Briefly, cell-seeded 
scaffolds (n=3) were treated with 10% alamarBlue® in growth media for 3.5 h at 37°C. The 
fluorescence intensity was then measured using microplate reader (Gen5 Biotek) at 
excitation/emission wavelengths of 530/590 nm. AlamarBlue® solution (10%) incubated without 
any cells were used for blank correction.  
The films seeded with C2C12 cells were fixed in 4% paraformaldehyde solution (20 min) 
after 3 days in culture to study cell adhesion and spreading. The films were then washed with 
DPBS three times, followed by permeablization and blocking using 0.1% Triton X-100 and 3% 
bovine serum albumin (BSA) in DPBS, respectively. Cell nuclei and actin were stained using 
NucBlue® Fixed Cell Stain (Life Technologies) and ActinGreen™ 488 ReadyProbes® Reagent 
(Life Technologies), respectively. To eliminate the strong autofluorescence of APS and APS-co-
PEG polymers, samples were treated with Sudan Black [193]. Briefly, 0.3% (w/v) Sudan Black 
solution was prepared in 70% ethanol and filtered through 0.45 μm syringe filter. Polymer films 
were immersed in this solution for 24 h and washed three times before imaging. Confocal images 
were obtained using inverted confocal laser scanning microscope (Olympus Fluoview 1000) 
under 20X and 40X objectives. 
3.2.9 Statistical analysis 
Experimental data were presented as mean ± standard deviation. Student’s paired t-test was used 
for comparisons between two groups. Statistical differences between multiple groups were 
analyzed using one-way ANOVA followed by Tukey’s post-hoc analysis. p values less than 0.05 
were considered significant. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Pre-polymer synthesis and chemical characterization 
APS-co-PEG pre-polymers were synthesized by two-step polycondensation reaction (Fig. 1). 
The synthesis conditions of APS-co-PEG pre-polymers, such as reaction time for the first and 
second step as well as monomer feeding ratio were first optimized based on the molecular weight 
characterization of APS-40PEG1K by GPC (Table 7). Among all the conditions in our trials, 
optimum durations for the 1st and 2nd step reaction to obtain low polydispersity index (PDI) 
were determined to be 48 h and 12 h, respectively. It is well known that the monomer feeding 
ratio plays an important role in determining the MW of final product during step polymerization 
[194]. As DAHP and G both have three functional groups, we also synthesized a batch with 
SA:G:DAHP:PEG molar ratio of 3:0.4:0.8:1.2, in which case, all free hydroxyl groups are 
expected to react with carboxylic groups of SA (stoichiometry balance, denoted as APS-
40PEG1K STOIC). As expected, an increase in molecular weight was observed for APS-
40PEG1K STOIC due to the strict stoichiometry (Table 7). However, the mechanical properties 
of the polymeric film were adversely affected (data discussed in the mechanical properties 
section). The decrease in the mechanical properties of APS-40PEG1K STOIC films was 
attributed to the unavailability of free hydroxyl groups required for crosslinking of polymeric 
chains during the thermal crosslinking step. Therefore, this monomer feeding ratio was not 
adopted for further experiments.  
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Table 7. Molecular weight of APS-40PEG1K pre-polymers under different reaction condition. 
 
 
APS-40PEG1K (SA:G:DAHP:PEG molar ratio of 3:0.6:1.2:1.2) synthesized under 
optimal conditions was subjected to chemical characterization by 1H-NMR and FTIR. 1H-NMR 
characterization of the first step reaction product exhibited a new peak at 4.2 ppm (Fig. 2a) 
corresponding to the αH adjacent to the ester bond, indicating the formation of new ester bonds 
and a successful reaction between SA and PEG. In addition, the methylene hydrogen peaks of 
SA were present at 1.30, 1.62, and 2.35 ppm, and that of PEG at ppm and 3.65 ppm, 
respectively. In the second step, G and DAHP were added to obtain APS-co-PEG pre-polymer. 
The 1H-NMR spectrum of the copolymer APS-40PEG1K after completion of 2nd step did not 
show any peaks from the monomers G or DAHP (Fig. 2a). Instead, due to the ester and amide 
bond formation, the αH in glycerol shifted from 3.5-3.7 ppm to 4.2 ppm and that in DAHP 
shifted from 2.5-2.7 ppm to 3.72 ppm. Taken together, these results indicated successful 
completion of the reaction. The actual mole % of PEG calculated from 1H-NMR by comparing 
methylene hydrogen within PEG and SA correlated well with the theoretical mole %, indicating 
good control over the polymer synthesis process (Table 5). 
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Figure 2. The chemical characterization of APS-co-PEG elastomers by H-NMR and FTIR. 
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(a). H-NMR spectra of DAHP, glycerol and APS-40PEG1K pre-polymer. Peaks assignment for 
APS-15PEG1K are shown as a representative for APS-co-PEG pre-polymers. First step product 
had the peak at 4.2ppm (pointed by the arrow), which was the peak of αH beside the newly 
formed ester bond. The αH in G and DAHP has shifted from 3.5-3.7 ppm and 2.5-2.7 ppm to 
4.20 ppm and 3.72 ppm, respectively. 
 
The FTIR spectra of APS-40PEG1K pre-polymer, APS pre-polymer and PEG further 
demonstrated successful completion of the reaction (Fig. 2b). Of note, the carbonyl peak (1730 
cm-1) observed in the spectra of APS and APS-40PEG1K indicated the formation of ester bonds 
between SA and G/PEG while amide (1646 and 1552 cm-1) peaks indicated bonds between SA 
and DAHP in the pre-polymer chains. In addition, the intensity ratios of the amide I (1646 cm-1) 
to carbonyl peak of ester bond (1730 cm-1) and amide II (1552 cm-1) to carbonyl peak of ester 
bond (1730 cm-1) were lower in the FTIR spectrum of APS-40PEG1K than the corresponding 
ratios observed in the spectrum of APS (Fig. 2c). This is due to the reduced amide bond 
formation in APS-co-PEG pre-polymer than that in APS and may be attributed to the reduced 
SA: DAHP ratio with addition of PEG (Table 5). The increase in ester bond formation with 
addition of PEG also suggested that PEG was covalently bonded to SA and not physically 
blended in the copolymer structure. In addition, peaks at 1100, 1464 and 1343 cm-1 characteristic 
of C-O-C stretching and C-H bending peaks of PEG [187, 195] were observed in the spectrum of 
APS-40PEG1K pre-polymer, but not in the APS pre-polymer spectrum (Fig. 2b). Taken 
together, these data indicated successful covalent linkage of PEG to APS backbone. 
Based on the optimized reaction conditions, we synthesized a series of APS-co-PEG pre-
polymers by changing PEG mole % (15, 25 and 40% of PEG1K) and PEG molecular weight 
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(400Da, 1kDa, 2kDa and 4kDa at 25% PEG) to tune the physicochemical, mechanical and 
degradation properties of the copolymer. These polymers were labeled as APS-15PEG1K, APS-
25PEG1K, APS-40PEG1K (Table 5), and APS-25PEG400, APS-25PEG2K, and APS-
25PEG4K (Table 6). Indeed, compared to the poor solubility of APS in major solvents (only 
soluble in 1,1,1,3,3,3-hexafluoroisopropanol, HFIP), APS-co-PEG pre-polymers exhibited 
increased hydrophilic nature and could be dissolved in commonly used solvents such as 
chloroform and ethanol (Table 8). For instance, APS solubility was less than 5mg/ml in ethanol 
and chloroform, while APS-co-PEG solubility was more than 200mg/ml in both solvents. The 
increased copolymer solubility allowed for their chemical characterization by NMR spectroscopy 
and GPC and potentially increased the processability of the pre-polymer. 
Table 8. Solubility of APS-co-PEG pre-polymers in different solvents (mg/ml). 
 
 
The effect of PEG mole % on the chemical properties of APS-co-PEG pre-polymers is 
shown in Fig. 3. Mw /PDI and actual PEG molar percentage for each pre-polymer are listed in 
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Table 5. Molecular weight of APS-co-PEG pre-polymers increased with the increase in PEG 
mole %. This trend is in accordance with that observed for PGS-co-PEG pre-polymers, where 
pre-polymer molecular weight also increased with PEG mole % [192]. In all batches, the actual 
mole % of PEG from NMR correlated well with the theoretical estimation (Table 5), indicating 
good control over the polymer synthesis process. As expected, the intensity ratio of the amide I 
to carbonyl peak (1646/1730 cm-1) and Amide II to carbonyl peak of ester bond (1552/1730 cm-
1) decreased with increasing PEG mole % in the pre-polymer (Fig. 3 b and c). With the increase 
in PEG mole %, intensity of C-O-C stretching peak (1110 cm-1) and C-H bending peaks (1464 & 
1343 cm-1) of PEG also increased, indicating increased amount of PEG segments in the 
copolymer chains (Fig. 3 b).  
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Figure 3. The chemical characterization of APS-15PEG1K, APS-25PEG1K, APS-40PEG1K 
pre-polymers. 
(a) H-NMR spectra APS-15PEG1K, APS-25PEG1K, APS-40PEG1K pre-polymers. (b) FTIR 
spectra APS-15PEG1K, APS-25PEG1K, APS-40PEG1K pre-polymers. (c) Decrease in bond 
intensity ratio of amide peaks I/II (1646/1552 cm-1) to ester peak (1730 cm-1) suggests 
decreased amide formation due to reduced DAHP molar ratio to SA and increased ester 
formation due to PEG incorporation into APS backbone. 
 
The effect of PEG molecular weight on the chemical properties of APS-co-PEG pre-
polymers is summarized in Table 6 and Fig. 4. Their analyses are similar to those obtained from 
Table 5 and Fig. 3. Briefly, the effect of increasing PEG molecular weight was similar to that of   
increasing PEG mole % and led to a predominant increase in intensity of C-O-C stretching peak 
(1110 cm-1) and C-H bending peaks (1464 & 1343 cm-1) of PEG, indicating increased amount of 
PEG segments in the co-polymer chains. 
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Figure 4. The chemical characterization of APS-25PEG400, APS-25PEG1K, APS-25PEG2k, 
APS-25PEG4k pre-polymers. 
(a) H-NMR spectra of APS-25PEG400, APS-25PEG1K, APS-25PEG2k, APS-25PEG4k pre-
polymers. (b) FT-IR spectra of APS-25PEG400, APS-25PEG1K, APS-25PEG2k, APS-
25PEG4k pre-polymers 
 
DSC was used to examine the thermal properties of APS-co-PEG pre-polymers. Ideal 
elastomers for biomedical applications should have a Tg lower than body temperature to ensure 
that the elastomeric properties could be exhibited in vivo [28]. PEG is a known a semi-crystalline 
polymer with different degree of crystallinity determined by molecular weight [196, 197] while 
APS is determined to be amorphous [182]. Therefore, it is worthwhile to interrogate the effect of 
PEG incorporation on the thermal properties of newly synthesized polymers. In this study, the 
samples were first heated to 150°C to eliminate thermal history. The cooling cycle (from 150°C 
to -70°C) was used to obtain Tc and ∆Hc while the second heating cycle (-70°C to 150°C) was 
used to obtain Tg, Tm and ∆Hm.  
 The effect of PEG mole % on the thermal properties of APS-co-PEG pre-polymers is 
summarized in Fig. 5. Similar to APS pre-polymer, APS-15PEG1K did not show any 
crystallization peak. Increase in the PEG concentration to 25% resulted in the appearance of 
crystallization peak at -28.37°C. With further increase in PEG concentration to 40%, Tc shifted to 
higher temperatures and higher ∆Hc indicated improved crystallization capacity. Previously, Li et 
al. reported that decreasing the content of rigid segments in poly (ester urethane) elastomers 
increased the chain flexibility and improved the crystallization capacity of the elastomer [198]. 
Similarly, improved crystallization was observed in APS-co-PEG copolymers containing higher 
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than 15 mole % PEG and could be attributed to the increased crystalline PEG segments and 
increased chain flexibility resulting from incorporation of PEG segments. The Tg of APS was 
determined to be 5.98°C (Fig. 5b and c). APS-15PEG1K and APS-25PEG1K were observed to 
have much lower Tg of -33.29°C and -39.09°C, respectively. The Tg of APS-40PEG1K cannot be 
clearly identified in the temperature range studied here. Decrease in Tg with increase in PEG 
mole% may be due to enhanced polymer chain flexibility by a higher number of PEG segments 
in the copolymer chain [194]. This also suggests that PEG exhibits its plasticizer effect on the 
copolymer chains. Low Tg (below body temperature) promises the application of these 
elastomers in tissue engineering. Also, higher Tm and ∆Hm were observed with the increase in the 
PEG mole%. This observation was in agreement with the previous thermal study on PCL-PEG, 
where increasing content of PEG resulted in higher Tm and stronger melting peaks [187]. It also 
indicated that the crystallization tendency as well as the degree of crystallization was higher in 
APS-co-PEG pre-polymers with higher PEG content [197].  
 
Figure 5. Effect of PEG molar ratio on the thermal properties of APS-co-PEG pre-polymers. 
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(a) DSC curves of the cooling cycle (2nd) of APS-co-PEG pre-polymers, (b) DSC curves of the 
heating cycle (3rd) of APS-co-PEG pre-polymers, (c) Summary of the thermal properties of 
APS-co-PEG pre-polymers. 
 
The effect of PEG molecular weight on the thermal properties of APS-co-PEG pre-
polymers with 25 mole % PEG is summarized in Fig. 6. APS-25PEG400, which has the lowest 
PEG MW (400Da), did not show melting/crystallization peaks. Increasing PEG MW to 1000, 
2000, and 4000Da resulted in a dramatic shift in crystallization peaks to higher temperatures of -
28.37, 20.57 and 23.89°C, respectively with simultaneous increase in ∆Hc. A similar effect was 
observed for Tm and ∆Hm (Fig. 6b and 6c). These results correlated well with the published 
results that PEG of higher molecular weight (either alone or in a copolymer network) resulted in 
higher Tm and ∆Hm [187, 197].  In summary, addition of PEG (at high mole % or higher MW) 
resulted in increased crystallinity of the copolymer thereby increasing crystallization enthalpies 
(Fig. 5c and 6c). A similar trend was observed ∆Hm also suggesting an increased mobility of 
copolymer chains in the presence of PEG. 
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Figure 6. Effect of PEG molecular weight on the thermal properties of APS-co-PEG pre-
polymers.  
(a) DSC curves of the cooling cycle (2nd) of APS-co-PEG pre-polymers, (b) DSC curves of the 
heating cycle (3rd) of APS-co-PEG pre-polymers, (c) Summary of the thermal properties of 
APS-co-PEG pre-polymers. 
 
3.3.2 Chemical properties of APS-co-PEG films 
The synthesized APS-co-PEG pre-polymers were subsequently fabricated into elastomer films 
by thermal crosslinking. In this study, pre-polymers were thermally cured under vacuum for 24 h 
to 72 h. Unfortunately, APS-co-PEG pre-polymers containing longer PEG chains (APS-
25PEG2K and APS-25PEG4K) cannot be fabricated into polymer films even after 96 h of curing 
at a temperature of 170°C. It suggests that longer PEG chains may have impeded crosslinking 
between hydroxyl and carboxylic groups due to steric hindrance created by the long polyether 
chains. This problem could potentially be overcome by increasing the mole fraction of G or 
DAHP. All other APS-co-PEG pre-polymer series, once cured, could not be dissolved in any 
solvents and did not flow upon heating, indicating successful thermal crosslinking. The 
crosslinking process was also confirmed by comparing the FTIR spectra of the pre-polymer and 
cured film samples. Of note, the intensity ratios of the amide I to carbonyl peak of ester bond 
(1646/1730 cm-1) and amide II to carbonyl peak (1552/1730 cm-1) were lower in spectrum of 
cured elastomer than those of the pre-polymers (Fig. 7), indicating formation of new ester bonds 
in cured elastomer during the process of crosslinking as reported for cured APS films [182].  
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Figure 7. FT-IR spectra of APS-15PEG1K pre-polymer and cured elastomer.  
3.3.3 Mechanical properties of APS-co-PEG films 
It is important that the APS-co-PEG polymer films maintain their elastomeric properties after 
PEG incorporation for their application in soft tissue engineering. It is also envisioned that 
different PEG ratios could widely tune the mechanical properties to broaden the narrow property 
spectrum of APS. Earlier reports have shown that the monomer feeding ratio, curing time, and 
curing temperature all play a role in determining the mechanical properties of polymeric 
materials [82, 83, 199]. APS-co-PEG pre-polymers could not be crosslinked at temperatures 
lower than 170 °C, hence the curing temperature was fixed at 170°C. Hence, we explored 1) 
curing time; 2) PEG mole % and molecular weight; and 3) monomer feeding ratio to tune the 
mechanical properties of APS-co-PEG pre-polymers. It was found that APS-25PEG400 and 
APS-15PEG1K could be crosslinked within 24 h, while APS-25PEG1K and APS-40PEG1K 
required 48 h and 72 h for thermal curing, respectively. Thus, pre-polymers with higher PEG 
mole % required a longer time for thermal crosslinking. This may suggest that longer PEG 
segments in the pre-polymer interfere with the crosslinking mechanism due to increased steric 
hindrance. These data are also in accordance with our observation that pre-polymers with higher 
molecular weight (PEG 2K and 4K) could not be crosslinked even after 96 h of thermal curing.  
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Figure 8. Mechanical properties of APS-co-PEG polymer film.  
(a)-(d) Effect of curing time on the mechanical properties of APS-co-PEG polymer film (N=4) 
Significant differences at p < 0.05 (*) compared to 24 h curing and (#) compared to 48 h curing. 
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(e)-(h) Effect of PEG ratio and stoichiometry ratio on the mechanical properties of APS-co-PEG 
polymer film (N=4). All films were thermally cured for 72h. Significant differences at p < 0.05 
(*) compared to APS, (#) compared to APS-15PEG1K, (##) compared to APS-25PEG400, (@) 
compared to APS-25PEG1K, ($) compared to APS-40PEG1K. 
 
The effect of curing time on the mechanical properties of the polymer films is 
summarized in Fig. 8 a-d. APS-15PEG1K exhibited different mechanical properties after curing 
at 12, 48, or 72 h. The crosslinking density increased with curing time, which resulted in a 
significant increase in UTS (0.17 MPa to 1.21 MPa) and elastic modulus (0.05 MPa to 2.26 
MPa), while elongation was reduced significantly from 338% to 123% (p<0.05, One-way 
ANOVA). Importantly, by only changing the curing time of the same pre-polymer, we were able 
to tune more than a 6-fold difference in UTS and 40 fold differences in elastic modulus. Similar 
trends of mechanical properties were also observed in APS-25PEG1K that was cured for 48 h 
and 72 h (Table 9). 
Table 9. Summary of the mechanical properties of APS-co-PEG polymer film (N=4). 
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The effect of PEG content and monomer feeding ratio on the mechanical properties of the 
polymer films are summarized in Fig. 8 e-h. Here, curing time for each copolymer film was 
fixed at 72 h to ensure direct comparison of different APS-co-PEG elastomers. The increase in 
PEG mole % from 15% to 40% resulted in the significant reduction in UTS (from 1.21 MPa to 
0.30 MPa) and elastic modulus (from 2.26 MPa to 0.11 MPa) (p<0.05, One-way ANOVA). This 
also led to significant increase in elongation (123 to 326%) (p<0.05, One-way ANOVA) 
suggesting the formation of more elastic and ductile films. The effect of PEG molecular weight 
on the mechanical properties of the films was assessed by comparing APS-25PEG400 with APS-
25PEG1K. APS-25PEG400 exhibited significantly higher UTS, elastic modulus, and elongation 
(p<0.05, Student’s paired t-test). As the presence of higher molecular weight PEG segments in 
APS-25PEG1K increased its degree of crystallization (Fig. 6), it was expected that the 
corresponding films should be stronger and stiffer than low molecular weight PEG containing 
pre-polymer (APS-25PEG400) [194]. However, opposite trends were observed. These results 
could be explained based on the reduced crosslinking density. It is noteworthy to mention that 
presence of higher mole % or molecular weight of PEG segments interfered with the crosslinking 
of thermally cured films, leading to reduced crosslinking density at the same thermal curing 
condition. This result was in accordance with our observation that APS-25PEG2K and APS-
25PEG4K cannot be cured due to the steric hindrance of increased PEG segments posed on the 
crosslinking process. Another possible explanation for reduced UTS and increased elongation 
with higher PEG concentration and molecular weight can be based on the plasticizer effect of 
PEG (reduced Tg observed by DSC, Figs. 5 and 6) as reported previously for chitosan films 
[200]. The addition of PEG into chitosan films resulted in reduced Tg as well as tensile stress 
along with higher elongation, which was attributed to its plasticizer effect [200]. 
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The effect of monomer feeding ratio on the mechanical properties of the films was 
assessed by comparing APS-40PEG1K and APS-40PEG1K STOIC polymer. APS-40PEG1K 
STOIC exhibited significantly weaker mechanical properties as shown in Table 9 (4 fold 
reduction in UTS). This may be attributed to the reduced availability of free hydroxyl groups (of 
G and DAHP) for crosslinking, leading to a reduced crosslinking density and consequently, 
decreased UTS and elastic modulus, however remarkably higher extensibility (more than 
1000%) (p<0.05, Student’s paired t-test). When compared to the mechanical properties of 
existing elastomers, APS-40PEG1K STOIC is among the most elastic ones, with a similar elastic 
modulus (0.02 ± 0.002 MPa) to that of human smooth muscle [201]. However, its weak 
mechanical strength may limit its biomedical application.  
In summary, these results demonstrate that the mechanical properties of APS-co-PEG 
elastomers could be carefully tuned by varying curing time, PEG ratio as well as monomer 
feeding ratio. APS-co-PEG expanded the mechanical properties of APS by increasing UTS, 
reducing elastic modulus and increasing elongation. APS-co-PEG polymers possessed much 
wider range of mechanical properties compared to the existing thermoset elastomers such as PGS 
[82], APS [182] and PGS-co-PEG [192] (Fig. 9) as evident from the comparative fold change 
(highest/lowest values). For example, APS-co-PEG series of elastomers offer 150-fold change in 
elastic modulus compared to only 40-fold change for PGS-co-PEG series. Similarly, UTS values 
for APS-co-PEG series showed 34-fold change vs only 14.9-fold change for PGS-co-PEG series. 
Such wide range of mechanical properties of APS-co-PEG elastomers and ability to further fine-
tune them by changing crosslinking time, PEG amount or MW will be useful in many 
applications in tissue engineering. 
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Figure 9. Summary of mechanical properties of PGS, APS, and APS-co-PEG polymer films.  
3.3.4 Hydration properties and physiological degradability 
Hydration and degradation studies were carried out on copolymer films cured for 72 h. 
Hydration is an important factor for tissue engineering applications because it influences the 
mechanical properties, diffusion properties, and degradation rate of the scaffolds in vivo [111, 
192, 202]. It has been shown that the addition of PEG to the hydrophobic polymer backbone 
imparts hydrophilic characteristic to block copolymers [203]. To assess the hydrophilicity of 
crosslinked polymer films, the water-in-air contact angle of the copolymer films fabricated from 
different pre-polymers was measured. Increase in amount or molecular weight of PEG in the 
copolymer chain exhibited significant decrease in contact angles (p<0.05, One-way ANOVA) 
due to the increase in hydrophilicity of the APS-co-PEG polymers (Fig. 10a). Hydration of the 
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APS-co-PEG films was then investigated by monitoring the water uptake capacity. The swelling 
study under physiological conditions (DPBS, pH 7.4) revealed that APS-25PEG400 and APS-
15PEG1K reached the equilibrium hydration on day 1, while copolymers containing higher PEG 
content (APS-25PEG1K and APS-40PEG1K) reached the equilibrium hydration on day 2. These 
data imply that increased amount of PEG chains in the copolymer films leads to delayed 
equilibrium hydration. It is possible that different crosslinking densities of APS-co-PEG may 
influence the kinetics of hydration [204]. Importantly, there was almost a 10-fold difference in 
equilibrium hydration between APS (14.0 ± 2.3%) and APS-40PEG1K (133.5 ± 3.7%) elastomer 
films (p<0.05, One-way ANOVA) (Fig. 10b). A high water uptake within a tissue-engineered 
scaffold is important to promote the mechanical deformation with minimum hysteresis under 
dynamic in vivo conditions [111, 202]. Therefore, PEG incorporation enables the tuning of 
hydration properties. 
 
Figure 10. Hydration and degradation properties of APS and APS-co-PEG polymer films.  
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(a) Water in air contact angle measurement of APS and APS-co-PEG polymer films (n=4). 
Significant differences at p < 0.05 (*) compared to APS, (#) compared to APS-25PEG400, (##) 
compared to APS-15PEG1K, (@) compared to APS-25PEG1K. (b) Equilibrium hydration of 
APS and APS-co-PEG polymer films in DPBS (n=3). Significant differences at p < 0.05 (*) 
compared to APS and (#) compared to APS-15PEG1K. (c) The percent weight loss of APS and 
APS-co-PEG polymer films in DPBS after equilibrium hydration was reached (n=3). (d) The 
percent change in thickness of APS and APS-co-PEG polymer films in DPBS after equilibrium 
hydration was reached (n=3). Significant differences at p < 0.05 (*) compared to APS, (#) 
compared to APS-25PEG400, (##) compared to APS-15PEG1K. 
 
The degradation study was conducted after each polymer film reached equilibrium 
hydration. On day 14 after equilibrium hydration, APS, APS-25PEG400, APS-15PEG1K, APS-
25PEG1K, and APS-40PEG1K polymer films exhibited 12.93 ± 0.5%, 8.33 ± 0.2%, 23.5 ± 
1.0%, 24.7 ± 1.0% and 35.2 ± 1.3% of mass loss, respectively (Fig. 10c). The increase in 
degradation rate with the PEG molar ratio was due to the increased hydrophilicity of polymer 
network, resulting in higher water uptake (Fig. 10a, b) and thus, accelerating the rate of 
hydrolysis. Diffusion of water into polymer chains is also determined by Tg of the polymer. In 
general, lower Tg leads to higher rate of water diffusion in the bulk [92].  As shown in Fig. 5 and 
6, incorporation of PEG in the copolymers decreased their glass transition temperature from 
5.98°C (APS) to below -30°C for APS-co-PEG polymers, thus enhancing their water uptake 
capacity and degradation except in APS-25PEG400. The results are consistent with previous 
results reported for the degradation of PEGylated elastomer [192]. However, APS-25PEG400 
showed slower degradation than APS and other APS-co-PEG elastomers (Fig. 10c) despite of 
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similar water uptake to that of APS, suggesting minor role of water uptake in its degradation. 
Further, addition of PEG may increase the crystallinity of the polymer structure and therefore, 
slow down the degradation rates. However, we did not observe any cold crystallization peak in 
the DSC of APS-25PEG400, ruling out that possibility. Thus, slower degradation observed for 
APS-25PEG400 cannot be explained in our studies and needs further investigation. During 
degradation, there was a gradual decrease in thickness along with the mass loss in each polymer 
film, which was also observed in the degradation study of PGS film [205]. The percentage 
decrease in thickness on day 14 for APS, APS-25PEG400, APS-15PEG1k, APS-25PEG1k, and 
APS-40PEG1k polymer films were 8.8 ± 2.2%, 7.13 ± 1.5%, 10.5 ± 2.6%, 10.9 ± 2.1%, and 16.6 
± 2.3%, respectively (Fig. 10d). Almost constant rates of mass loss and linear decreases in the 
film thickness were observed in all series of APS-co-PEG elastomers. This suggested that the 
degradation of APS-co-PEG films was probably via the surface erosion mechanism. Ideally, the 
degradation mechanism should be further confirmed by examining the change in molecular 
weight of the sample during degradation. However, since APS and APS-co-PEG elastomers are 
thermoset elastomers, it is difficult to measure their molecular weight once they are crosslinked. 
 Instead, we compared the morphology of as-prepared and degraded samples by SEM 
(Fig. 11). APS-40PEG1K, which exhibited the highest rate of degradation after 14 days, was 
further characterized for change in film morphology after degradation. Both APS and APS-
40PEG1K samples before degradation showed almost smooth surface, while the roughness of 
film surface increased in degraded films. Of note, no pores or cracks were observed on the 
surfaces of degraded samples. Importantly, cross-section of both degraded APS and APS-
40PEG1K films showed morphology similar to that of films before degradation, indicating that 
the central portion of the films had little or no degradation. High magnification SEM images 
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suggested that APS-40PEG1K films might have degraded via surface erosion. Previous 
degradation study of PLGA, a representative thermoplastic polymer, exhibited bulk degradation, 
accompanying surface fracture and pore formation, a hallmark of heterogeneous degradation 
[183]. Such degradation mechanism is usually not favored as it results in sudden and drastic 
change in mechanical properties during degradation, leading to mechanical failure of the scaffold 
[92]. On the contrary, elastomers degraded by surface erosion are expected to exhibit gradual 
change in the mechanical properties due to their homogeneous surface degradation and a 
constant rate of mass loss, as observed in case of APS-co-PEG elastomers (Fig. 10c, d and Fig. 
11).  
 
Figure 11. SEM images of as prepared APS and APS-40PEG1K film and APS and APS-
40PEG1K film after 14days in PBS degradation.  
Images were taken on both the surface and the cross section of the sample. Scale bars represent 1 
µm in all images. 
 
Thus, mechanical properties of degraded APS and APS-40PEG1K were measured to 
determine the effect of degradation. APS showed almost 30% decrease in UTS after about 13% 
mass loss. On the other hand, APS-40PEG1K showed similar decrease in UTS even after three-
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fold higher (35.2 ± 1.3%) mass loss (Fig. 12a). Interestingly, APS-40PEG1K exhibited increased 
elastic modulus after degradation (Fig. 12b), which was probably due to the preferential loss of 
the amorphous region compared to crystalline domains. Both APS and APS-40PEG1K 
elastomers exhibited reduced elongation after degradation (Fig. 12c). These results are in 
accordance with previous reports where elastomer films showed reduced elongation after 
degradation/hydration [192, 206]. APS-co-PEG elastomers demonstrated gradual change in 
mechanical strength and elastic modulus after degradation, which shows their important 
advantage over classical polyesters such as PCL, PLGA and their copolymers since these 
polyesters exhibit large discrepancy in their mechanical properties in dry and wet conditions. It is 
suggested that this may be one of the reasons for the mechanical failure of these classical 
polyesters in vivo [207].  
 
Figure 12. Comparison between as prepared and degraded APS and APS-40PEG1K films.   
(a)-(c) Mechanical properties of APS and APS-40PEG1K polymers after 14 days of degradation 
in PBS. (N=3) p < 0.05 (*) compared to as prepared samples. (d) FT-IR spectra of APS and 
APS-40PEG1K cured polymers and cured polymer after degradation of 14 days in PBS. 
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Further, FTIR studies were performed on the degraded samples (Fig. 12d) in order to 
determine the functional groups of copolymer films susceptible to hydrolysis during degradation. 
In the FTIR spectra of APS-40PEG1K after degradation, marked increase in the intensity ratios 
of the amide I to carbonyl peaks of ester bond (1646/1730 cm-1) was observed. Additionally, by 
comparing the spectra of APS-40PEG1K before and after degradation, a marked reduction in 
intensity of C-O-C stretching peak (1110 cm-1) and C-H bending peaks (1464 & 1343 cm-1) of 
PEG was noted (Fig. 12d). Taken together, these data indicated that APS-co-PEG copolymers 
degrade by preferential hydrolysis of ester bonds over amide bonds, resulting in faster loss of 
PEG segments, confirming the increased elastic modulus after degradation.  
Overall, the preliminary degradation study demonstrated the ability to tune the 
degradation rates of APS-co-PEG elastomers over a wider range. Of note, the degradation of 
APS-40PEG1K is via surface erosion and preferential hydrolysis at the ester bonds in the APS-
co-PEG backbone. The degradation of other APS-co-PEG elastomers needs to be studied 
individually and complete degradation study such as enzymatic degradation over longer periods 
of time in vitro and in vivo is required for the determination of suitable applications for this novel 
class of elastomers. 
3.3.5 Cell attachment and viability 
The biocompatibility of APS-co-PEG elastomers was studied by examining the cellular activities 
of C2C12 cells seeded on APS and APS-co-PEG elastomer films (Fig. 13). One of the most 
prominent properties of biodegradable elastomers is that they can withstand the dynamic stretch 
and relax without the mechanical failure [28]. This property is critical for tissue engineering 
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applications, particularly for soft tissues like skeletal muscle. Previously, we have shown that 
elastomeric APS/PCL electrospun scaffold is a promising candidate for skeletal muscle tissue 
engineering [208]. C2C12 cell line is one of the widely used cell lines for the regeneration of 
skeletal muscle [209]. Therefore, C2C12 cell line is chosen as the model cell line to examine the 
biocompatibility of APS-co-PEG. Since films were transferred to the new wells 24 h after initial 
seeding, cell metabolic activities measured by alamarBlue® assay on day 1 reflect the initial cell 
attachment to the films. AlamarBlue® fluorescence reading on day 1 suggested that the 
attachment of C2C12 cells on APS-co-PEG films was lower than APS film (Fig. 13a), which 
may be due to reduced cell adhesion on the film surface in the presence of hydrophilic PEG 
segments. However, cells cultured on all films exhibited significant increase (p < 0.05) in 
metabolic activities on day 3 as compared to day 1 (Fig. 13a). This suggests that once cells are 
attached to the films, the presence of PEG did not affect cell proliferation. The increase of PEG 
molecular weight or molar ratio did not significantly affect cell proliferation. Of note, cells 
seeded on APS-co-PEG films exhibited higher proliferation rates than that of APS films as 
indicated by the larger fold increase of alamarBlue® fluorescence reading between day 1 and day 
3 (Fig. 13b). In order to minimize the strong autofluoresence of APS and APS-co-PEG polymers 
while imaging, the films were stained with Sudan Black as reported previously [193]. On day 3, 
C2C12 cells cultured on APS and APS-co-PEG films exhibited similar cell spreading (Fig. 13c). 
Cell morphology appears different for different polymers. This may be attributed to the 
differences in initial cell attachment and cell number. As shown in Fig. 13a, APS showed the 
highest metabolic activity and thus, cell number compared to PEGylated polymers on day 1 and 
3 which is also evident in Fig. 13c, showing completely confluent cells on APS. On the other 
hand, APS-25PEG1K and APS-40PEG1K had less number of cells and hence, more available 
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area for spreading, which may have resulted in the observed differences in their morphology. 
These results suggest that APS-co-PEG elastomers support cell proliferation and can potentially 
be used for tissue engineering applications. 
 
Figure 13. Cytocompatibility of APS-co-PEG films.   
(a) Metabolic activity (Alamar blue) of C2C12 cells on APS and APS-co-PEG films showing 
increased cell proliferation over 3 days on all films. (N=3) p < 0.05 (*) compared to day 1 
readings in each group, (#) compared to APS day 3 reading. (b) Fold change of the RFU reading 
from day 3 to day 1 calculated from data in (a). (c) C2C12 cells on APS and APS-co-PEG films 
showing similar cell morphology at day 3. Cells were fixed and actin cytoskeleton was stained 
with ActinGreen (green) and nuclei stained with NucBlue (blue). Scale bars represent 100 µm in 
all images. 
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3.3.6 Summary 
We successfully synthesized a series of novel APS-co-PEG elastomers by varying the molar 
percentage and molecular weight of PEG. The physicochemical, mechanical, and degradation 
properties could be tailored by altering the amount and molecular weight of PEG within the APS 
backbone. APS-co-PEG films showed increased hydrophilicity and wide range of mechanical 
and degradation properties. Importantly, APS-40PEG1K degraded by surface erosion with 
gradual change in mechanical properties during degradation. The incorporation of PEG reduced 
the initial attachment of C2C12 cells but supported cell growth and spreading. This study 
demonstrated that APS-co-PEG elastomers have broadened the property spectrum of currently 
available elastomers and will allow fine-tuning of physicochemical, mechanical and degradation 
properties of tissue engineered scaffolds to match that of a wide range of tissues to facilitate their 
regeneration. 
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4.0  FABRICATION AND CHARACTERIZATION OF ELECTROSPUN 
NANOFIBERS OF PEGYLATED ELASTOMERS 
[Xue Y, Yatsenko T, Patel A, Stolz DB, Phillippi JA, Sant V, and Sant S. (2017) Polymers for 
Advanced Technologies, 28: 1097–1106.] 
4.1 BACKGROUND 
One important goal of tissue engineering (TE) is to fabricate extracellular matrix (ECM)-mimetic 
biomaterial scaffolds [145] that can provide initial structural support and guidance to the seeded 
or recruited cells and allow for diffusion of nutrients and waste through the porous matrix [142]. 
Through appropriate biochemical and/or biomechanical guidance cues, cells can migrate, 
proliferate and differentiate in the scaffold and eventually, degrade the scaffold matrix and 
replace it with de novo synthesized ECM [142]. In addition to the scaffold architecture, another 
important design principle for TE scaffolds is to create mechanically analogous tissue substitutes 
[102]. Specifically, for soft tissues such as skeletal muscle and heart valves, biodegradable 
synthetic elastomers are considered to be one of the most promising materials because of their 
outstanding mechanical compliance and the ability to withstand cyclic mechanical loading 
without early structural failure [28, 180, 210]. Moreover, synthetic elastomers offer many 
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advantages over natural polymers such as facile production with less batch-to-batch variation and 
less immunogenicity [28, 210].  
Currently, biodegradable thermoplastic polymers such as poly lactic-co-glycolic acid 
(PLGA) are widely used for various TE applications [22, 211]. However, these polymers often 
suffer from bulk degradation mechanisms in vivo, causing unfavorable sudden mechanical failure 
[183]. Therefore, there is a growing interest in biodegradable thermoset elastomers such as poly 
(1,3-diamino-2-hydroxypropane-co-polyol sebacate) (APS) [182, 184, 208]. Biodegradable 
thermoset elastomers usually degrade by surface degradation, leading to more predictable loss of 
mechanical properties while cells infiltrate the matrix and secrete their own ECM [92].  
Our group has recently synthesized a series of PEGylated biodegradable thermoset 
elastomers, poly(1,3-diamino-2-hydroxypropane-co-glycerol sebacate)-co-poly(ethylene glycol) 
(APS-co-PEG) by varying PEG molecular weights and molar percentages [212, 213]. PEG is a 
well-recognized nontoxic polymer, which has been shown to reduce protein adsorption [190] and 
thrombogenicity of the implanted medical devices including TE scaffolds in general and 
currently available heart valve substitutes, in particular [120, 214]. Importantly, we have 
demonstrated that the mechanical properties of APS-co-PEG elastomers can be tuned by the 
choice of PEG molar percentage, PEG molecular weight, monomer feed ratio and cross-linking 
time [213]. Specifically, cross-linked APS-co-PEG elastomeric films exhibited a wide range of 
ultimate uniaxial tensile strength (0.07–2.38 MPa), elastic modulus (0.02–3.0 MPa) and 
elongation (93–993%). Additionally, the solubility of APS-co-PEG pre-polymers in common 
organic solvents was significantly improved compared to non-PEGylated APS elastomers [213].  
Electrospinning has been comprehensively investigated for applications in TE due to its 
versatility and ease in processing porous scaffolds with high surface area-to-volume ratio that 
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can mimic native fibrous ECM [87, 88, 215-217]. We and others have shown that the 
electrospinning of thermoset elastomer pre-polymer along with a carrier polymer can result in 
elastomeric electrospun scaffolds [89, 180, 181, 208, 218]. As an example, poly(glycerol 
sebacate) (PGS), a benchmark biodegradable thermoset elastomer, has been studied extensively 
as electrospun scaffolds [87, 179, 180, 216], demonstrating the feasibility and effectiveness of 
electrospinning of thermoset elastomer pre-polymer along with a carrier polymer. The 
electrospun PGS/PCL scaffolds have tunable mechanical properties and improved biological 
properties than that of PCL alone. Moreover, PGS/PCL scaffolds have been shown to promote 
cell attachment/spreading, promote de novo ECM synthesis and support stem cell differentiation 
[87, 179, 180, 216]. 
This study reports the fabrication and characterization of electrospun scaffolds composed 
of newly synthesized APS-co-PEG elastomers with varying PEG molar ratio (APS-15PEG, APS-
25PEG and APS-40PEG). PCL is used as a carrier polymer. We also demonstrate that these 
scaffolds support adhesion/spreading of skeletal muscle cells (C2C12) and human aortic valve 
cells. Importantly, we demonstrate that PEGylation of elastomers markedly reduces platelet 
adhesion on these scaffolds while maintaining their excellent mechanical properties, suggesting 
potential applications in soft tissue engineering such as skeletal muscle and heart valve tissue 
engineering. 
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4.2 METHODS 
4.2.1 Materials 
All organic solvents used in the study and 1, 3-diamino-2-hydroxy-propane (DAHP), glycerol 
(G), sebacic acid (SA), poly (ε-caprolactone) (PCL, Mw=70-90 kDa) were purchased from 
Sigma-Aldrich (St. Louis, MO). PEG (Mw=1kDa) was obtained from Dow Chemical (Midland, 
MI). Cell culture supplies including media, trypsin-EDTA and antibiotics were obtained from 
Corning (Corning, NY), unless otherwise mentioned. 
4.2.2 Polymer synthesis 
APS and APS-co-PEG pre-polymers were synthesized as described in section 3.2.1.  
4.2.3 Scaffold fabrication by electrospinning 
Following APS and APS-co-PEG polymer synthesis, porous scaffolds were fabricated using the 
electrospinning technique. Electrospinning parameters such as polymer concentration, voltage 
and distance were varied (Table 10) to obtain the optimal electrospinning conditions that result 
in bead-free fibers. Briefly, APS or APS-co-PEG (APS-15PEG, APS-25PEG and APS-40PEG) 
and ε-PCL were dissolved in hexafluoroisopropanol (HFIP) in a 4:1 w/w ratio with total polymer 
concentration kept constant at 17.5% w/v in HFIP. Electrospinning was conducted on a 
conventional electrospinning setup, using aluminum foil as collector. Solutions were electrospun 
at 17 kV for 1 h at a rate of 1 mL/h. The distance between the needle and collector was kept 
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constant at 10 cm. The obtained electrospun scaffolds were dried in a vacuum desiccator for 1 
week. Scaffolds were then soaked in deionized water to allow for the removal of any sprayed 
polymer and remaining solvent. APS-PCL scaffold were used as control scaffold in all 
experiments. 
Table 10. The optimization process of electrospinning parameters. 
Polymer Concentration Polymer Ratio Distance (cm) Voltage (kV) 
15% 
4:1 10 10 17.5% 
20 % 
17.5% 
5:1 
10 10 4:1 
2:1 
17.5% 4:1 
8 
10 10 
12 
17.5% 4:1 10 
8 
10 
12 
14 
15 
17 
4.2.4 Fourier-transform infrared spectroscopy (FTIR) 
Chemical composition of the scaffolds was studied using Fourier Transform Infrared (FTIR) 
spectroscopy with attenuated total reflection (ATR-FTIR). The spectra were recorded in 
absorption mode with a resolution of 4 cm-1 using Bruker Vertex 70 FTIR spectrometer (Bruker, 
Billerica, MA). The results are presented as an average of 256 scans. The intensities of ester, 
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amide I, and amide II peaks were integrated for semi-quantitative analysis using Origin8 
software as reported earlier [212]. 
4.2.5 Scanning electron microscopy (SEM) 
Scaffold morphology and porosity was characterized using scanning electron microscopy (SEM) 
(JEOL 6335F Field Emission SEM, Japan). Fibrous scaffolds were sputter-coated with 5 nm of 
gold-palladium using Cressington 108 auto sputter-coater (Cressington Scientific Instruments, 
UK) and images were obtained using accelerated voltage of 3kV. Fiber diameter measurements 
were performed using NIH ImageJ software. 100 fibers were considered for calculating fiber 
diameters. 
4.2.6 Differential scanning calorimetry (DSC) analysis  
The thermal properties of electrospun scaffolds were studied by differential scanning calorimeter 
(DSC) (Mettler Toledo, Allison Park, PA). The scaffold (approx. 5 mg) was sealed in an 
aluminum pan and first heated from room temperature to 150 °C, then cooled to −70 °C, and 
finally reheated to 150 °C at a heating/cooling rate of 10 °C/min. All the processes were carried 
out under nitrogen atmosphere. Crystallization temperature (Tc) and enthalpy (∆Hc) were 
obtained from the cooling cycle (150 °C to -70 °C) whereas glass transition temperature (Tg), 
melting temperature (Tm) and enthalpy (∆Hm) were obtained from the second heating cycle (-70 
°C to 150 °C). DSC data was analyzed using STARe software. 
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4.2.7 Uniaxial mechanical testing  
Scaffold mechanical properties were studied using uniaxial tensile tests with ADMET MTEST 
Quattro mechanical testing system (ADMET, Norwood, MA). Scaffolds were cut into 
rectangular shapes (15×7 mm2, n=8 per group) and stretched until failure at a constant jogging 
speed of 10 mm/min. The stress (MPa) was obtained by dividing the applied force (N) with 
cross-section area (mm2); percent elongation (strain, ε) was obtained from equation 1, where Lo 
was initial gauge length and L was instantaneous gauge length. Ultimate tensile strength (UTS), 
maximum strain to total failure (% elongation), toughness (area under the curve of stress-strain 
curve), and elastic modulus in the linear region at 5-15% strain was recorded for each scaffold 
tested. Cyclic mechanical testing was performed at a jogging rate of 10 mm/min, by sample 
extension until 20% elongation during 10 consecutive cycles. 
Elongation (ε, %) = (L-Lo)×100/Lo     Eq. (1) 
4.2.8 Degradation study  
In vitro degradation properties were studied by submerging 10×10 mm2 scaffold samples (n=3) 
in 10 mL PBS solution in 50 mL falcon tubes. Solutions were maintained in a shaking incubator 
at 37 °C and 50 rpm. At predetermined intervals, the scaffolds were weighed after gentle 
washing in deionized water and fresh PBS solution was replaced in the falcon tubes. Mass loss, 
compared to the original hydrated scaffold mass, and solution pH were measured. The 
percentage of mass loss was calculated using Equation 2, where Wo is the initial weight of as-
prepared scaffold and Wt is the weight of scaffold at each time point.  
Mass loss (%) = (Wo – Wt)×100/Wo     Eq. (2) 
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4.2.9 Cytocompatibility of electrospun scaffolds using mouse myoblast (C2C12) cells  
The preliminary cytocompatibility of the electrospun scaffolds was studied by evaluating 
attachment, spreading and proliferation of mouse myoblast cells (C2C12) from ATCC (CRL-
1772™) (kind gift from Dr. Adam Feinberg (Carnegie Mellon University, Pittsburgh PA)) 
seeded onto the scaffolds. The cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) (Hyclone, Marlborough, MA) and 
1% Penicillin/Streptomycin solution. Cells in passages 3-7 were used. The scaffolds (9 mm x 9 
mm, n=3) were sterilized by exposing to 70% isopropanol under UV light for 30 min, washed 
with DPBS thrice, and seeded with C2C12 cells at a density of 45,000 cells/scaffold in a 24-well 
plate. The media was replenished every day.  
The cell attachment and spreading of C2C12 cells were studied by staining actin 
(ActinGreen™ 488 ReadyProbes® Reagent, Life Technology, Waltham, MA) and nuclei of 
seeded cells (NucBlue® Fixed Cell Stain, Life Technology, Waltham, MA) after 6h of culture. 
The cell-seeded scaffolds were fixed in 4% paraformaldehyde solution (30 min), washed with 
DPBS thrice, followed by permeabilization and blocking using 0.1% Triton X-100 and 3% 
bovine serum albumin (BSA) in DPBS. Confocal images were obtained using an inverted 
confocal laser scanning microscope (Olympus Fluoview 1000, Japan) under 20X and 40X 
objectives. 
The metabolic activity was measured over a period of 7 days using the alamarBlue® 
assay (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Briefly, cell-seeded 
scaffolds (n=4) were treated with 10% v/v alamarBlue® solution in growth medium for 4 h at 37 
°C. The fluorescence intensity was then measured using a microplate reader (Gen5 Biotek, 
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Winooski, VT) at excitation/emission wavelengths of 530/590 nm. alamarBlue® solution (10% 
w/v) incubated without any cells was used for blank correction.  
4.2.10 Platelet adhesion assay  
Human platelet-rich plasma (PRP) with a platelet density of 1 million/mL was obtained as a kind 
gift from Dr. Rocky Tuan lab (University of Pittsburgh, Pittsburgh, PA). Platelet adhesion assay 
protocol was adopted from literature [36]. The scaffolds (9 mm x 9 mm) were placed in 0.5 ml of 
PRP in a 24-well plate. All scaffolds were then incubated at 37 °C for 1h with gentle mixing. 
Scaffolds were rinsed twice with PBS and fixed with glutaraldehyde solution in PBS (2.5% v/v) 
for 2 h at room temperature; then the samples were dehydrated in vacuum and images using 
SEM as described above. 
4.2.11 Adhesion and spreading of human aortic valve cells  
Freshly isolated human aortic valve cells were a kind gift from Dr. Thomas Gleason (University 
of Pittsburgh, Pittsburgh, PA), obtained from human aortic valves with the University of 
Pittsburgh's Institutional Review Board approval and with informed patient consent. Valve 
tissues were digested in 2.5 mg/mL Collagenase IV with DMEM (+1% Penicillin/Streptomycin 
+1% Fungizone) for 30 min at 37 °C with gentle rocking. Digested tissue was passed through 70 
µm filter and saved at 37 °C. Undigested tissue was further digested with 0.8 mg/mL 
Collagenase IV for 1h at 37 °C with gentle rocking. Digested tissue was passed through 70 µm 
filter and pool with previous digested tissue. The pooled digested tissue was centrifuged at 2000 
rpm for 5 min at 4 °C and then the supernatant was discarded. Cells were resuspended in T75 
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flask with 12 mL Endothelial medium supplemented by Gentamicin (60µL) and Fungizone (120 
µL). The cells were propagated using Endothelial Cell Growth Media Kit (Cell Applications, San 
Diego, CA) according to established protocols. The scaffolds (9 mm x 9 mm) were sterilized by 
exposing to 70% isopropanol under UV light for 30 min, washed with DPBS thrice, and seeded 
with valve cells using a seeding density of 300,000 cells/scaffold in a 24-well plate. After 4 days 
in culture, the cell-seeded scaffolds were fixed and permeabilized as described above. Human 
valve cell adhesion and spreading were studied by staining actin (ActinGreen™ 488 
ReadyProbes® Reagent), α-smooth muscle actin (α-SMA, Mouse Anti-Human Actin, Dako, 
Carpinteria, CA) and nuclei of the seeded cells (NucBlue® Fixed Cell Stain). Confocal images 
were obtained as described above. 
4.2.12 Statistical analysis  
Experimental data are presented as mean ± standard deviation. Data between multiple groups 
were analyzed using one-way ANOVA or two-way ANOVA followed by Tukey’s post-hoc 
analysis. P-values less than 0.05 were considered as significant.  
4.3 RESULTS AND DISCUSSION 
4.3.1 Fabrication of electrospun scaffold and scaffold morphology 
The electrospinning conditions for preparing fibrous APS/PCL and APS-co-PEG/PCL were first 
optimized according to Table 10. It was found that hybrid APS/PCL and all APS-co-PEG/PCL 
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electrospun scaffolds with proper fiber formation could be successfully fabricated using 
optimized electrospinning parameters, namely total polymer concentration (17.5% w/v), solvents 
(HFIP), voltage (17kV), flow rate (1 mL/h) and collector-to-needle distance (10 cm). PCL was 
used as a carrier polymer. The weight ratio between APS-co-PEG and PCL was kept constant at 
4:1 throughout the study to highlight the effect of APS-co-PEG.  
 
Figure 14. Fiber morphology of electrospun APS-co-PEG/PCL scaffolds studied by scanning 
electron microscopy.   
(a) Fiber morphology of electrospun APS-co-PEG/PCL scaffolds studied by scanning electron 
microscopy at ×5000 (top) and ×15000 (bottom) magnification. Scale bars in top rows represent 
5 µm; scale bars in bottom rows represent 2 µm (b) Average fiber diameters (n=100 fibers per 
group), * p<0.05 with respect to APS/PCL scaffolds. 
 
Scanning electron microscopy revealed fibrous and porous structure of all scaffolds (Fig. 
14a). The nanofibrous porous structure of electrospun scaffolds mimics the fibrous structure of 
native ECM and has been shown to improve the exchange of nutrients and waste products and 
promote cell attachment/spreading, thereby leading to higher cell proliferation [219]. SEM image 
analysis revealed that the average fiber diameters of all electrospun scaffolds were approximately 
300 nm (Fig. 14b). These scaffolds exhibit a desirable fiber diameter range since cells seeded on 
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polymer scaffold secrete ECM proteins, like collagen, which often form fibrils of similar size 
[220]. It should be noted that different PEGylated elastomers did not significantly alter fiber 
morphology and the average fiber diameter of all scaffolds remained in the same range (around 
300 nm). This is attributed to the processing of all polymer blends using constant electrospinning 
parameters such as polymer concentration, voltage and needle-to-collector distance, which have 
been shown to be the main determinants for scaffold morphology and average diameter [146].  
4.3.2 Chemical properties of electrospun scaffolds 
FTIR was used to characterize the chemical composition of electrospun scaffolds. The detailed 
FTIR analysis on APS-co-PEG polymers was presented in our previous studies [212, 213]. 
Briefly, APS-co-PEG polymers showed characteristic carbonyl (1730 cm-1), amide I (1646 cm-1), 
amide II (1552 cm-1) peak from APS moiety and C-O-C stretching (1110 cm-1) and C-H bending 
(1464 &1343 cm-1) peaks of PEG moiety in their FTIR spectra. FTIR curves of APS-co-
PEG/PCL scaffolds showed peaks from both APS-co-PEG and PCL (Fig. 15a). Amide to 
carbonyl peak intensity ratios can be used to determine the ratio of amide and ester bonds in the 
polymer blends [212]. Since there is ester bond but no amide bond in the PCL structure, the 
FTIR spectra of APS-co-PEG/PCL scaffolds showed decreased amide I: carbonyl and amide II: 
carbonyl ratios when compared to those of APS-co-PEG polymer alone, respectively (Fig. 15b). 
In addition, with the increase in PEG molar ratio, there is further decrease in amide: carbonyl 
ratio in the FTIR spectra of APS-co-PEG/PCL scaffolds, which is similar to the trend observed 
in APS-co-PEG elastomers [212]. Overall, FTIR results suggest that PCL was physically blended 
in the scaffolds with no chemical interaction with APS or APS-co-PEG elastomers, as the 
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characteristic carbonyl peaks of PCL (~1730 cm-1) were not shifted after incorporation of PCL 
into the scaffolds. 
 
Figure 15. FTIR characterization of electrospun scaffolds.   
(a) FTIR spectra of electrospun PCL, APS/PCL and APS-co-PEG/PCL scaffold. Ester, amide I 
and amide II peaks are highlighted for semi-quantitative analysis. (b) Polymer/PCL showed 
decreased amide peaks I (1646 cm-1) to carbonyl peak (1730 cm-1) and amide II (1552 cm-1) to 
carbonyl peak (1730 cm-1) intensity ratio than those of corresponding polymer alone group. 
4.3.3 Thermal properties of electrospun scaffolds 
The thermal properties of the scaffolds were investigated by DSC (Fig. 16a and b). In this study, 
the scaffolds were first heated to 150 °C to eliminate the thermal history. The cooling cycle 
(from 150 °C to -70 °C) was used to obtain crystallization temperature (Tc) and enthalpy (∆Hc) 
while the second heating cycle (-70 °C to 150 °C) was used to obtain glass transition temperature 
(Tg), melting temperature (Tm) and enthalpy (∆Hm). PCL, being semicrystaline polymer, did not 
exhibit Tg in the temperature range studied here. APS/PCL scaffolds exhibited Tg of -1.4 °C, 
which decreased with increasing PEG molar percentage in the APS-co-PEG elastomers from 15 
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to 40 mole% (Fig. 16c). This may be attributed to the plasticizer effect of PEG, consistent with 
our previous report on characterization of PEGylated elastomers [213]. It should be noted that all 
the scaffolds had a Tg in the range of -23 to -1 °C, which is significantly lower than the body 
temperature. Low Tg is usually favorable for the elastomeric scaffold since such material will be 
elastic in vivo [211]. We also examined the crystallization and melting behaviors of the scaffolds. 
There were no significant differences in Tc and Tm of all scaffolds, further supporting our 
conclusion that PCL is physically blended with APS or APS-co-PEG elastomers (Fig. 16a-c). As 
revealed by high values of ∆Hc and ∆Hm, electrospun PCL scaffolds maintained crystalline 
nature of PCL polymers while the presence of amorphous APS polymers in APS/PCL hybrid 
scaffolds reduced the crystallinity of these scaffolds. Interestingly, there was an increase in ∆Hc 
and ∆Hm of APS-co-PEG/PCL hybrid scaffolds with the increase in the PEG ratio in APS-co-
PEG elastomers.  This observation is in accordance with previous reports that the addition of 
PEG resulted in the increased crystallization tendency as well as the degree of crystallization 
[187, 197]. 
 
Figure 16. Thermal properties of electrospun APS-co-PEG/PCL scaffolds. 
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(a) DSC curves of the cooling cycle and (b) the heating cycle of APS-co-PEG pre-polymers; (c) 
Summary of the thermal properties of electrospun scaffolds. Tg: glass transition temperature; Tc: 
crystallization temperature; ∆Hc: crystallization enthalpy; Tm: melting temperature; ∆Hm: melting 
enthalpy. 
4.3.4 Uniaxial mechanical properties of electrospun scaffolds 
To test the mechanical properties of the scaffolds, uniaxial tensile test was performed (Fig. 17a). 
The ultimate tensile stress (Fig. 17b), stiffness (Fig. 17c) and toughness (Fig. 17d) of scaffolds 
increased with PEG concentration in APS-co-PEG (p<0.05, One-way ANOVA). This direct 
relationship was expected since the increase in degree of crystallization (Fig. 16c) usually leads 
to stronger and stiffer materials [221]. Overall, APS-co-PEG/PCL scaffolds showed tunable 
mechanical properties. It is noteworthy that the mechanical properties of these scaffolds may be 
further tuned by changing the ratio of APS-co-PEG/PCL ratio and other electrospinning 
parameters. It has been widely acknowledged that tailoring the mechanical properties of TE 
scaffold with that of native tissue is crucial to guide the tissue regeneration [92]. Therefore, APS-
co-PEG/PCL scaffolds with wide range of mechanical properties might be promising constructs 
for TE biomaterials used in an array of tissues. 
 86 
 
Figure 17. Mechanical properties of electrospun APS/PCL and APS-co-PEG/PCL scaffolds. 
(a) Representative stress strain curves of APS-PEG/PCL electrospun scaffold; (b) ultimate 
tensile strength (UTS); (c) elastic modulus; and (d) toughness of APS-co-PEG/PCL scaffolds 
(n=8). Significant differences at p < 0.01 (*) or p<0.001 (**) when compared to APS/PCL. 
 
4.3.5 Physiological degradability 
From the in vitro degradation study, it was found that all scaffolds degraded at a similar rate, 
with no statistical differences between APS-co-PEG/PCL and APS/PCL (Fig. 18a). All scaffolds 
exhibited around 50% mass loss after 2 weeks in PBS. Degradation of all scaffolds followed a 
linear trend suggesting that the primary mechanism was probably through surface degradation 
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[222]. Scaffold degradation by surface erosion is generally considered advantageous since it 
maintains the scaffold geometry with gradual decrease in mechanical properties unlike the 
sudden mechanical failure observed during bulk degradation. Interestingly, the varying amounts 
of PEG did not influence the degradation rate of scaffolds unlike in the case of thermally cross-
linked APS-co-PEG films [213]. This may be attributed to multiple reasons. First, in our 
previous study, the varying degradation rates of thermally cross-linked APS-co-PEG films 
containing different PEG amounts were partially attributed to the different crosslinking density 
of the polymer structure [213]. However, in this study, APS-co-PEG pre-polymers were used, 
which rules out the possible influence of polymer crosslinking density thereby minimizing the 
difference in degradation rates. Also, nanofibrous APS-co-PEG/PCL scaffolds have significantly 
higher surface area than those of the cross-linked films, resulting in higher degradation rates than 
film scaffolds.   
 
Figure 18. Degradation properties of electrospun APS/PCL and APS-co-PEG/PCL scaffolds. 
(a) Percentage mass loss of APS-co-PEG/PCL scaffold after degradation in PBS at 37oC (n=3); 
(b) Change in pH of PBS during degradation (n=3); (c) Scaffold morphology after 14 days of 
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degradation. All scale bars represent 2 μm. (d) Average fiber diameters of as prepared and 
degraded scaffolds. (n=100 fibers per group) * p<0.05 
 
The pH change during degradation is an important parameter since acidic degradation 
products might cause in vivo inflammatory responses [223]. A slightly lower pH compared to the 
initial buffer pH of 7.1 was observed throughout the study for all experimental groups (Fig. 18b), 
indicating that acidic degradation products were released from all scaffolds particularly at the 
beginning of the study. However, the pH of degradation solution in all APS-co-PEG/PCL groups 
was found to be near or higher than 7 at all times during degradation (Fig. 18b). Of note, on day 
1, all APS-co-PEG/PCL scaffolds had less pH reduction in degradation media than APS/PCL 
scaffold. Also, the drop of pH in degradation solution was less after day 1, despite a constant rate 
of mass loss rate (Fig. 18a). These results suggested that APS-co-PEG/PCL scaffolds might lead 
to less in vivo inflammatory responses due to acidic degradation products, but confirmation will 
require further study.  
Scaffold morphology was investigated after 2-week degradation by SEM (Fig. 18c). 
SEM images showed that all scaffolds maintained nanofibrous structure even after about 50% 
mass loss, although the scaffold surface showed increased roughness. Furthermore, mean fiber 
diameter of each group was significantly reduced after the degradation study, affirming that the 
degradation was probably by surface degradation (open vs. lined squares in Fig. 18d) (p<0.05, 
Two-way ANOVA). 
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4.3.6 Cytocompatibility of electrospun scaffolds 
Biocompatibility is a crucial factor in determining the application of TE scaffolds. A mouse 
myoblast cell line (C2C12) was chosen as a model system to evaluate biocompatibility of 
different scaffolds. Initial attachment and spreading of C2C12 cells on scaffolds were examined 
by immunostaining of cell nuclei and cytoskeleton after 6h of culture following cell seeding 
(Fig. 19a). APS/PCL (control) scaffolds exhibited high initial cell attachment and spreading 
morphology, which is consistent with previous study on APS/PCL scaffold [208]. As expected, 
APS-co-PEG/PCL groups showed reduction in initial cell attachment, which may be attributed to 
the increased scaffold hydrophilicity resulted from the presence of PEG in the elastomer [224]. 
Previously, APS-co-PEG elastomer films also showed reduced initial cell attachment compared 
to APS film [213]. However, APS-co-PEG/PCL scaffolds did support cell spreading, indicated 
by the stretched cell morphology similar to APS/PCL groups 6h post cell seeding. Cell 
proliferation on scaffolds were investigated from day 1 to day 7 using alamarBlue® assay, which 
measures the metabolic activity of cells (Fig. 19b). We observed that all the scaffolds supported 
cell proliferation, indicated by an increase in alamarBlue® fluorescence reading from day 1 
through day 7. Of note, there was no difference in cell proliferation between APS-co-PEG/PCL 
scaffolds and APS/PCL scaffolds on day 1 and day 3. However, on day 7, there was a higher 
metabolic activity for cells seeded on APS-25PEG/PCL scaffolds than all other scaffolds 
(p<0.05, Two-way ANOVA). All other APS-co-PEG/PCL scaffolds had similar cell viabilities to 
that of APS/PCL scaffold, consistent with the notion that they all support cell proliferation. 
These results indicate that APS-co-PEG/PCL scaffolds are biocompatible and can be explored 
further for soft tissue engineering. 
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Figure 19. Cytocompatibility of electrospun APS/PCL and APS-co-PEG/PCL scaffolds with 
mouse myoblast (C2C12). 
4.3.7 Potential of APS-co-PCL scaffolds for heart valve tissue engineering 
Current heart valve substitutes such as mechanical valves have thrombogenicity issue or suffer 
from poor mechanical compliance, which results in the biomechanical mismatch between the 
device and the tissue, ultimately leading to the device failure [225]. Tissue engineered heart 
valve substitutes with tailored mechanical properties offer important alternative therapeutic 
strategy for patients with valvular heart disease [12, 76, 78, 226]. More importantly, tissue 
engineered heart valves can be designed from biodegradable polymers functionalized to reduce 
the thrombogenicity observed with mechanical valve substitutes. It has been shown that the 
presence of a PEG moiety can markedly decrease the thrombogenicity of polymeric materials 
[214, 227]. Therefore, PEGylated elastomers offer excellent opportunities for heart valve TE 
where high mechanical compliance of the elastomers can sustain dynamic mechanical 
environment present in the native valve tissue. Furthermore, presence of PEG in the elastomer 
backbone can mitigate the thrombogenicity observed for currently available heart valve 
substitutes.  
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To test our hypothesis that PEGylation results in less thromobogenicity, we exposed 
control PCL, APS/PCL and PEGylated APS/PCL (APS-15PEG/PCL, APS-25PEG/PCL and 
APS-40PEG/PCL) scaffolds to PRP and investigated their ability to resist platelet adhesion. All 
APS-co-PEG/PCL scaffolds displayed lower platelet adhesion than PCL and APS/PCL scaffolds 
as qualitatively assessed from SEM images (Fig. 20). Furthermore, the morphology of adhered 
platelets was evaluated by Cooper’s classification of platelet adsorption [227, 228]. In PCL and 
APS/PCL groups, adhered platelets exhibited spreading and dendritic morphology, which 
represent late stage of platelet activation. On the other hand, platelets in APS-PEG/PCL groups 
exhibited round morphology with no pseudopodia. Overall, these results indicate the better 
hemocompatibility of PEGylated APS-co-PEG/PCL scaffolds.  
 
Figure 20. SEM images of platelet adhesion assay at ×3,000 and ×10,000 magnification.  
Arrows indicate platelet adhesion. Scale bars in top row represent 10 μm. Scale bars in bottom 
row represent 5 μm. 
 
Another advantage of PEGylated elastomers as material for heart valve TE is their 
elastomeric properties, which can maintain the scaffold integrity in dynamic mechanical 
environment in cardiovascular system. Mechanically analogous scaffolds have shown beneficial 
effect in maintaining the structural integrity of the scaffold in dynamic in vivo setting and 
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guiding cell proliferation and tissue regeneration [229]. Hence, we compared the uniaxial 
mechanical properties of APS-co-PEG scaffolds with that of the native valve tissue (available 
from the literature, [110]). We also investigated cyclic mechanical properties and cell 
attachment/spreading as initial assessment of suitability of APS-co-PEG scaffolds for potential 
heart valve TE application. Comparing the APS-co-PEG/PCL scaffold properties to those of 
human heart valves, it is observed that the stress-strain curves of APS-25PEG/PCL overlap 
closely with that of human aortic valve tissues reported in the published literature [110] (Fig. 
21a). In fact, both, the scaffolds and the heart valves exhibit initial flat region in the curve, where 
the material undergoes strain but experiences very little stress (0-5% strain). The resilience of 
APS-25PEG/PCL scaffold was further investigated by cyclic tensile tests. It was observed that 
APS-25PEG/PCL scaffolds could withstand 10 cycles of loading and unloading with minimal 
energy loss during the process (Fig. 21b). This is especially important for heart valve TE 
application since the implanted scaffold should withstand the dynamic mechanical environment 
in vivo, ideally over the lifespan of the patient. As a proof of concept, human aortic valve cells 
were cultured on APS-25PEG/PCL scaffolds for 4 days. It was found that human valve cells 
could attach and spread on APS-25PEG/PCL scaffolds and express the valve interstitial cell 
marker α-SMA (Fig. 21c). Taken together, APS-25PEG/PCL scaffolds may have potential in 
heart valve TE and further detailed studies are underway to investigate cellular behaviors of 
human valve interstitial cells seeded on these scaffolds. 
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Figure 21. Mechanical and biological properties of electrospun APS-co-PEG/PCL scaffolds 
applicable to heart valve TE.  
(a) Overlay of the stress-strain curve of APS-25PEG/PCL with those from different human aortic 
valves. (data on human aortic valve samples adopted from Hasan et al. 2014); (b) Stress-strain 
curve of APS-25PEG/PCL scaffold during 10 cycles of tensile loading; (c) Spreading and 
morphology of human aortic valve cells seeded on APS-25PEG/PCL scaffold at 4 days after 
seeding. Actin cytoskeleton was stained with actinGreen (green); α-SMA was stained with anti-
smooth muscle actin (red) and nuclei stained with NucBlue (blue). 
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4.3.8 Summary 
A series of APS-co-PEG/PCL nanofibrous electrospun scaffolds have been successfully 
fabricated using PEGylated elastomers. The APS-co-PEG/PCL scaffolds exhibited low Tg below 
body temperature and wide range of mechanical properties, which may be exploited for various 
tissue engineering applications. The scaffolds degraded via surface erosion without creating 
acidic degradation environment. Importantly, APS-co-PEG/PCL scaffolds exhibited similar or 
better cell proliferation than APS-PCL scaffold. Our results show that APS-25PEG/PCL scaffold 
is mechanically analogous to human aortic valve, can withstand cyclic mechanical stretch, 
exhibits reduced platelet adhesion and supports valvular cell attachment/spreading. Overall, 
APS-co-PEG/PCL scaffolds may be promising scaffold for soft tissue engineering such as heart 
valve tissue engineering. 
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5.0  ANISOTROPIC FIBROUS SCAFFOLD FABRICATION AND THEIR BIAXIAL 
MECHANICAL CHARACTERZATION  
[Xue Y, Ravishankar P., Zeballos MA, Sant V, Balachandran K, and Sant S. Manuscript in 
submission] 
5.1 BACKGROUND 
Scaffold-based tissue engineering approach has emerged as one of the central themes in 
regenerative medicine and disease modeling. The fabrication of extracellular matrix (ECM)-
mimetic biomaterial scaffolds is an important strategy to improve tissue engineering outcomes 
[145]. Such ECM-mimetic scaffolds provide the initial structural support to the seeded or 
recruited cells and allow for diffusion of nutrients and waste, and more importantly, present 
suitable biophysical and biomechanical cues to guide the normal cell and tissue functions [142]. 
Soft tissues, such as heart valve leaflets, possess unique biophysical and biomechanical features 
that confer on them complex non-linear, exponential stress-strain properties [230, 231]. Their 
anisotropic nature enables them to withstand a larger stiffness in the circumferential (or fiber 
[232]) direction compared to its radial (or cross-fiber [232]) direction. These microenvironmental 
cues also determine the behavior of valvular cells. The phenotype of valvular interstitial cells 
(VICs), the most abundant and plastic cell population in the valve, could be modulated by the 
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cell culture substrates/matrix [233, 234]. It has been revealed that matrix stiffness affects the 
activation and osteo-differentiation of VICs [235-237]. Moreover, the morphology and 
architecture of the matrix have been shown to instruct the attachment and spreading of VICs [76, 
78]. Several studies have performed uniaxial testing on tissue-engineered scaffolds, but this 
testing modality is insufficient to fully characterize the scaffold mechanical properties as it fails 
to capture the complex cross-coupling (stress along one axis are affected by the strain level along 
the perpendicular axis) experienced by anisotropic tissues [232, 238]. Planar biaxial testing helps 
to overcome this problem and provides a better understanding of the anisotropic mechanical 
properties. The stress applied to an anisotropic sample like heart valve leaflet in a planar biaxial 
tester represents the actual stress states/conditions experienced in vivo. Thus, biaxial mechanical 
testing helps in optimization of the critical features of scaffolds to withstand in vivo mechanical 
environment and support cellular behaviors for normal tissue regeneration. Although the 
anisotropic mechanical properties of native valves have been extensively studied using biaxial 
tensile testing [108, 109, 232, 238, 239], the biaxial tensile properties of tissue engineered 
scaffolds have rarely been studied.  
Currently, hydrogel-based substrates have been the popular VIC culture platforms for 
studying the effect of matrix properties on the VIC behavior [131, 237]. Although hydrogels are 
viscoelastic in nature with easily tunable matrix stiffness [130, 240], most hydrogel-based 
systems mostly employed in their bulk hydrogel form fail to closely mimic the fibrous structure 
of the native valve ECM. Overall, scaffolds with fibrous structures as well as anisotropic and 
tunable mechanical properties are still limited.  
To fabricate fibrous scaffolds mimicking native ECM, electrospinning of different natural 
and synthetic polymers have been widely used [215, 241]. We have previously developed 
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isotropic (random) fibrous scaffolds by electrospinning polymer blends of poly(1,3-diamino-2-
hydroxypropane-co-glycerol sebacate)-co-poly(ethylene glycol) (APS-co-PEG) and 
polycaprolactone (PCL) [242]. By changing the PEG amount (15-40 mole%) in APS-co-PEG 
polymer, the uniaxial mechanical properties of these scaffolds could be readily modulated [242]. 
Interestingly, one of the polymers (APS-25PEG) yielded scaffolds with uniaxial mechanical 
properties similar to those of native valve leaflet [242]. Electrospinning also enables the 
modulation of scaffold mechanical properties by simply changing the polymer formulation 
parameters (such as polymer concentration and co-polymer ratios) [243-245]. Specifically, the 
polymer blend system developed by our group enabled modulation of three key parameters in the 
polymer formulation: 1) PEG amount in APS-co-PEG, 2) APS-co-PEG concentration in polymer 
blend with PCL, and 3) total polymer concentration. However, these scaffolds possessed 
isotropic fiber alignment and failed to recapitulate the anisotropic nature of heart valve. 
The electrospinning collector can be designed to control the fiber morphology [80, 153]. 
As an example, aligned fibers were obtained when two parallel gold electrodes were used to 
collect electrospun polymer fibers [153]. Further, these aligned fibers were assembled into 
multilayered structures with more sophisticated patterns [153]. Others have designed the 
electrospinning collectors to modulate the fiber morphology to match that of a native valve [41]. 
In this study, we designed a valve leaflet-inspired ring-shaped collector to fabricate anisotropic 
fibrous scaffolds made of synthetic polymer blends of APS-co-PEG and PCL.  
In this study, we aim to fabricate fibrous scaffolds with anisotropic fiber alignment 
(structure) and study its effect on the biaxial tensile behaviors of scaffold (function). We 
hypothesized that electrospinning polymer solution on a valve leaflet-inspired ring-shaped 
collector will yield anisotropic scaffolds compared to the isotropic scaffolds obtained on a 
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conventional flat aluminum foil surface. We further hypothesized that by changing the three 
parameters in the APS-co-PEG/PCL polymer blend formulation, namely 1) PEG amount in APS-
co-PEG, 2) APS-co-PEG concentration, and 3) total polymer concentration will enable widely 
tunable structural and mechanical properties of fibrous scaffolds. 
5.2 METHODS 
5.2.1 Materials 
All organic solvents used in the study and the chemicals, 1, 3-diamino-2-hydroxy-propane, 
glycerol, sebacic acid, poly (ε-caprolactone) (PCL, Mw = 70–90 kDa) were purchased from 
Sigma-Aldrich (St. Louis, MO). Polyethylene Glycol (PEG, Mw = 1 kDa) was obtained from 
Dow Chemical (Midland, MI). Cell culture supplies including media, trypsin–EDTA, and 
antibiotics were obtained from Corning (Corning, NY), unless otherwise mentioned. APS-co-
PEG pre-polymers were prepared via the one-pot two-step condensation polymerization as 
described earlier [213]. Here, three APS-co-PEG pre-polymers were synthesized by varying PEG 
mole percentage (15%, 25%, and 40% of PEG to sebacic acid) and labeled as APS-15PEG, APS-
25PEG, and APS-40PEG. 
5.2.2 Electrospinning process 
Fibrous scaffolds were fabricated by electrospinning. Briefly, blends of APS-co-PEG (APS-
15PEG, APS-25PEG, and APS-40PEG) and ε-PCL of different polymer concentrations were 
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dissolved in a mixture of ethanol and chloroform at a volume ratio of 1:9 (detailed formulation 
and nomenclature summarized in Table 11-13). For fabricating isotropic scaffolds, 
electrospinning was conducted using a conventional electrospinning set-up with a flat aluminum 
foil as a collector. For fabricating anisotropic scaffolds, a custom-made ring-shaped copper wire 
(Fig. 22a) was used as a collector. For both electrospinning set-ups, solutions were electrospun 
at 17 kV at a rate of 1 mL/h. The distance between the 21G needle and collector was kept at 12 
cm. The obtained electrospun scaffolds were dried in a vacuum desiccator overnight before 
further experiments. 
Table 11. Polymer formulations to study the effect of PEG amount in APS-co-PEG. 
 
Table 12. Polymer formulations to study the effect of APS-25PEG concentration. 
 
Table 13. Polymer formulations to study the effect of total polymer concentration. 
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5.2.3 Morphology of electrospun scaffolds 
Scaffold morphology and fiber alignment was characterized using scanning electron microscopy 
(SEM) (Zeiss Sigma500 VP, UK). Fibrous scaffolds were sputter-coated with 5 nm of gold–
palladium using Denton auto sputter coater (Denton Vacuum, Moorestown, NJ), and images 
were obtained using accelerated voltage of 3 kV. Images were analyzed for fiber diameters and 
alignment using NIH ImageJ Software with DiameterJ [246] and OrientationJ [247] plugins. At 
least four images (at 2000X magnification) were used from each group for analysis. 
5.2.4 Uniaxial mechanical testing 
Scaffold mechanical properties were studied using uniaxial tensile tests with MTEST Quattro 
mechanical testing system (ADMET, Norwood, MA). Scaffolds were cut into rectangular shapes 
(~15 × 7 mm2, n = 4 per group) and stretched at a constant displacement rate of 10 mm/min until 
sample failure. All anisotropic fibrous scaffolds were tested with the fibers oriented in the 
direction of the stress. The stress (MPa) was obtained by dividing the applied force (N) with 
cross-section area (mm2) while percentage elongation (strain, ε) was obtained from ε 
(%)=100×(L-L0)/ L0, where, L0 was initial gauge length and L was instantaneous gauge length. 
Elastic modulus in the linear region at 5–15% strain was calculated for each scaffold tested. 
5.2.5 Biaxial mechanical testing 
The electrospun scaffolds were cut into 12 × 12 mm2 (n = 6 per group) and mounted on a frame 
with the specimen edges aligned to the circumferential and longitudinal axis of the planar biaxial 
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system (TestResources Inc., USA). After mounting, four dots were made using a permanent 
marker on the sample for deformation tracking. All tests were performed in 0.9% saline 
maintained at 37 °C. The specimens were brought to a tare load of 0.05N along each axis and 
preconditioned equibiaxially with a maximum membrane tension of 90 N/m for 20 cycles on 
each axis to mimic the physiological condition experienced by native aortic valves [102, 108]. 
After preconditioning, three more equibiaxial cycles (90:90 tension ratio on each axis) were 
conducted and used for analysis. A high-speed camera (Basler AG, Germany) and software 
(Pylon, Basler AG, Germany) was used to capture the deformation of the scaffolds under the 
equibiaxial protocol. A custom-developed MATLAB code was used to track the movement of 
the dots and calculate the deformation gradient tensor (F) [232]. The Green’s strain (E) was 
calculated using: E=0.5(F^T×F-I), where I is the identity matrix. The equibiaxial stress-strain 
curves were plotted and analyzed to calculate the samples’ linear modulus, and degree of 
anisotropy (Fig. 22b). The linear modulus (LM) calculated as the slope of the stress-strain curve 
at the linear region experienced at high loads. The degree of anisotropy (DA) was calculated by 
the ratio of maximum strains experienced on both axes at maximum loading. The DA closer to 1 
denotes that the samples are isotropic in behavior while DA less than 1 denotes anisotropic 
behavior. 
5.2.6 Isolation and culture of human valve interstitial cells (hVICs)  
Human aortic valve interstitial cells (hVICs) were isolated from a healthy donor with normal 
valve function. De-identified human valvular tissues were collected from the University of 
Pittsburgh Medical Center (UPMC) as per the protocols approved by the University of Pittsburgh 
Institutional Review Board, PRO16050264 (St. Hilaire) and PRO0702120 with informed consent 
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(Dr. Gleason). The hVICs were isolated from donor tissue as per our previously reported 
protocol [248]. The hVICs were then propagated and cultured using DMEM supplemented with 
10% fetal bovine serum according to the established protocol. All experiments were carried out 
by using cells between passages 4 and 8. 
5.2.7 Seeding of hVICs on scaffold  
Prior to cell seeding, the scaffolds (10×10 mm2) were sterilized by exposing to 70% isopropanol 
under UV light for 30 min and rinsed with 1X DPBS thrice to remove any residual ethanol. The 
hVICs were seeded on to these scaffolds at a density of 100,000 cells/scaffold in a 24-well plate. 
After 24 h, scaffolds were transferred to a new well to remove the non-adherent cells. The 
culture was continued with media being replenished every other day. 
5.2.8 Cell proliferation by alamarBlue® assay 
The proliferation of hVICs seeded on the scaffolds was measured via monitoring cell metabolic 
activity over a period of 14 days using the alamarBlue® assay (Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol. Briefly, cell-seeded scaffolds were treated with 10% v/v 
alamarBlue® solution in hVIC culture medium for 4 h at 37°C. The fluorescence intensity of 
solution in each well was then measured using a microplate reader (Gen5 Biotek, Winooski, VT) 
at excitation/emission wavelengths of 530/590 nm. alamarBlue® solution (10% w/v) incubated 
without any cells was used for blank correction. 
 103 
5.2.9 Immunofluorescence staining  
The morphology and spreading of hVICs were studied by staining actin (ActinGreen™ 488 
ReadyProbes® Reagent, Life Technology, Waltham, MA) and nuclei of cells (NucBlue® Fixed 
Cell Stain, Life Technology, Waltham, MA) seeded on isotropic and anisotropic scaffolds (APS-
25PEG/PCL, 6+12%) after 7 days of culture. The cell-seeded scaffolds were fixed in 4% 
paraformaldehyde solution (30 min), followed by permeabilization and blocking using 0.1% 
Triton X-100 and 3% bovine serum albumin in DPBS. Confocal images were obtained using an 
inverted confocal laser scanning microscope (Olympus Fluoview 1000, Japan) under 10X 
objectives. The images were quantified for its actin orientation using NIH ImageJ Software using 
OrientationJ [247] plugin as previously described. 
5.2.10 Statistics  
Experimental data are presented as mean ± standard deviation unless otherwise mentioned. Data 
between multiple groups were analyzed using one-way or two-way ANOVA followed by 
Tukey’s post-hoc analysis. p values less than 0.05 were considered as significant.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Fabrication of anisotropic fibrous scaffold  
Based on our established polymer blend formulation of APS-co-PEG and PCL, we tuned the 
PEG amount in APS-co-PEG copolymer, concentration of APS-co-PEG, and the total polymer 
concentration to test the versatility of the proposed electrospinning collector and obtain scaffolds 
with a wide range of mechanical properties. All polymer formulations to be tested in this study 
(Table 11-13) were successfully electrospun onto both collectors using the same sets of 
electrospinning parameters. This enabled decoupling the effects of the collector and polymer 
formulation on the structural and mechanical properties of fibrous scaffolds.  
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Figure 22. Electrospun fiber collected on ring collector showed anisotropy.  
(a) Image of the ring collector; (b) Example of how linear modulus and max strain (used to 
calculate degree of anisotropy) were analyzed from the equibiaxial stress-strain curves; (c) SEM 
images of isotropic and anisotropic APS-25 PEG:PCL (6+12%, w/v) scaffolds, arrow indicates 
the fiber alignment; (d) Fiber alignment quantification by OrientationJ plugin in NIH ImageJ 
(n=at least 4 images); (e) Average fiber diameter quantified by NIH ImageJ (n=at least 4 
images); (f) Biaxial stress-strain plots of fibrous scaffold; (g) Degree of anisotropy calculated 
from biaxial stress-strain plots. *indicates p<0.05 (Unpaired t-test). 
 
Taking APS-25PEG:PCL (6+12%) formulation as an example, we first aimed to compare 
the differences between scaffolds collected on the flat aluminum foil and ring-shaped collectors. 
SEM image quantification revealed that fibrous scaffolds obtained from the flat aluminum foil 
had randomly aligned fibers showing an isotropic characteristic while those collected on the 
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ring-shaped collector were more aligned and anisotropic as shown by the sharp peak in the fiber 
alignment quantification (Fig. 22c and d). It was also revealed that the fibers collected on two 
collectors possessed different average diameters (1.527 µm ± 0.065 µm for isotropic scaffold and 
1.246 µm ± 0.081 µm for isotropic scaffold) although other electrospinning parameters were kept 
constant (Fig. 22e). This is in accordance with previous reports that the geometry of the 
electrospinning collector could influence the fiber architecture including fiber diameter [249].  
Compared to the uniaxial tensile testing, biaxial tensile testing is considered to be a more 
accurate characterization method to quantify the mechanical behavior of anisotropic tissues such 
as heart valves. Hence, we compared the differences in mechanical properties between the 
scaffolds obtained on flat aluminum foil and ring-shaped collector by the equibiaxial mechanical 
testing. These tests demonstrated that the scaffolds collected on the flat aluminum foil exhibited 
similar mechanical properties in two perpendicular directions, showing an isotropic behavior. On 
the other hand, scaffolds obtained on the ring-shaped collector behaved differently in their fiber 
and cross-fiber directions, showing mechanical anisotropy (Fig. 22f). Further quantification 
revealed that the scaffolds collected on aluminum foil had a DA closer to 1, indicating an 
isotropic mechanical behavior while the DA of scaffolds collected on the ring-shaped collector 
was significantly lower (and less than 1), suggesting an anisotropic behavior (Fig. 22g). As 
hypothesized, we showed that electrospinning on to a ring-shaped collector could be utilized to 
produce anisotropic scaffolds. In the following sections, we refer to the scaffolds collected on 
aluminum foil as isotropic scaffolds and those from the ring-shaped collector as anisotropic 
scaffolds. 
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Figure 23. Biaxial stress-strain plots of isotropic fibrous scaffolds.  
5.3.2 Effect of PEG amount in APS-co-PEG polymer on the mechanical properties of 
anisotropic electrospun scaffolds 
We then aimed to elucidate the effect of polymer formulation on the scaffold mechanical 
properties and screen for the polymer formulation that can mimic the native valve mechanical 
properties. Our previous studies had indicated that the PEG amount in APS-co-PEG (PEG molar 
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ratio in the polymer backbone from 15%-40%) influenced the scaffold mechanical properties 
[213]. Here, the concentration of APS-co-PEG and PCL were kept constant at 6% and 12%, 
respectively, to decouple the effect of PEG amount in APS-co-PEG (Table 11). The 
corresponding results regarding the isotropic scaffolds from same formulations are reported in 
Fig. 23. Since isotropic scaffolds displayed similar mechanical properties in the two directions, 
we focused on the anisotropic scaffolds in the following studies due to their unique structural and 
mechanical properties.  
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Figure 24. PEG amount in APS-co-PEG affected the scaffold structural and mechanical 
properties.  
(a) SEM images at magnification of 2000X; (b) Fiber alignment quantification by OrientationJ 
plugin in NIH ImageJ (n=at least 4 images); (c) Average fiber diameter quantified by NIH 
ImageJ (n=at least 4 images); (d) Elastic modulus of scaffolds obtained from uniaxial tensile test; 
(e) Biaxial stress-strain plots of fibrous scaffolds; (f) Degree of anisotropy (DA) and (g) Linear 
modulus calculated from biaxial stress-strain plots. *indicates p<0.05 (One-way ANOVA, 
Tukey’s post-hoc test). PAV: porcine aortic valve.  
 
SEM images and quantification revealed the anisotropic fiber alignment of electrospun 
scaffolds shown by the sharp peak of fiber orientation distribution from all three groups (Fig. 
24a and b). It was also observed from Fig. 24b that APS-25PEG scaffold seemed to have a 
higher degree of fiber alignment as compared to the other two types of scaffolds. All scaffolds 
had average fiber diameter ranging from 1-1.5 µm. Of note, APS-15PEG scaffolds had 
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significantly higher average fiber diameter than the other two copolymer formulations (Fig. 24c). 
It suggested that changing the amount of PEG in APS-co-PEG impacted the fiber morphology. 
Such effects may probably be due to the change in the hydrophilicity of polymer solutions with 
the changes in the PEG amount [146]. Uniaxial mechanical test showed that the scaffolds had an 
elastic modulus within the range of 4-6 MPa while native valve has been shown to have modulus 
from 2-15 MPa [110]. We also observed that APS-40PEG scaffolds had significantly higher 
modulus than APS-25PEG scaffolds (Fig. 24d). This is in agreement with our previous study on 
isotropic APS-co-PEG scaffolds where a higher modulus of APS-40PEG was attributed to its 
higher degree of crystallization [213].  
Biaxial mechanical behavior of the scaffolds was also influenced by the amount of PEG 
in APS-co-PEG (Fig. 24e). In accordance with the fiber alignment quantification (Fig. 24b), 
APS-25PEG scaffold demonstrated the lowest DA among the three formulations and was 
significantly lower than its isotropic counterpart (Fig. 24f). Interestingly, the anisotropic APS-
25PEG scaffold possessed a DA close to that of a porcine aortic valve (PAV). It was also noted 
that for APS-15PEG and APS-40PEG scaffolds, the DA of isotropic and anisotropic scaffolds 
were not significantly different. This observation was in agreement with the quantification of 
fiber alignment (Fig. 24b), indicating that the fiber architecture affected the anisotropy in biaxial 
tensile properties. The linear modulus of scaffolds in the fiber direction and cross-fiber direction 
was quantified from the equibiaxial stress-strain curves (Fig. 24g). APS-15PEG and APS-25PEG 
scaffolds had a linear modulus close to that of PAV at around 1000 kPa. Also, APS-15PEG 
scaffolds had significantly higher linear modulus compared to APS-25PEG and APS-40PEG 
scaffolds. This trend was not in complete agreement with the elastic modulus results from the 
uniaxial tensile test (Fig. 24d). We speculate that both, fiber architecture (alignment, Fig. 24b 
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and fiber diameter, Fig. 24c) and the intrinsic properties of the polymer blends (such as the 
crystallinity of the formulation) contributed to the scaffolds’ biaxial mechanical behaviors. It is 
also possible that when scaffolds were stressed on both axes simultaneously, the mechanical 
behaviors may differ from those when stressed uniaxially.  
It is also noted that the polymeric scaffolds and native valve tissue were not identical in 
their biaxial mechanical behaviors. As shown in the equibiaxial stress-strain plots obtained using 
physiological level of stress (Fig. 24e), PAV displayed non-linear mechanical behavior with two 
distinct linear regions. The initial toe region is attributed to the stretching of coiled collagen 
fibers, which is followed by a second stage where further elongation of the straightened collagen 
fibers results in a steep rise in tensile stress until the tissue attains maximum extensibility [250]. 
On the other hand, polymeric scaffolds, in general, as shown by us and others [250-253], have a 
relatively linear mechanical behavior. We speculate that the observed differences may also be 
due to the missing gel-like and glycoprotein-enriched spongiosa layer of native valve in the 
fabricated fibrous scaffolds. It is well known that spongiosa layer provide shock-absorbing and 
viscoelastic mechanical behaviors to the valve.   
Overall, we demonstrated that the amount of PEG in the APS-co-PEG polymer backbone 
modulated fiber alignment and biaxial mechanical properties. Due to the lowest DA (and similar 
to that of PAV) achieved by anisotropic APS-25PEG scaffold, we selected APS-25PEG as a 
polymer of choice in the following studies. 
 112 
5.3.3 Effect of APS-co-PEG concentration on the mechanical properties of anisotropic 
electrospun scaffolds 
We continued to study the effect of APS-co-PEG concentration on the structural and mechanical 
properties of fibrous scaffolds. The concentration of APS-co-PEG in the polymer blend can 
potentially impact the scaffold properties via changes in hydrophilicity, polarity, and crystallinity 
[254, 255]. However, this effect has not been carefully investigated in our previous study. Here, 
the concentration of PCL (carrier polymer, which dominates the solution viscosity) was kept 
constant at 12% w/w while changing the concentration of APS-25PEG from 3% to 12% (Table 
12). This study design allowed the investigation on the effect of APS-25PEG concentration. 
However, it should be noted that the total polymer concentration was also changed in the 
process. To better study the effect of total polymer concentration (solution viscosity), we fixed 
the ratio between APS-25PEG and PCL at 1:2 and proportionately increased both polymer 
concentrations in section 5.3.4. 
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Figure 25. APS-25PEG concentration (3-12%) in the polymer blend affected the structural and 
mechanical properties of fibrous scaffolds.  
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(a) SEM images at magnification of 2000X; (b) Fiber alignment quantification by OrientationJ 
plugin in NIH ImageJ (n=at least 4 images); (c) Average fiber diameter quantified by NIH 
ImageJ (n=at least 4 images); (d) Elastic modulus of scaffolds obtained from uniaxial tensile test; 
(e) Biaxial stress-strain plots of fibrous scaffolds; (f) Degree of anisotropy and (g) Linear 
modulus calculated from biaxial stress-strain plots. *indicates p<0.05 (One-way ANOVA, 
Tukey’s post-hoc test). 
 
SEM images and quantification revealed the anisotropic fiber alignment of all 
electrospun scaffolds with different APS-25PEG concentrations (Fig. 25a and b). All APS-
25PEG scaffolds had high degrees of fiber alignment as observed by the single sharp peak in 
their fiber alignment distribution. Decrease in the APS-25PEG concentration (from 12% to 3%) 
resulted in an increase in average fiber diameter (Fig. 25c) and reduction in elastic modulus as 
measured by uniaxial mechanical testing (Fig. 25d). It is well-known that electrospun fiber 
diameter inversely correlates with the elastic modulus [256], which is in line with our 
observations. These results suggested that APS-25PEG concentration played an important role in 
determining the fiber morphology and elastic modulus.  
Regardless of the APS-25PEG concentration, biaxial tensile testing revealed that all 
scaffolds exhibited anisotropy shown by the different mechanical behaviors in the fiber and 
cross-fiber directions (Fig. 25e). It was noted that the APS-25PEG concentration had no/minimal 
effect on the DA as DA of all scaffolds was similar to that of PAV (Fig. 25f). These results are in 
accordance with the fiber alignment quantification as shown in Fig. 25b. Similar to that noted in 
Fig. 25d, a decrease in APS-25PEG concentration (from 12% to 3%) showed a trend of 
reduction in the linear modulus obtained from the biaxial tests (Fig. 25g). We speculate that the 
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reduction in the modulus may be due to the increased fiber diameter with decreasing APS-
25PEG concentration, as explained earlier. Interestingly, the scaffold prepared with 12% APS-
25PEG had linear modulus similar to the PAV in both fiber and cross-fiber directions. Overall, 
APS-25PEG concentration in the polymer blend served as a tunable parameter to modulate 
biaxial mechanical properties of the electrospun scaffolds without affecting their anisotropy.  
5.3.4 Effect of total polymer concentration on the mechanical properties of anisotropic 
electrospun scaffolds 
Finally, we investigated the effect of total polymer concentration on the structural and 
mechanical properties of fibrous scaffolds. Polymer concentration in the electrospinning solution 
has been considered as a key parameter in determining the fiber architecture and uniaxial 
mechanical properties [244, 245, 257]. However, the effect of polymer concentration on the 
scaffold’s anisotropic fiber alignment and biaxial mechanical properties remains largely 
unexplored. Therefore, we formulated polymer blends of APS-25PEG and PCL by keeping a 
constant weight ratio of 1:2 and the total polymer concentration was changed from 5+10% to 
6+12% and 8+16% (Table 13). 
SEM image quantification revealed that the scaffolds were aligned with one single 
narrow peak in distribution of fiber alignment (Fig. 26a and b). The increase in the total polymer 
concentration (from 5+10% to 8+16%) resulted in the increase in the average fiber diameter 
(Fig. 26c) and elastic modulus (Fig. 26d). This observation is in agreement with the existing 
literature that increase in the total polymer concentration without changing other electrospinning 
parameters often leads to an increase in fiber diameter and tensile properties such as elastic 
modulus [244, 258]. Such effect of increased polymer concentration and hence, increased 
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solution viscosity has been attributed to the higher frequency of polymer chain entanglements 
and opposing jet stretching under the applied electric field [243, 259], thus increasing the 
average fiber diameter. 
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Figure 26. Total polymer concentration affected the structural and mechanical properties of 
scaffolds. 
(a) SEM images at magnification of 2000X; (b) Fiber alignment quantification by OrientationJ 
plugin in NIH ImageJ (n=at least 4 images); (c) Average fiber diameter quantified by NIH 
ImageJ (n=at least 4 images); (d) Elastic modulus of scaffolds obtained from uniaxial tensile test; 
(e) Biaxial stress-strain plots of fibrous scaffolds; (f) Degree of anisotropy and (g) Linear 
modulus calculated from biaxial stress-strain plots. *indicates p<0.05 (One-way ANOVA, 
Tukey’s post-hoc test) 
 
Biaxial tensile testing revealed that all three scaffolds displayed a mechanical anisotropy 
in the fiber and cross-fiber direction as compared to their isotropic counterparts (Fig. 26e and f). 
Regardless of the total polymer concentration (from 5+10% to 8+16%), the DA of all the 
scaffolds was similar to that of PAV (Fig. 26f) and this observation correlated with the fiber 
alignment distribution (Fig. 26b). Based on Fig. 25 and 26, anisotropy of fiber alignment is 
mainly determined by the electrospinning collector rather than the polymer formulation of APS-
25PEG and PCL. Similar to the uniaxial tensile properties, linear modulus from biaxial testing 
revealed the same trend where the increase in polymer concentration led to stiffer scaffolds (Fig. 
26g). Of note, 8+16% had similar linear modulus to PAV in the radial direction but higher in the 
circumferential direction. Therefore, changing total polymer concentration provides an 
alternative method to tune the structural and biaxial mechanical properties of fibrous scaffolds. 
Interpreting from all the above results, we concluded that fiber alignment closely affected 
the biaxial mechanical properties of fibrous scaffolds. Specifically, anisotropic fiber alignment 
led to anisotropic biaxial tensile properties while isotropic fiber alignment resulted in similar 
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tensile properties in two perpendicular directions. Moreover, we demonstrated the feasibility of 
tuning the structural and mechanical properties of the fibrous scaffold by changing multiple 
polymer formulation parameters.  
5.3.5 The cellular behavior of hVIC on isotropic and anisotropic scaffolds 
We further examined the effect of fiber anisotropy in directing the cellular behaviors of cultured 
cells. We selected hVICs as our cell model. In human valves, VICs are the most abundant cell 
type and actively involved in a number of activities related to the valve development, ECM 
remodeling, and direct disease progression [260, 261].  
After 14 days of culture, the metabolic activity of cells seeded on the scaffolds was 
assessed via alamarBlue® assay (Fig. 27). All scaffolds showed an increase in the metabolic 
activity of hVICs over time, indicating the active cell proliferation on the scaffolds. Importantly, 
there was no difference observed between the isotropic and anisotropic scaffolds of the same 
polymer formulation. Previously, we have shown the comparable cytocompatibility of isotropic 
APS-co-PEG and PCL composite scaffolds to PCL only scaffolds [242]. Taken together, these 
results indicated that the cytocompatibility of scaffolds was not affected by their architecture or 
formulation. This is advantageous as it allows the changes in polymer formulation to modulate 
other cellular behaviors without influencing cell proliferation.  
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Figure 27. Isotropic and anisotropic scaffolds supported the proliferation of hVICs as 
demonstrated by alamarBlue® assay at day 3, 7, and 14. 
 
It has been shown that the architecture of the cell culture substrate can direct the cell 
attachment and alignment, including VICs [78, 89].  Therefore, we investigated the cell-
instructive ability of our anisotropic scaffolds by seeding them with hVICs. We chose scaffolds 
prepared using APS-25 PEG:PCL (6+12%) to demonstrate the difference between isotropic and 
anisotropic scaffolds since these scaffolds showed the lowest DA and comparable mechanical 
properties to PAV. After 7 days of culture, hVICs seeded on the isotropic scaffold demonstrated 
a random cell alignment. On the contrary, the cells on anisotropic scaffolds adopted a more 
aligned morphology as demonstrated by a single narrow peak in the quantification of actin 
orientation (Fig. 28). Thus, we showed that the anisotropic scaffold may serve as a promising 
lead for developing heart valve tissue engineered scaffolds which can instruct cellular alignment 
via the anisotropic fiber alignment and mechanical properties. 
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Figure 28. hVICs displayed different morphology when cultured on isotropic and anisotropic 
scaffolds. 
5.3.6 Conclusion 
Overall, we demonstrated the feasibility to fabricate anisotropic fibrous scaffolds with tunable 
and controllable structural and mechanical properties. Fine-tuning of polymer formulations and 
electrospinning collector yielded scaffolds with valve-mimetic mechanical properties. This study 
provides a facile alternative strategy to the current pool of fabrication methods for biologically 
relevant tissue-engineered scaffolds. Although the fibrous scaffolds developed in this study were 
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not identical to the native valve tissue in their biaxial mechanical behaviors, we envision this 
study will inspire fibrous tissue-engineered scaffold design from its architectural and mechanical 
perspectives.  
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6.0  SHAPE-SPECIFIC NANOCERIA MITIGATE OXIDATIVE STRESS-INDUCED 
CALCIFICATION IN PRIMARY HUMAN VALVULAR INTERSTITIAL CELL 
CULTURES 
[Xue Y, St. Hilaire C, Hortells L, Phillippi JA, Sant V, and Sant S. Cellular and Molecular 
Bioengineering (2017) 10: 483.] 
6.1 BACKGROUND 
Valve calcification remains a major healthcare burden in developed countries, resulting in 
~17,000 deaths per year in the United States and currently affecting a quarter of the senior 
population older than 65 [1]. Calcification of the aortic valve, if not treated properly, can impair 
the normal valve movement and eventually lead to valve stenosis and heart failure [262]. 
Currently, the mainstream treatment option for valve calcification is valve replacement using 
either mechanical valves or bioprostheses, the former requires life-long anticoagulant therapy 
and the latter is still unfortunately susceptible to calcification and also need re-operation [263, 
264].  
There is a lack of pharmacological treatments for valve calcification [265]. Therefore, it 
is of great significance to elucidate the underlying mechanisms responsible for valve 
calcification, which can further be targeted for development of new therapies to prevent, halt, or 
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reverse calcification [266]. Potential mechanisms contributing to valve calcification include 
inflammatory cell infiltration [267], lipid accumulation [7], oxidative stress [154, 268], and local 
mechanical stress [269], all of which initiate an active cell-driven process that drives valve 
interstitial cells (VICs) to acquire myofibroblast phenotype and/or to differentiate into osteoblast 
phenotype [128]. As a result, excessive amounts of extracellular matrix proteins and calcium 
phosphate are secreted, which stiffen the valve and compromise its opening and closing [270]. 
Of the different mechanisms of valve calcification, oxidative stress has been recognized as a key 
upstream driving force in the early stages of the disease [154]. Increased reactive oxygen species 
(ROS) such as superoxide and hydrogen peroxide (H2O2) levels were found in the calcified 
regions of human stenotic valve tissues [155]. Moreover, instead of being merely a consequence 
of valve calcification progression, ROS production was found to precede the valve calcification 
in a mice model [156]. ROS have also been shown to induce fibrosis and mineralization by 
promoting pro-fibrotic and pro-osteogenic signaling pathways such as AKT pathway and TGF-β 
pathway [271, 272]. Furthermore, adenoviral transduction of catalase (CAT), a key antioxidant 
enzyme, decreased oxidative stress-induced differentiation of quiescent or myofibroblastic VIC 
into osteogenic phenotype and reduced calcific nodule deposition in human valve sclerosis-
derived cells [273]. However, the benefits of antioxidant therapies, which directly target 
oxidative stress to treat valve calcification, are yet to be studied.  
It should be noted that much of the current understanding of valve calcification is based 
on in vitro studies using either porcine or ovine models [274]. However, these animal models 
may not fully share the pathobiology of human valve calcification. It was reported that porcine 
VICs did not form mineral deposits when treated with osteogenic media with TGF-β1 [275] and 
became contact-inhibited monolayers, which behave unstably during long-term cell culture 
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[276]. Other studies have utilized non-valvular cells, such as vascular smooth muscle cells, as a 
cell model to study the calcification progression and explore potential therapeutics [277]. 
Although oxidative stress is a central component in directing both valvular and vascular 
calcification [278], there are striking differences in the mechanisms of inducing oxidative stress 
in these two types of calcifications [268]. Specifically, increased expression and activity of 
NAD(P)H oxidase is a major source of ROS production in vascular, but not valvular, 
calcification [279]. Additionally, when blood vessels are under oxidative stress, there is usually a 
compensatory increase in the activity of antioxidant enzymes (e.g. catalase, CAT and superoxide 
dismutase, SOD) [280]. However, in calcified valves, the activities of these antioxidant enzymes 
were found to be greatly reduced, which further exacerbate the oxidative stress-induced damage 
[155]. Therefore, use of human (normal or patient-derived) VICs (hVICs) (where calcific 
deposits initiate [281]) is of significant importance to delineate the underlying ROS-mediated 
mechanisms of initiation and progression of human valve calcification. Furthermore, hVICs-
based cell model will be more physiologically relevant for screening potential therapeutics in 
vitro. In this study, the first goal was to determine if the hydrogen peroxide (H2O2)-mediated 
oxidative stress could induce calcification in hVICs. We isolated hVICs from normal valve 
donor and patients with aortic valve stenosis. We further characterized normal and diseased 
hVICs for baseline SOD and CAT activity, mRNA expression levels of myofibroblast and 
calcification markers, as well as their response to H2O2-mediated oxidative stress. We also 
developed an in vitro oxidative stress-induced valve calcification model whereby treatment of 
inorganic phosphate (Pi) in presence of H2O2 induced calcification in diseased hVICs. 
The second goal of the study was to investigate the potential of cerium oxide 
nanoparticles (CNPs) to mitigate oxidative stress-mediated valve calcification as a novel 
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therapeutic intervention. CNPs act as self-regenerative ROS scavengers due to their catalytic 
activities by switching between Ce3+ and Ce4+ oxidation states [282]. CNPs can scavenge ROS 
such as H2O2 and superoxide by acting as CAT and SOD-mimetics, respectively [283-285]. 
CNPs are also effective scavengers for hydroxyl radical, nitric oxide radical, and peroxynitrite, 
making them broad spectrum antioxidants [282, 283]. CNPs have already been explored for 
several different cardiovascular applications as demonstrated in several studies in vitro [286, 
287] and in vivo [163, 288]. Thus, we hypothesized that ROS scavenging ability of CNPs can be 
exploited for preventing or treating oxidative stress-induced valve calcification.  
Metal oxide nanoparticles like CNPs can be synthesized in various shapes and sizes using 
controlled synthesis conditions [289]. However, most of the studies that use CNPs as 
antioxidants have been carried out without specifying nanoparticle shape. It is well known that 
nanoparticle shapes and sizes can have significant effect on their biological activities, such as 
intracellular uptake and localization [168] and therapeutic activity [169]. However, the effect of 
CNP shape on their ROS-scavenging activity has not been elucidated. Hence, we synthesized 
CNPs with controlled shapes such as spheres, short rods (SR), long rods (LR) and cubes. We 
compared the ROS modulating effect of shape-specific CNPs in diseased hVICs and investigated 
their potential therapeutic benefits in oxidative stress-induced valve calcification model in vitro. 
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6.2 METHODS 
6.2.1 Collection of human tissue samples and isolation and culture of human valvular 
interstitial cells (hVICs) 
We used de-identified human valvular tissues recovered at University of Pittsburgh Medical 
Center (UPMC) as per protocols approved by the University of Pittsburgh Institutional Review 
Board, PRO16050264 (St. Hilaire) and PRO0702120 with informed consent (Dr. Gleason). The 
subjects or their designates have given permission for the use of this tissue for medical research. 
Tissue and cell specimens do not have identifiers associated with them in order to protect human 
subjects’ identifiable information, privacy and confidentiality. Tissues and cells were collected 
regardless of gender, race or ethnic composition. To collect control tissue samples from autopsy, 
we have a Committee for Oversight of Research and Clinical Training Involving Decedents 
(CORID) protocol # 729. 
Human aortic valve cells were isolated from a healthy donor with normal valve (referred 
to as ‘normal’) and two patients with pre-operative diagnosis of valve stenosis (referred to as 
‘Diseased-1’ and ‘Diseased-2’). These hVICs were a kind gift from Dr. Thomas Gleason lab. 
Valve tissues were digested in Collagenase IV (2.5 mg/mL) with DMEM (+1% 
Penicillin/Streptomycin +1% Fungizone) for 30 min at 37 °C with gentle rocking. Digested 
tissue was passed through 70 µm filter and saved at 37 °C. Undigested tissue was further 
digested with Collagenase IV (0.8 mg/mL) for 1 h at 37 °C with gentle rocking. Digested tissue 
was again passed through 70 µm filter and pooled with the previously digested tissue. The 
pooled digested tissue was centrifuged at 2000 rpm for 5 min at 4 °C and then the supernatant 
were discarded. CD31-negative cells (VICs) were separated from the total cell population by 
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bead separation (Miltenyi, USA). Specifically, the entire population of VICs were mixed with Fc 
Blocking Reagent (Miltenyi 130-091-935) followed by addition of anti-CD31 beads (Miltenyi 
130-091-935). After 15 min incubation at 4˚C, the mixture was passed through a 30 µm pre-
separation filter (Miltenyi 130-041-407) into a 25 MS MACS Separation Column (Miltenyi 130-
042-201) and washed three times with culture medium. The resulting flow-through was retained 
as the CD31-negative portion of the cell population. The normal hVICs were propagated and 
cultured using DMEM supplemented with 10% fetal bovine serum according to established 
protocol [38]. Both diseased hVICs were propagated and cultured using Endothelial Cell Growth 
Media Kit (referred to as ‘hVIC culture media’) (Cell Applications, San Diego, CA) unless 
mentioned otherwise. All the experiments were carried out by using cells between passage 4 and 
8. 
6.2.2 Von Kossa Histological Stain 
Valves were excised from a healthy control (normal) and a patient with calcified valves 
(diseased). Tissue sections were fixed in freshly prepared paraformaldehyde (PFA, 4% w/v) in 
PBS for 2-4 h then washed with PBS for 1-2 h. Tissues were then serially washed in 30%, 50%, 
and 70% ethanol for 1-2 h each wash, then submitted to the University of Pittsburgh pathology 
core for embedding and sectioning onto glass slides. For Von Kossa staining, slides were heated 
to 65°C for 1 h, then deparaffinized by two 30 min washes in 100% xylene, followed by 3 min 
washes in 100% (twice), then one each of 90%, 80%, 70%, and 50% ethanol, followed by 
deionized water. Slides were then immersed in silver nitrate (3%, w/v) and exposed to UV light 
for 30 min, rinsed 3x in distilled water, then immersed in sodium thiosulfate (5%, w/v), rinsed in 
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3x in distilled water, and finally, counter stained with nuclear fast red for 5 min. Images were 
acquired using the EVOS® XL Imaging system. 
6.2.3 Immunostaining of CD31 and α-Smooth Muscle Actin (α-SMA) 
hVICs (50,000 cells/well) were cultured in 24-well plates for 2 days and fixed with PFA (4% 
w/v) for 20 min at room temperature. Subsequently, cell monolayers were permeabilized with 
Triton X-100 (0.1%, v/v) followed by blocking with bovine serum albumin (BSA, 3%, w/v) to 
avoid non-specific binding. Cell monolayers were incubated with primary antibodies against 
CD31 (Dako, pre-diluted) and α-smooth muscle actin (α-SMA; Dako, 1:200) diluted in blocking 
buffer for 2 h at room temperature along with a negative control (without primary antibody). 
After washing thrice with PBS, hVICs were incubated with Alexa Fluor 488-conjugated 
secondary antibodies (1:100) for 1 h at room temperature. Nuclei were counterstained with 
Hoechst (1:200). Images were acquired on a confocal microscope (Olympus Fluoview, 
Olympus) as a z-stack containing a series of 5 µm slices using 20X or 40X objectives. 
6.2.4 Superoxide dismutase (SOD) and catalase (CAT) assays 
SOD and CAT activity of normal and diseased hVICs were determined by SOD activity assay kit 
(Epigentek) and CAT activity assay kit (Cayman Chemical), respectively. Briefly, cell lysates 
were prepared by addition of radioimmunoprecipitation (RIPA) assay buffer containing Tris (50 
mM, pH 7.4), NaCl (150 mM), sodium deoxycholate (0.5% w/v), NP-40 (1% w/w), 
phenylmethane sulfonyl fluoride (PMSF, 0.05 mM) and protease inhibitor cocktail to the 
harvested cells on ice. The enzyme activity was measured in the extracted cell lysates according 
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to the manufacturers’ protocols. The enzyme activity was normalized to the total protein content, 
which was quantified by microbicinchoninic acid (BCA) protein assay (Pierce BCA, Thermo 
Scientific) according to the manufacturer’s protocol. 
6.2.5 Quantitative polymerase chain reaction (qPCR) 
mRNA expression of Vimentin (VIM), α-SMA and Runt-related transcription factor 2 (RUNX-2) 
and Osteopontin (OPN) were measured using real time quantitative polymerase chain reaction 
(qPCR). RNA was isolated using GeneJET RNA purification kit (Thermo Scientific, Lithuania, 
EU) according to the manufacturer’s protocol. RNA quality was measured by absorbance ratio at 
260/280 nm. Expression of VIM, α-SMA, OPN and RUNX-2 were analyzed by qRT-PCR using 
iTaq Universal SYBR one-step RT-PCR kit (BioRad Laboratories Inc., USA). Briefly, reaction 
mixtures containing 20 ng mRNA, 5 µL of 2X SYBR green master mix and respective primers 
(0.2 µM) were amplified in triplicate samples using an amplification protocol of 40 cycles of 
denaturation for 15 sec at 95 °C, annealing for 30 sec at 55 °C and extension for 30 sec at 72 °C 
(7500 Fast Real-Time PCR System, Applied Biosystems, USA). Gene expression was quantified 
using the ∆∆CT algorithm. Gene expressions in normal hVICs or respective untreated control of 
each patient cells served as a control for calculating fold change in mRNA expression as 
specified in each figure. Primer sequences are provided in Table 14. 
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Table 14. Summary of primers used. 
 Name Sequence 
1. β-actin F 5’-ACC TTCTAC AAT GAG CTG CG-3’ 
 β-actin R 5’-CCT GGA TAG CAA CGT ACA TGG-3’ 
2. Vimentin F 5’-CAA CCT GGC CGA GGA CAT-3’ 
 Vimentin R 5’-ACG CAT TGT CAA CAT CCT GTC T-3’ 
3. α-SMA F 5’-GGA ATC CTG ACC TTG AAG-3’ 
 α-SMA F 5’-CAC GAA GCT CAT TGT AGA-3’ 
4. RUNX-2 F 5’-CAGTTCCCAAGCATTTCATCC-3’ 
 RUNX-2 R 5’-TCAATATGGTCGCCAAACAG-3’ 
5. Osteopontin F 5’-TTGCAGCCTTCTCAGCCAA-3’ 
 Osteopontin R 5’-GATGCCTAGGAGGCAAAAGC-3’ 
 
 
6.2.6 Intracellular ROS detection by DCFH-DA assay 
The intracellular ROS levels in hVICs were measured by 2,7-Dichlorodihydrofluorescein 
diacetate (DCFH-DA) assay (Cayman chemical, USA). For DCFH-DA detection, media was 
removed and DCFH-DA (20 μM, 100 μL) in Hank's Balanced Salt Solution (HBSS) were added 
to each well and incubated for 30 min at 37 °C. DCFH-DA was then removed and cells were 
washed with HBSS. Subsequently, different treatments were given as described below and 
fluorescence intensity was measured at excitation/emission wavelength of 485/528 nm using a 
microplate reader (Synergy HT, BioTek instruments, USA). To ensure that the change in the 
fluorescence intensity was not due to the differences in the cell density or cell death, we adopted 
uniform cell seeding density and have selected the dose of H2O2 and CNPs that didn’t induce 
significant cell death. 
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6.2.7  Acute and long-term H2O2 treatment 
To determine the acute effect of H2O2 on hVIC behaviors, hVICs were seeded in a 96-well plate 
(9,000 cells/well) or a 24-well plate (100,000 cells/well) and allowed to attach for 24 h. 
Subsequently, hVICs were exposed to media containing H2O2 (100 μM, 100 μL) for 24 h. Cells 
were then subjected to ROS detection by DCFH-DA assay as described above. % ROS level was 
calculated using the equation below. Cell lysates and mRNA were analyzed for SOD/CAT 
activity and expression of VIM, α-SMA, OPN and RUNX-2, respectively. Cells without H2O2 
treatment were used as negative control.  
% ROS level = RFUH2O2 / RFUnegative × 100% 
To determine the long-term effect of H2O2 on hVIC behavior, hVICs were seeded in a 24-
well plate (100,000 cells/well) and allowed to attach for 24 h. Subsequently, hVICs were 
exposed to media containing H2O2 (100 μM, 100 μL) for up to 14 days with change of media 
(containing H2O2) every day. Calcium content of cell monolayers were analyzed at day 3, 7 and 
14. Cell lysates were analyzed for SOD/CAT activity on day 14. Cells without H2O2 treatment 
were used as negative control. 
6.2.8 Synthesis of shape-specific CNPs 
CNPs prepared in this study are denoted based on their shapes as observed in Transmission 
Electron Microscopy (TEM), namely cube, short rod (SR) and long rod (LR) and sphere. 
Spherical CNPs were prepared by ultra-sonication method [290]. Briefly, cerium nitrate 
hexahydrate (5 g, Sigma Aldrich, USA) and methoxy polyethylene glycol (mPEG, 5000 Da, 1 g, 
Acros Organics, USA) were dissolved in deionized water (100 mL). Subsequently, sodium 
 132 
hydroxide solution (5 mg/mL in deionized water, Sigma Aldrich, USA) was added at a rate of 5 
mL/min under constant sonication and stirring until the pH of the solution became 10. CNPs 
were washed with deionized water and ethanol several times until the pH of supernatant became 
neutral. CNPs were obtained by centrifugation followed by overnight drying at 100 °C.  Cube, 
SR, and LR CNPs were synthesized by hydrothermal method [289]. Briefly, cerium nitrate 
hexahydrate (0.868 g) was dissolved in deionized water (5 mL) and added in a drop-wise manner 
to sodium hydroxide solution (35 mL, 6 M for cube and SR while 9 M for LR) with stirring for 
30 min at room temperature. The solution was then sealed in a hydrothermal reactor and allowed 
to react at 100°C (SR and LR) or 180 °C (cube) for 24 h. Subsequently, CNPs were washed with 
deionized water and ethanol for several times until the pH of the supernatant became neutral. 
CNPs were obtained by centrifugation followed by drying overnight at 60 °C. 
6.2.9 Physicochemical characterization of CNPs 
The shapes of different CNPs were examined by TEM. Low concentration dispersions of CNPs 
were imaged on copper grids using electron microscope (JEOL 1011, Joel, Tokyo, Japan) 
operated at an accelerating voltage of 80 kV. Images were acquired without any staining. For 
characterization of particle size (hydrodynamic diameter), stock CNP dispersions (1 mg/mL) in 
HEPES buffer (pH=4, GE Healthcare, USA) were diluted to 25 µg/mL in hVIC culture media 
prior to measurements. Particle sizes were measured by dynamic light scattering (DLS) using a 
Malvern Zetasizer (Zetasizer 3000, Malvern, USA). To determine the effect of CNP shape on 
oxidation state of cerium (Ce3+ or Ce4+), the UV-Vis spectra (wavelengths 200-400 nm) were 
recorded using CNP dispersion (25 µg/mL) in deionized water using a SpectraMax M5e plate 
reader (Molecular Devices LLC, USA). 
 133 
6.2.10 AmplexRed® assays  
The H2O2 scavenging ability of CNPs was measured using Amplex® Red Hydrogen Peroxide 
Assay according to the manufacturer’s protocol (ThermoFisher Scientific, USA). CNPs (5, 25 
and 100 µg/mL) dispersed in HEPES buffer (0.01 M, 60 µL) were allowed to react with H2O2 
solution (10 µM, 60 µL) at room temperature for 30 min. Subsequently, equal volume (50 µL) of 
the reactants and working solution of Amplex® Red reagent (100 µM) and Horseradish 
Peroxidase (HRP, 0.2 U/mL) were allowed to react at room temperature for 30 min (n=4). The 
fluorescence intensity was then measured using microplate reader (Synergy HT, BioTek 
instruments, USA) at excitation/emission wavelengths of 540/590 nm. HEPES buffer (0.01 M) 
and butylated hydroxytoluene (BHT; 25 µM in 0.01M HEPES buffer) served as negative and 
positive control, respectively. Scavenged H2O2 was calculated using equation below.  
Scavenged H2O2 (%) = (RFUnegative-RFUCNP) / RFUnegative × 100% 
6.2.11 Cytotoxicity of CNPs by alamarBlue® assay   
The dose-dependent cytotoxicity of CNPs were determined by alamarBlue® assay (Thermo 
Scientific, USA) according to the manufacturer’s protocol. Briefly, hVICs (9,000 cells/well) 
were seeded in a 96-well plate and allowed to attach for 24 h. Subsequently, hVICs were 
incubated with shape-specific CNPs (0.01 - 100 µg/mL) in hVIC culture media (200 µL) for 24 
h. The cells were then incubated with alamarBlue® solution (10% v/v) prepared in hVIC culture 
media for 3 h at 37 °C. Fifty-microliter solution from each well was transferred to a 96-well plate 
and the fluorescence intensity was measured at excitation/emission wavelength of 530/590 nm 
using a microplate reader (Synergy HT, BioTek instruments, USA). The wells containing 
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alamarBlue® in media without cells were used as a negative control. Viability of CNP-treated 
cells was calculated using those without CNP treatment as 100% viability as per equation below.  
% Viability = RFUCNP / RFUnegative × 100% 
6.2.12 Treatment of CNPs to scavenge or prevent acute oxidative stress   
To determine shape-dependent effect of CNPs on scavenging H2O2-mediated pre-existing 
oxidative stress, the diseased hVICs were seeded in a 96-well plate (9,000 cells/well) or a 24-
well plate (100,000 cells/well) and allowed to attach for 24 h. Subsequently, hVICs were 
exposed to media containing H2O2 (100 μM, 100 μL). After 4 h incubation, CNPs were added at 
different doses (from 0.1-100 μg/mL, 100 μL) without removal of H2O2. The incubation was 
continued for another 24 h. Cells were then subjected to ROS detection by DCFH-DA assay.  
Cells treated with 100 µM H2O2 and 0 µg/mL CNPs served as positive control as 100% ROS 
generation and cells without H2O2 and CNPs served as negative control as 0% ROS generation. 
% ROS generation = (RFUCNP - RFUnegative)/( RFUpositive - RFUnegative) × 100% 
Alternatively, to investigate shape-dependent effect of CNPs on preventing acute ROS 
generation, hVICs were first exposed to media containing CNPs (25 μg/mL, 100 μL). After 24 h 
incubation, H2O2 (100 μM, 100 μL) were added without removal of CNPs. The incubation was 
continued for another 4 h. Cells were then subjected to ROS detection by DCFH-DA assay. Cells 
without any treatment with H2O2 and CNPs were used as negative control for ROS generation. 
Cells received hVIC culture media without CNPs and H2O2 containing were used as negative 
control as 100% ROS level. 
% ROS level = RFUtest / RFUnegative × 100% 
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To further determine the effect of CNP treatment on antioxidant enzyme activity as well 
as calcification potential, cell lysates and mRNA of LR CNP-treated groups (25 μg/mL) were 
analyzed for SOD/CAT activity and expression of VIM, α-SMA, OPN and RUNX-2, respectively. 
Cells without any treatment (neither H2O2 nor LR CNPs) were used as negative control while 
those exposed to only H2O2 without CNP treatment were used as positive control. 
6.2.13 Alizarin Red S staining   
The calcified nodule formation in hVIC cultures were determined by Alizarin Red S (ARS) 
staining [291]. At specific time points, media was removed, and cells were fixed using PFA (4%, 
w/v) for 15 min and incubated with ARS solution (40 mM, pH 4.3) for 30 min. Samples were 
washed with deionized water four times before imaging. 
6.2.14 Calcium content quantification   
Intracellular calcium was quantified as reported previously [292]. Calcium was extracted from 
cell monolayers by incubation with nitric acid (1 M) for 1 h. The supernatant (35 μL) was mixed 
with O-cresolphthalein (0.25 mg/mL, 35 µL) and 2-amino-2-methyl-1-propanol (150 mg/mL, 
87.5 µL) at room temperature for 20 min and the absorbance was measured at 575 nm. The 
amounts of proteins were then quantified by micro BCA protein assay (Pierce BCA, Thermo 
Scientific) as mentioned earlier and data is presented as amount of calcium normalized to the 
amount of protein. 
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6.2.15 ROS-mediated VIC calcification model   
To establish the Pi-induced calcification model in the presence of H2O2, diseased hVICs were 
cultured in 24-well plate (100,000 cells/well) in hVIC culture media for 48 h followed by 
calcification media (MEM-alpha supplemented with 10% fetal bovine serum) containing an 
additional 1 mM sodium phosphate monobasic (Pi) alone or in presence of 100 μM H2O2. Media 
was replenished every other day. ROS levels were measured after 2 h of each treatment by 
DCFH-DA assay. Calcification in hVICs cultures was determined using ARS staining and 
calcium content quantification at day 1, 4, and 7. To confirm that observed calcification was 
indeed mediated by oxidative stress, cells were also co-treated in parallel with an antioxidant 
(Vitamin E, 25 μM).  
To test the potential of CNPs in preventing calcification, hVICs were treated with LR 
CNPs (25 μg/mL) in the presence of Pi and H2O2 containing media. ROS were measured 2 h 
post-treatment while ARS staining and calcium content quantification were carried out 7 days 
after treatments. 
6.2.16 Statistical analysis   
Experimental data are presented either as mean ± standard error of the mean (SEM) or as mean ± 
standard deviation (SD) as specified in each figure legend. Multiple comparisons were analyzed 
for significance using one-way ANOVA or two-way ANOVA followed by Tukey’s post-hoc 
analysis. P-values less than 0.05 were considered as significant. 
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6.3 RESULTS AND DISCUSSION 
6.3.1 Characterization of patient derived hVICs 
Human heart valve consists of two major cell types, namely VICs and valvular endothelial cells 
(VECs) [128]. In this study, we isolated hVIC population from three different subjects, a normal 
healthy control (referred to as ‘normal’) and two patients with diseased (stenotic) aortic valves. 
The presence or absence of calcification in the valves from which hVICs were isolated was 
confirmed via histological analysis of neighboring tissue using Von Kossa stain (Fig. 29). 
Phenotype of hVICs was evaluated by immunofluorescence staining for α-SMA (VIC marker) 
and CD31 (VEC marker). All three cell populations stained positively for α-SMA but did not 
express CD31 (Fig. 30A), confirming that the cells used are predominantly interstitial cell 
population with no presence of an endothelial cell contaminant. Also, normal hVICs showed 
higher expression of α-SMA as compared to the diseased hVICs, which suggests that these 
diseased cells had less myofibroblastic VIC population. VICs are widely recognized as a 
heterogeneous and plastic cell population with diverse phenotypes including quiescent fibroblast, 
activated myofibroblast, diseased osteoblast and endothelial/mesenchymal progenitor cells [128]. 
The expression of α-SMA in hVICs is in accordance with earlier reports that VICs are 
spontaneously activated into myofibroblast phenotype, expressing α-SMA, in two-dimensional 
(2D) culture [261].  
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Figure 29. Valves isolated from a normal healthy control and a diseased patient were stained 
with Von Kossa. 
Scale bar = 100 µm. 
 
We further characterized the differences between normal and diseased hVICs by 
quantifying mRNA expression of key VIC markers including VIM (quiescent VIC marker 
[293]), α-SMA (activated VIC marker [293]), RUNX-2 and OPN (osteoblastic VIC marker 
[294]). Compared to the normal hVICs, both diseased hVICs demonstrated higher RUNX-2 and 
OPN levels, while showing similar mRNA levels of VIM (Fig. 30B). These results suggest that 
osteoblastic markers were upregulated in diseased hVICs isolated from patients with valve 
stenosis (a late stage of valve calcification). These results are in agreement with other reports that 
proposed involvement of osteoblastic differentiation of VICs during valve calcification process 
[154]. Diseased hVICs also exhibited reduced α-SMA levels compared to normal hVICs 
consistent with reduced α-SMA protein expression observed by immunostaining (Fig. 30A). 
Taken together, reduced expression levels of myofibroblast marker (α-SMA) coupled with 
increased levels of osteoblast (calcification) markers (RUNX-2 and OPN) in diseased hVICs 
suggest that diseased valves may have less myofibroblastic VIC population and more 
osteoblastic VIC population. This is highly plausible given that diseased VICs used in this study 
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were isolated from patients with valve calcification. Similar results were also observed in an in 
vitro VIC calcification model where α-SMA expression peaked and preceded the calcification 
and was then reduced in the later stage of calcification process [295].  
 
Figure 30. Patient-derived diseased hVICs exhibited higher expression of calcification markers 
and impaired antioxidant mechanisms. 
(A) Immunofluorescence staining of patient-derived hVICs revealed α–SMA positive but CD31 
negative cell population and similar morphology among the three populations in 2D culture. 
Scale bar = 100 µM; (B) Patient-derived diseased hVICs exhibited no change in expression of 
 140 
VIM, downregulated α-SMA expression (VIC activation marker) and upregulated RUNX-2 and 
OPN (calcification markers) when compared with normal hVICs (n=4); Patient-derived diseased 
hVICs exhibited decreased (C) SOD and (D) CAT activity when compared with normal hVICs 
(n=4); *indicates p<0.05 (One-way ANOVA). Data are presented as mean ± SEM. 
 
Impaired oxidative stress defense mechanisms due to reduced antioxidant enzyme 
expression and activity have been found in valve calcification [154, 268]. SOD and CAT are two 
key functional antioxidant enzymes in resolving oxidative stress [296]. Therefore, we measured 
the enzyme activities of SOD and CAT in normal and diseased hVICs (Fig. 30C and D).  
Diseased hVICs showed significantly lower SOD and CAT activities compared to normal hVICs 
similar to what was reported in human valve tissues [155]. Impairment of antioxidant enzyme 
activity may contribute to increased accumulation of H2O2. Indeed, Miller et al. demonstrated 
that calcified human aortic valves generate excessive amounts of superoxide and peroxide due to 
the impaired antioxidant defense mechanisms, namely, valvular CAT deficiency and reduced 
nitric oxide production [155]. 
6.3.2 H2O2-mediated oxidative stress in patient derived hVICs 
We compared the behaviors of normal and diseased hVICs in response to exogenous oxidative 
stress. H2O2 is a major type of peroxide found in a wide range of tissues and a major driving 
factor for ROS-mediated diseases [297]. Recent studies have highlighted the involvement of 
H2O2 in driving oxidative stress and exacerbating valve calcification [273, 277]. Therefore, H2O2 
was selected to induce oxidative stress in the current study. It was found that acute H2O2 
treatment (24 h) induced higher levels of ROS measured by DCFH-DA assay in the diseased 
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hVICs than in normal hVICs (Fig. 31A). Compromised or deficient defense mechanisms that are 
responsible for removal of ROS may have resulted in higher amount of (un-scavenged) ROS in 
the diseased hVICs. Indeed, we observed reduced antioxidant enzyme activities in both the 
diseased hVICs compared to normal hVICs (Fig. 30C and D). Furthermore, normal hVICs 
showed significantly decreased SOD and CAT activities after acute H2O2 treatment (Fig. 31B 
and C). We offer two explanations for this outcome. First, it is possible that these enzymes were 
utilized to scavenge H2O2-mediated oxidative stress. This explanation aligns with a recent report 
showing that the increased levels of ROS in the valve tissues were associated with the decreased 
local antioxidant enzyme activities rather than the induction of compensatory antioxidant 
enzymes activity, as seen in other tissues such as blood vessels [155]. Second, since both 
diseased hVICs showed lower antioxidant enzyme activities compared to those of normal hVICs 
(Fig. 30C and D), it is possible that their inherent antioxidant capacities were already deficient 
and could not adequately neutralize the oxidative stress assault.  
To further elucidate the effect of acute H2O2 treatment on the phenotypic changes in 
hVICs, mRNA expression of VIM, α-SMA, RUNX-2 and OPN were compared before and after 
acute H2O2 treatment in normal and diseased hVICs (Fig. 31D). In all three hVICs, mRNA 
expression of VIM and α-SMA were unaffected, indicating H2O2 may not have a direct impact 
on the VIC activation in 2D cell culture. Importantly, H2O2-induced RUNX-2 and OPN mRNA 
expression levels were upregulated in both the diseased hVICs but not in normal hVICs. The 
differential behaviors of diseased and normal hVICs could be due to the ability of normal hVICs 
to better resolve H2O2-induced acute oxidative stress than that of diseased VICs (Fig. 31A). 
These data indicate that acute unresolved H2O2-induced oxidative stress promoted the 
differentiation of quiescent or myofibroblastic hVICs towards the osteoblast-like phenotype, 
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which may contribute to the valve calcification process. Previously, acute H2O2 treatment has 
been shown to upregulate gene expression of RUNX-2 in vascular smooth muscle cells [298], 
and the osteogenic transcription factors MSX2 in mouse aorta adventitial myofibroblasts [299]. 
The current study supports prior studies demonstrating that oxidative stress is one of the critical 
factors contributing to ectopic calcification. Taken together, the diseased hVICs showed 
impaired abilities to scavenge ROS and respond to oxidative stress-induced changes by 
promoting gene expression of upstream markers of calcification. Hence, diseased VICs were 
chosen as the cell model for studying the oxidative stress-induced calcification and exploring 
potential calcification prevention agents. 
 
Figure 31. Patient-derived diseased hVICs were more susceptible to H2O2-mediated oxidative 
stress and stress-induced upregulation of calcification markers. 
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(A) Acute treatment with exogenous H2O2 (100 µM, 24 h) resulted in higher intracellular ROS 
levels in the diseased hVICs than the normal hVICs (n=4). *indicates p<0.05 (One-way 
ANOVA); (B, C) Normal hVICs, but not diseased hVICs demonstrated reduction in the 
SOD/CAT activities after H2O2 treatment. (n=4); (D) H2O2-mediated oxidative stress did not 
affect VIM and α-SMA expression in normal and diseased hVICs. Diseased hVICs exhibited 
elevated expression of calcification markers compared to the untreated controls while normal 
hVICs maintained basal expression levels of calcification makers after treatment with H2O2. 
*indicates p<0.05 (Two-way ANOVA). Data are presented as mean ± SEM. 
6.3.3 CNPs characterization and abiotic ROS scavenging properties 
In the light of lack of pharmacological treatments for valve calcification, we explored shape-
specific CNPs as a novel antioxidant therapy for the treatment of oxidative stress-induced valve 
calcification. Furthermore, we investigated the effect of CNP shape on their antioxidant 
properties. Four shape-specific CNPs were synthesized via hydrothermal reactions (cube, short 
rod (SR) and long rod (LR) CNPs) or ultra-sonication (sphere CNPs) between cerium nitrate and 
sodium hydroxide and characterized for their physico-chemical properties. TEM revealed 
uniform shapes in each batch of the nanoparticles (Fig. 32A), thus enabling investigation on the 
effect of nanoparticle shapes on their antioxidant properties. Synthesized shape-specific CNPs 
showed aspect ratio ranging from 1:1 to 21:1 (measured by TEM image analysis) and 
hydrodynamic sizes ranging from 120 nm to 220 nm (Table 15). The oxidation state of cerium is 
a key characteristic of CNPs as their antioxidant activity is highly dependent on their ability to 
switch reversibly between Ce3+ and Ce4+ oxidation state [282, 283]. UV-Vis absorbance is a 
facile method to determine the oxidation state of CNPs in aqueous solution [300]. None of the 
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CNPs demonstrated significant peak at 250 nm (Fig. 32B), suggesting low or negligible 
percentage of Ce3+ population [300]. SR, LR and sphere CNPs showed strong absorbance peaks 
at 300 nm (Fig. 32B), suggesting predominant presence of Ce4+ population [300]. Cube CNPs 
showed less intense absorbance peaks at 300 nm, indicating lower percentage of Ce4+ population 
in cube CNPs compared to SR, LR and sphere CNPs.  
Table 15. Aspect ratio and hydrodynamic size of four shape-specific CNPs. 
 Cube Short Rod (SR) Long Rod (LR) Sphere 
Aspect ratio
#
 1:1 8:1 21:1 1:1 
Hydrodynamic 
size (nm)
##
 
220.1±3.6 121.8±0.8 119.7±1.5 121.1±1.2 
  
#  Aspect ratio is defined as the ratio of length to width of a nanoparticle as measured by TEM image 
analysis. 
## Hydrodynamic size is determined by using CNP suspension (25 µg/mL) in hVIC culture media by 
dynamic light scattering. 
 
The intrinsic ability of CNPs to scavenge H2O2 (non-cellular) was measured by Amplex® 
Red assay. SR, LR and sphere CNPs exhibited significantly higher dose-dependent H2O2 
scavenging ability (5-100 µg/mL) than cube CNPs (Fig. 32C). This observation is in accordance 
with a previous report that cube CNPs synthesized by hydrothermal method had lower ROS 
scavenging ability than that of other shapes such as rod and sphere [301]. As suggested earlier, 
this may be attributed to differences in the morphology, agglomeration, and Ce3+/Ce4+ ratio of 
different shape-specific CNPs [301]. Additionally, the lower ROS scavenging ability of cube 
CNPs may also be associated with its lower Ce4+ population as shown in Fig. 32B since catalase 
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(CAT)-mimetic activity of CNPs requires predominantly Ce4+ oxidation state to scavenge H2O2 
[302].  
 
Figure 32. Physico-chemical characterization of shape-specific CNPs. 
(A) Transmission electron microscopy (TEM) images revealed shape-specific CNPs with defined 
shapes. Scale bar = 200 nm; (B) UV-Vis spectra of shape-specific CNPs showing presence of 
predominantly Ce4+ oxidation state; (C) Hydrogen peroxide (H2O2) scavenging ability of shape-
specific CNPs measured by AmplexRed assay (n=4). * indicates p<0.05 (Two-way ANOVA). 
Data are presented as mean ± SD. 
 
To measure the acute cytotoxicity of CNPs, the diseased hVICs were exposed to different 
doses of CNPs (0.01 μg/mL-100 μg/mL in hVIC culture media) for 24 h. None of the CNPs 
posed significant acute cytotoxicity (Fig. 33), demonstrating their good cytocompatibility. Of 
note, low dose of CNP treatment (0.01 μg/mL) showed increased cell viability when compared 
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with untreated control. CNPs have been shown to enhance primary mouse embryonic fibroblast 
proliferation at similar low dose range, which was attributed to its ability to maintain redox 
balance for enhanced intracellular homeostasis and metabolism [303]. Our results indicate that 
shape-specific CNPs do not exhibit acute cytotoxicity in the dose range of 0.01-100 μg/mL. 
 
Figure 33. Shape-specific CNPs demonstrate no significant acute (24 h) cytotoxicity in the 
diseased hVICs as measured by alamarBlue® assay.  
(n=3, Data are presented as mean ± SEM) 
6.3.4 In vitro ROS scavenging properties of CNPs in hVICs 
The ROS scavenging ability of CNPs in the diseased hVICs were first determined by measuring 
the intracellular ROS levels in response to 4 h pre-treatment of H2O2 (100 µM) to induce acute 
oxidative stress followed by 24 h CNP treatment (0.1-100 μg/mL). This experimental design 
allows us to explore the dose- and shape-dependent activity of CNPs to scavenge pre-existing 
ROS induced by pre-treatment of H2O2. Consistent with the results from the non-cellular H2O2 
scavenging assay (Fig. 32C), SR, LR and sphere CNPs exhibited dose-dependent ROS 
scavenging ability in both populations of diseased hVICs (Fig. 34A). It is noted that at 100 
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μg/mL, SR, LR and sphere CNPs were able to scavenge all the ROS generated by H2O2. On the 
other hand, cube CNPs were unable to scavenge pre-existing ROS even at a high dose of 100 
μg/mL. Although antioxidant activity of CNPs has already been reported in a variety of in vitro 
and in vivo studies [163, 286], shape-dependent effect on the ROS scavenging activity has only 
been studied in a non-cellular system [301] and remains unexplored in cellular systems. Here, for 
the first time, we demonstrated that CNPs exhibited shape-dependent ROS scavenging activity in 
the diseased hVICs under acute oxidative stress. Since the IC50 values of SR, LR and sphere 
CNPs in scavenging ROS in the diseased hVICs were less than 25 µg/mL (Table 16), we chose 
25 µg/mL as an effective dose for exploring the shape-dependent effects of CNPs in the 
following studies. We compared therapeutic activity of different shapes at a single dose of 25 
µg/mL (Fig. 34B). SR, LR and sphere CNPs but not cube CNPs exhibited ROS scavenging 
ability in both diseased hVICs.  
Table 16. Summary of IC50 values of shape-specific CNPs in scavenging ROS in the diseased 
hVICs 
IC50 (µM) Cube SR LR Sphere 
Diseased-1 N/A 21.7±1.34 22.8±1.36 16.45±1.22 
Diseased-2 N/A 12.55±0.88 13.46±1.13 17.18±1.15 
 
 
 The ability of CNPs to prevent ROS generation in the diseased hVICs was evaluated by 
measuring the intracellular ROS levels after 24 h CNP pre-treatment (25 μg/mL) followed by 4 h 
treatment of H2O2 (100 µM) to induce oxidative stress. Diseased-1 hVICs pre-treated with SR, 
LR and sphere CNPs but not cube CNPs showed significant reduction in ROS levels compared 
to 0 μg/mL CNP pre-treated group (Fig. 34C). Diseased-2 hVICs pre-treated with all CNPs 
showed significant reduction in ROS levels compared to cells without CNP treatment (Fig. 34C). 
These results indicated the ability of CNPs in protecting hVICs from exogenous oxidative stress. 
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Figure 34. Shape-specific CNPs scavenged acute H2O2-mediated oxidative stress in the diseased 
hVICs.  
(A) As illustrated in the experimental workflow, SR, LR and sphere but not cube CNPs 
scavenged in a dose-dependent manner, pre-existing intracellular ROS generated by H2O2 (100 
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µM, 4 h) in both diseased hVICs as measured by DCFH-DA assay (n=4). *indicates p<0.05 
(Two-way ANOVA); (B) At the dose of 25 µg/mL, SR, LR and sphere but not cube CNPs 
scavenged pre-existing intracellular ROS generated by H2O2 (100 µM, 4 h) in diseased hVICs as 
measured by DCFH-DA assay (n=4). *indicates p<0.05 (One-way ANOVA); (C) As illustrated 
in the experimental workflow, pre-treatment with CNPs (25 µg/mL, 24 h) prevented intracellular 
ROS accumulation following treatment with H2O2 (100 µM, 4 h) in diseased hVICs in a shape-
dependent manner (n=4). * indicates p<0.05 compared to H2O2 only treatment (One-way 
ANOVA). Data are presented as mean ± SEM. 
 
Together, these data show that LR CNPs are effective in scavenging pre-existing ROS 
and in preventing ROS generation in both diseased hVICs. Therefore, we chose to focus on LR 
CNPs and study their therapeutic effects in combating oxidative stress-induced VIC calcification 
in the following studies. 
To elucidate the mechanisms by which LR CNPs are able to reduce the intracellular 
ROS, we further measured the SOD/CAT activities of the diseased hVICs after H2O2 pre-
treatment followed by LR CNP treatment. LR CNP treatment significantly increased SOD and 
CAT activities in both diseased hVIC populations (Fig. 35A and B). In addition to its intrinsic 
ability to scavenge ROS (Fig. 32C), LR CNPs may have exerted their ROS scavenging effect by 
enhancing the cellular antioxidant enzyme activities as means of maintaining redox balance. 
CNPs are known for their broad spectrum antioxidant mechanisms [283, 284]; however, to the 
best our knowledge, the ability of CNPs to enhance cellular antioxidant enzyme activity in vitro 
has not been demonstrated. Due to limited studies in the field, the exact antioxidant mechanisms 
(scavenging of radicals, superoxides or peroxides) required for inhibiting valve calcification 
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remain elusive. Previously, antioxidants such as tempol and lipoic acid [277], as well as 
adenovirus-mediated over-expression of SOD or CAT [273], have been explored for treating 
valve calcification. In these previous studies, supplement of antioxidant (either in the form of 
small molecule drug or antioxidant enzyme) did not demonstrate consistent therapeutic effects on 
mitigating the progression of valve calcification. Therefore, CNPs with broad intrinsic ROS 
scavenging mechanisms as well as the ability to enhance cellular antioxidant enzyme activities 
(SOD/CAT-mimetic) may be advantageous in mitigating oxidative stress-induced valve 
calcification. 
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Figure 35. Shape-specific CNPs scavenged acute H2O2-mediated oxidative stress in the diseased 
hVICs. 
LR CNP treatment upregulated SOD (A) and CAT (B) activity after H2O2-mediated oxidative 
stress (100 µM, 24 h) in the diseased hVICs (n=3); LR CNPs didn’t change expression of 
fibroblast and myofibroblast markers in the diseased hVICs (C) and (D); LR CNPs decreased 
H2O2-induced expression of calcification markers in the diseased hVICs (E) and (F) (n=3). 
*indicates p<0.05 (One-way ANOVA). Data are presented as mean ± SEM. 
 
Given the excellent ROS scavenging ability of CNPs in hVICs (Fig. 34), we further 
evaluated if CNP treatment can inhibit oxidative stress-induced upregulation of markers that 
precede calcification. As shown in Fig. 35C, LR CNP treatment after oxidative stress induction 
by H2O2 had no significant effect on the mRNA expression levels of VIM and α-SMA but 
reduced the expression of upstream calcification markers (RUNX-2 and OPN) in the diseased 
hVICs. Since we also observed that oxidative stress was able to upregulate calcification marker 
expression (Fig. 31D), this noted reduction in the presence of LR CNPs suggests that LR CNP is 
able to scavenge ROS (Fig. 34) and upregulate SOD/CAT activities (Fig. 35A and B). These 
results suggest that LR CNPs may be able to mitigate oxidative stress-induced calcification in 
hVIC cultures. 
6.3.5 In vitro calcification model of hVICs 
Although we observed increased calcium content in the Diseased-1 hVICs cultured with long 
term (14-day) H2O2 treatment, H2O2 treatment alone did not induce ARS-positive calcific nodule 
formation in the Diseased-1 hVICs (data not shown). Therefore, we further explored to enhance 
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oxidative stress (H2O2)-induced calcification by combining with the inorganic phosphate (Pi)-
induced in vitro calcification model. Although Pi-induced in vitro calcification model has been 
widely used in studying ectopic vascular and breast calcification [292, 304], we did not find any 
report on Pi-induced valve calcification in vitro. Nonetheless, hyperphosphatemia is suggested to 
be one of the major driving factors for in vivo calcification [270], further highlighting the 
significance of studying Pi-induced valve calcification in vitro. To optimize the experimental 
conditions for Pi-induced hVIC calcification, Diseased-1 hVICs were treated with different 
concentrations of Pi (1-10 mM) for 14 days and calcification was evaluated by ARS staining and 
calcium content quantification. Treatment with exogenous Pi alone induced ARS-positive 
calcific nodule formation in Diseased-1 hVICs in a dose-dependent manner (Fig. 36) and 1 mM 
Pi was sufficient to induce a substantial amount of calcification and therefore, chosen as the dose 
for further study.  
 
Figure 36. Inorganic phosphate (Pi) induced calcification in a dose-dependent manner in 
diseased-1 hVICs in 14 days. 
(A) positive Alizarin Red S staining and (B) calcium content quantification by o-cresolphthalein 
assay (n=3). * indicates p<0.05 (One-way ANOVA). Data are presented as mean ± SEM. 
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 To investigate the role of oxidative stress in promoting hVIC calcification, H2O2 (100 
µM) was supplemented with the Pi-containing (1 mM) calcification media. The presence of Pi 
and oxidative stress (H2O2) recapitulated two major microenvironmental cues that co-exist in the 
calcified valves [266, 268] to serve as a physiologically relevant in vitro diseased model. The 
acute ROS generation was measured by DCFH-DA assay 2 h post-treatment with the 
calcification media. In accordance with a previous study that showed Pi-induced acute ROS 
generation in vitro (within 1-2 h) [305], we also observed Pi-induced ROS generation in the 
Diseased-1 hVICs, which was enhanced by the addition of H2O2 and reduced by concurrent 
administration of antioxidant Vitamin E (Fig. 37A). Similar results of ROS generation were also 
observed in the Diseased-2 hVICs when treated with Pi alone, Pi+H2O2, and Pi+H2O2+Vitamin E 
(Fig. 38). Diseased-1 hVICs were chosen as the cell model for further study. The addition of 
H2O2 increased Pi-induced positive ARS staining and calcium content in a time-dependent 
manner compared to Pi alone treatment in a 7-day study. Such increased calcification was 
diminished by the concurrent administration of vitamin E (Fig. 37B and C), thus validating the 
role of exogenous oxidative stress in promoting VIC calcification. This observation is in 
agreement with the previous finding that ROS generation precede and mediate valve calcification 
[156]. Overall, these data demonstrate that oxidative stress could further exacerbate calcification 
progression in hVICs in a Pi-induced calcification model. 
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Figure 37. H2O2-mediated oxidative stress further enhanced calcification in the inorganic 
phosphate (Pi)-induced in vitro calcification model. 
Diseased-1 hVICs were cultured in the presence of additional Pi (1mM) alone, Pi + H2O2 (100 
µM) or Pi + H2O2 + Vitamin E (50 µM) for 2 h, 1, 4 and 7 days. (A) Addition of H2O2for 2 h 
increased intracellular ROS levels compared to Pi alone treatment and addition of Vitamin E 
prevented such H2O2-induced ROS (n=4). *indicates p<0.05 (One-way ANOVA); (B) Positive 
alizarin red S (ARS) in Pi-treated cultures exhibited a time-dependent increase that was 
enhanced by addition of H2O2. Co-treatment with antioxidant Vitamin E inhibited H2O2-induced 
ARS positive staining; (C) Diseased-1 hVICs showed increased calcium content when treated 
with Pi + H2O2 when compared with Pi treatment alone as measured by o-cresolphthalein assay. 
Co-treatment of hVICs with Vitamin E inhibited the calcium secretion in the presence of Pi and 
H2O2 (n=3). *indicates p<0.05 (Two-way ANOVA). Data are presented as mean ± SEM. 
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Figure 38. Addition of H2O2 increased intracellular ROS levels within 2 h in Diseased-2 hVICs. 
Addition of Vitamin E prevented such increase (n=4). * indicates p<0.05 (One-way ANOVA). 
Data are presented as mean ± SEM. 
6.3.6 Anti-calcification properties of CNPs in hVICs calcification model 
We further tested the hypothesis that CNPs will be able to mitigate the oxidative stress-induced 
hVIC calcification in vitro. As expected, the concurrent administration of LR CNPs decreased 
the H2O2-induced ROS generation (2 h) (Fig. 39A). We further revealed that long term (7-day) 
co-treatment of LR CNPs with Pi and H2O2 significantly increased the SOD and CAT activities 
in the Diseased-1 hVICs (Fig. 39B and C), suggesting the beneficial role of CNPs in modulating 
cellular antioxidant enzymes to combat oxidative stress. These results agree with the observation 
of increased SOD and CAT activities in diseased hVICs after short-term (24 h) co-treatment of 
LR CNPs with H2O2 (Fig. 35A and B).  
 Finally, the therapeutic benefit of LR CNPs in mitigating the Pi and H2O2-induced 
calcification was demonstrated by ARS staining and calcium quantification. Compared to the 
control group treated only with Pi and H2O2 without CNP treatment, the addition of LR CNPs 
reduced calcified nodule formation as revealed by less ARS staining and decreased total calcium 
content (Fig. 39D), which may be attributed to the ROS scavenging ability of LR CNPs. 
Previously, CNPs have been shown to inhibit osteogenic differentiation of primary mouse bone 
marrow stromal cells revealed by inhibition of mineralized nodules formation and alkaline 
phosphatase activity [306]. However, the underlying mechanisms were not explored. Our results 
strongly suggest that SOD/CAT-mimetic activity coupled with their ROS scavenging ability 
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allow CNPs to efficiently mitigate H2O2-induced oxidative stress and hence, inhibit the in vitro 
calcification in hVIC cultures. 
 
Figure 39. LR CNPs decreased calcium content in Pi and H2O2-induced calcification model. 
(A) LR CNPs reduced Pi+H2O2-induced acute intracellular ROS levels after 2 h treatment 
measured by DCFH-DA assay (n=4); LR CNPs enhanced SOD (B) and CAT (C) activities of 
diseased hVICs after 7-day treatment (n=3). (D) After 7-day treatment, LR CNPs reduced Pi + 
H2O2-induced calcification as revealed by decreased Alizarin Red S staining and calcium content 
by O-cresolphthalein assay (n=3); *indicates p<0.05 (One-way ANOVA). Data are presented as 
mean ± SEM. 
6.3.7 Study limitations and outlook 
The current study investigated the role of oxidative stress in mediating valve calcification by 
developing novel ROS-induced hVIC calcification model in vitro and proposed CNPs as a novel 
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potential treatment option. Although the presence of both Pi and oxidative stress were taken into 
consideration in our study, there are some limitations that we would like to acknowledge. First, 
the current studies were conducted in 2D cell culture, which may not directly reflect the VIC 
activities in vivo since VICs are known to undergo phenotypic changes in 2D cultures [295]. 
Future study investigating the role of oxidative stress and potential therapeutics in a 3D VIC 
culture system using suitable matrix will be informative. Second, in the current study, LR CNPs 
were co-administrated with Pi and H2O2. However, to further facilitate the translation of the 
therapy, it is worthwhile to explore the effect of time of treatment with LR CNPs on preventing 
and possibly, reversing the progression of pre-existing calcification caused by Pi and H2O2. Last 
but not least, we studied only two different calcified VIC populations and one normal VIC 
population. Therefore, it might not be appropriate to generalize our observations for all stenotic 
and normal VICs based on such small sample size. In order to make general conclusions on each 
group (normal vs. diseased) on the whole, future studies are required to include calcified and 
normal VIC populations from larger number of patients to fully understand gene regulation 
across normal physiology and various pathological states.  
In order to facilitate the potential translation of CNP for valve calcification therapy, we 
envision that the local delivery of CNPs via a tissue-engineered construct [264] or polymeric 
drug carrier [307] will minimize the systemic exposure and prevent the calcification of valve 
replacement. 
6.3.8 Summary 
In conclusion, we demonstrated that hVICs derived from calcified valves exhibited impaired 
antioxidant defense mechanisms and were more susceptible to oxidative stress than normal 
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hVICs. CNPs scavenged H2O2-induced oxidative stress in hVICs in a shape- and dose-dependent 
manner. The intrinsic ROS scavenging ability of CNPs and their ability to induce cellular 
antioxidant enzyme activities may confer protection to hVICs from oxidative stress-exacerbated 
calcification. In a nutshell, our results suggest CNPs to be a promising antioxidant therapy for 
treating valvular calcification and deserve further investigations. 
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7.0  PEGYLATED ELASTOMER-CNP NANOCOMPOSITE FIBROUS SCAFFOLDS 
WITH REDUCED CALCIFICATION TENDENCY  
7.1 BACKGROUND 
As the mainstay of treatment for valvular heart diseases, the currently available valve 
replacements are far from ideal [31, 264]. To name a few, valve replacement by a bioprosthetic 
valve often lead to ectopic calcification in vivo and its tendency towards mechanical failure 
further shortens its durability [8]. On the other hand, mechanical valve replacements demand 
long-term anticoagulant therapy and may be subjected to life-threatening hemodynamic failure 
[9, 10]. More importantly, both valve replacements are not viable and cannot grow with patients 
[11]. As a result, these valve replacements are likely to require re-operation, often multiple re-
operations, especially for pediatric patients [12].   
Tissue engineering based regenerative heart valve therapy, which employs a viable valve 
replacement with the potential to grow and remodel upon implantation is of huge interest. Prior 
research in the field have not only illustrated several key parameters in the design of tissue 
engineered valve as mentioned in Chapter 1 [78, 95, 101, 264, 308] but also led to several 
important achievements such as the encouraging proof-of-concept results from preliminary large 
animal studies and clinical trials [136, 309]. It has been widely acknowledged that a 
biodegradable tissue-engineered valve replacement, which can withstand the dynamic in vivo 
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environment, mimic the native valve ECM structure and properties, and guide the valve 
regeneration, is highly advantageous [310-312]. Many studies have demonstrated the feasibility 
and functionality of scaffolds, which possess these properties individually [37, 38, 57, 58, 74, 
181]. However, fewer studies have incorporated multiple design criteria in a single tissue 
engineered valve. Moreover, since calcification of native valves and valve replacements have 
been shown to be an active rather than a passive degenerative process [313], the implanted tissue 
engineered scaffold are also susceptible to calcification and thereby device failure [128]. 
Unfortunately, most of the current studies on heart valve tissue engineering have overlooked the 
potential issue of scaffold calcification and specific strategy to overcome this problem is in 
critical need.  
Applying the tissue engineering principles, we have previously developed biodegradable, 
anti-thrombogenic, anisotropic, and elastomeric fibrous scaffolds, which could mimic the 
mechanical aspects of the native valve and support human valvular interstitial cell (hVIC) 
proliferation ([242] and Chapter 5). Specifically, we have demonstrated that the scaffolds made 
from biodegradable elastomer blends of PCL and APS-25PEG were able to mimic the uniaxial 
and biaxial mechanical properties of native valve leaflet hVICs ([242] and Chapter 5). We have 
also revealed the unique properties of cerium oxide nanoparticles (CNPs) in mitigating the 
oxidative stress-induced calcification of hVICs due to their reactive oxygen species (ROS) 
scavenging properties [248]. Biocompatible rod and sphere shaped CNPs could scavenge both 
abiotic and intracellular ROS in a dose-dependent manner. Therefore, these two CNPs were 
effective in mitigating the oxidative stress-induced calcification in hVICs.  
Engineering nanocomposite biomaterial represents an emerging approach to confer 
functionality to the original biomaterial [314]. In the current study, we hypothesized that CNP 
 161 
encapsulated elastomeric scaffolds will have diminished potential of calcification without 
interfering with the other desired properties of the scaffold. Towards this goal, we investigated 
the rod and sphere CNPs encapsulated APS-25PEG-PCL scaffold. We first demonstrated the 
feasibility of co-electrospinning nanoparticles with polymer solution followed by examining the 
effect of CNP encapsulation on the morphology, mechanical properties, ROS scavenging 
properties, cytocompatibility, and anti-calcification properties of these nanocomposite scaffolds.   
7.2 METHODS 
7.2.1 Materials 
All chemical and biological agents used in the study were same as reported in the previous 
chapters, unless otherwise noted. APS-co-PEG polymers were synthesized according to section 
3.2.1. CNPs were prepared according to section 6.2.8.  
7.2.2 Scaffold fabrication by electrospinning 
Briefly, CNPs (0.5% or 1% w/w to total polymer weight) were first added to a mixture of ethanol 
and chloroform at a volume ratio of 1:9 (detailed material formulation in Table 17). This 
suspension was dispersed using a probe sonicator (Sonic Dismembrator Model 500, Fisher 
Scientific, USA) for 15s at 10% amplitude every 10s over a 20 min time period. APS-25PEG and 
ε-PCL (6% and 12% w/v, respectively) were then dissolved in this suspension. To fabricate 
anisotropic scaffolds, a custom-made ring-shaped copper wire was used as electrospinning 
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collector. Solutions were electrospun at 17 kV at a rate of 1 mL/h. The distance between the 21G 
needle and collector was kept at 12 cm. The obtained electrospun scaffolds were dried in a 
vacuum desiccator overnight before further experiments. 
Table 17. Polymer and CNP formulations for fabricating nanocomposite scaffolds 
 
7.2.3 Scanning electron microscopy (SEM) 
Scaffold morphology was characterized using scanning electron microscopy (SEM) (Zeiss 
Sigma500 VP, UK). Fibrous scaffolds were sputter-coated with 5 nm of gold–palladium using 
Denton auto sputter coater (Denton Vacuum, Moorestown, NJ), and images were obtained using 
accelerated voltage of 3 kV. Images were analyzed for fiber diameters and alignment using NIH 
ImageJ Software with DiameterJ [246] and OrientationJ [247] plugins. At least four images (at 
2000X magnification) from each group were used for analysis. 
7.2.4 Uniaxial mechanical testing 
Scaffold mechanical properties were studied using uniaxial tensile tests with MTEST Quattro 
mechanical testing system (ADMET, Norwood, MA). Scaffolds were cut into rectangular shapes 
(~15 × 7 mm2, n = 4 per group) and stretched at a constant displacement rate of 10 mm/min until 
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the sample failure. The stress (MPa) was obtained by dividing the applied force (N) with cross-
section area (mm2); percent elongation (strain, ε) was obtained from ε (%)=100×(L-L0)/L0, 
where L0 was initial gauge length and L was instantaneous gauge length. Elastic modulus was 
calculated in the linear region at 5–15% strain. 
7.2.5 Abiotic reactive oxygen species (ROS) scavenging assay  
The ROS scavenging capabilities of scaffolds were measured using the 2,2-Diphenyl-1- 
picrylhydrazyl (DPPH) assay. Stocks of DPPH (Aldrich, USA, 1 mM) were prepared in ethanol 
prior to the assay. Scaffolds (10 mg) were first immersed in ethanol (800 μL) and vortexed 
vigorously. The DPPH stock solution (200 μL) was then added to the scaffold containing 
solution (800 μL) and mix well. The mixture was allowed to reaction in dark for 30 min at room 
temperature. Subsequently, the absorbance was read at 520 nm (n = 4) using a microplate reader 
(Synergy HT, BioTek Instruments, USA). The scaffolds with 0% CNPs served as a negative 
control. Percentage of DPPH scavenged was calculated from the formula below: 
Scavenged DPPH (%) = (Anegative control-Atest)/Anegative control * 100% 
7.2.6 Culture of hVICs on nanocomposite scaffolds  
The hVICs were obtained and cultured according to our prior publication [248]. For both 
biocompatibility and calcification study, the scaffolds (10 × 10 mm2) were first sterilized by 
exposing to 70% isopropanol under UV light for 30 min and rinsed with 1X DPBS thrice to 
remove any residual ethanol. The hVICs were seeded on to these scaffolds at a density of 
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100,000 cells/scaffold in a 24-well plate. After 24 h, cell seeded scaffolds were transferred to 
new wells to avoid the interference of from the unattached cells.  
7.2.7 In vitro biocompatibility by alamarBlue® assay  
The hVIC proliferation on scaffold was measured via monitoring cell metabolic activity at day 7 
and 21 using the alamarBlue® assay (Invitrogen, Carlsbad, CA) following the protocol described 
in section 4.2.9. At day 21, hVICs were decellularized by trypsin and the scaffolds were 
collected for mechanical testing.  
7.2.8 In vitro calcification model on electrospun scaffolds  
After cell seeding, hVICs were allowed to attach to scaffold for 48 h followed by changing to 
calcification media. First, to establish the role of oxidative stress in promoting calcification, 
hVICs were cultured on 0% CNP scaffold using MEM-alpha supplemented with 10% fetal 
bovine serum (FBS) containing an additional 1 mM sodium phosphate monobasic (Pi) and 100 
μM H2O2. The cells cultured using the same media except without 100 μM H2O2 were served as 
negative control. Next, hVICs were cultured on 0% CNP or 1% rod scaffolds using MEM-alpha 
supplemented with 10% FBS containing an additional 1 mM Pi and 100 μM H2O2. The cells 
cultured on the 0% CNP scaffolds were served as positive control. Media was replenished every 
day. Calcification in hVICs cultures was determined using calcium content quantification (as 
described in section 7.2.9) and mRNA expression of calcification and fibrosis genes (α-SMA, 
OPN, RUNX-2, COLLAGEN-1, as described in section 7.2.10) at day 7. 
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7.2.9 Cellular calcium content quantification  
At day 7, hVICs were trypsinized from the scaffolds to obtain the cell pellets. Calcium was then 
extracted from the cell pellets by incubation with nitric acid (1M) for 1h followed by 
centrifugation. The supernatant (35 µL) was mixed with O-cresolphthalein (0.25 mg/mL, 35 µL) 
and 2-amino-2-methyl-1-propanol (150 mg/mL, 87.5 µL) at room temperature for 20 min and the 
absorbance was measured at 575 nm. 
7.2.10 Analysis of mRNA expression by qPCR  
Similar to section 6.2.9, hVIC cell pellets were obtained at day 7. This was followed by RNA 
extraction and qRT-PCR as described in section 6.2.5. 
7.2.11 Statistical analysis  
Experimental data are presented either as mean ± standard error of the mean (SEM) or as mean ± 
standard deviation (SD) as specified in each figure legend. Multiple comparisons were analyzed 
for significance using one-way ANOVA or two-way ANOVA followed by Tukey’s post-hoc 
analysis. P-values less than 0.05 were considered as significant. 
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7.3 RESULTS AND DISCUSSION 
7.3.1 Fabrication of nanocomposite scaffolds and scaffold morphology 
We first studied the feasibility of co-electrospinning CNPs with polymer blends to obtain 
nanocomposite scaffolds. Sphere and rod CNPs showed excellent antioxidant properties in our 
earlier studies ([248] and Chapter 6), and thus, were selected in the current study. Meanwhile, 
APS-25PEG/PCL (6+12%) formulation studied in our previous report yielded anisotropic fiber 
alignment and biaxial mechanical properties similar to the porcine aortic valve leaflet (Chapter 
5). Therefore, we interfaced sphere and rod CNPs into the APS-25PEG/PCL (6+12%) 
formulation at two different concentrations (0.5% and 1% w/w to the total polymer 
concentration, Table 17). All CNP-encapsulated scaffolds were successfully fabricated using 
ring-shaped electrospinning collector (as reported in Chapter 5). We first investigated the effect 
of CNP encapsulation on the scaffold morphology. SEM imaging revealed that 1% sphere and 
rod CNP-encapsulated scaffolds maintained their micro/nano-fibrous structure as seen in low 
magnification (2000 X) images (Fig. 40a and b) without obvious nanoparticle aggregation as 
seen in high magnification images (5000 X) (Fig. 40c and d). Furthermore, CNP-encapsulated 
scaffolds maintained the anisotropic fiber alignment as revealed by the single sharp peak in the 
quantification of fiber orientation (Fig. 40e and f). These results suggested that CNPs were 
amenable to be encapsulated into the polymer formulation without interfering with the 
electrospinning process.   
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Figure 40. SEM images and fiber alignment of 1% sphere and rod CNP-encapsulated scaffolds.  
(a, b): SEM images at 2000X magnification; and (c, d): 5000X magnification; (e, f): Fiber 
alignment quantification by OrientationJ plugin in NIH ImageJ (n=at least 4 images) 
7.3.2 ROS scavenging ability of electrospun scaffolds 
One of the major rationales of encapsulating CNPs into the fibrous scaffolds is to utilize their 
ROS scavenging ability to create scaffolds with enhanced ROS scavenging properties. Therefore, 
we first examined whether the CNPs encapsulation could improve the ROS scavenging ability of 
fibrous scaffolds. The DPPH scavenging assay is a direct measurement of the radical scavenging 
properties of a therapeutic agent [315]. Compared to the 0% CNP scaffold of the same weight, 
sphere and rod CNP encapsulated scaffolds resulted in significant reduction in DPPH level (Fig. 
41), indicating their enhanced radical scavenging abilities. This observation was in agreement 
with our previous results that rod and sphere CNPs displayed similar antioxidant properties in 
aqueous dispersion [248, 285]. It was also noted that there is no significant difference between 
scaffolds containing different CNP concentrations (0.5% and 1%). These results indicated that 
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CNP encapsulation in fibrous scaffold led to enhanced ROS scavenging ability of nanocomposite 
scaffolds.  
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Figure 41. The radical scavenging capability of CNP-encapsulated nanocomposite scaffolds by 
DPPH assay.  
*indicates p<0.05 as compared to 0% CNP scaffold (n = 3, One-way ANOVA, Tukey’s Post-hoc 
test). 
7.3.3 Viability of hVICs cultured on scaffolds 
We have previously shown that APS-25PEG/PCL scaffold supported hVIC proliferation ([242] 
and Chapter 5) and both rod and sphere CNPs possessed minimal cytotoxicity to hVICs at 
concentration less than 100 µg/mL ([248] and Chapter 6). However, it is challenging to 
extrapolate these results when CNPs are encapsulated into fibrous scaffolds where multiple 
factors such as nanoparticle dissolution and release could potentially cause the fluctuation of 
CNP concentration in the culture media. Therefore, we monitored the hVIC viability 1 and 3 
weeks after seeding onto the CNP-encapsulated scaffolds. The hVICs cultured on CNP-
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encapsulated scaffolds demonstrated cell viability similar to those cultured on 0% CNP scaffolds 
at both time points (Fig. 42), indicating that up to 1% w/w encapsulation, CNP-encapsulated 
scaffolds supported the hVIC proliferation similar to the prototype APS-25PEG/PCL scaffold.  
 
Figure 42. The hVIC cytocompatibility of CNP encapsulated electrospun scaffolds after 1 week 
and 3 week of culture by alamarBlue® assay.  
*indicates p<0.05 as compared to 0% CNP scaffold (n = 4, One-way ANOVA, Tukey’s Post-hoc 
test). 
7.3.4 Mechanical properties of nanocomposite scaffolds 
Next, we continued to study the effect of CNP encapsulation on the mechanical properties of the 
electrospun scaffolds. Acting as filler, nanoparticles are known to reinforce the mechanical 
properties of polymeric scaffolds when encapsulated in polymeric scaffold [316]. In the current 
study, encapsulation of neither 0.5% nor 1% sphere CNPs changed the stiffness of the scaffold 
significantly (Fig. 43). On the contrary, encapsulation of both 0.5% and 1% rod CNP resulted in 
a significant increase in the scaffold stiffness (Fig. 43). It was speculated that such differences 
could be due to the size of the two types of CNPs. Sphere CNPs had lower actual particle size 
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than that of rod CNPs (Fig. 32) and may not be able to effectively reinforce the scaffold. Overall, 
such effects of CNPs on the mechanical properties of the scaffold provide us with alternative 
strategy to fine tune the scaffold mechanical properties if necessary.  
Additionally, at the end of the three-week culture, we measured the mechanical properties 
of the decellularized scaffolds. The stiffness of all scaffolds increased as compared to 
corresponding as-prepared scaffolds (Fig. 43), indicating the possible de novo ECM protein 
deposition during the culture. These promising results obtained in this preliminary 
cytocompatibility study on the CNP-encapsulated scaffolds warrant further long-term studies on 
the biocompatibility of CNP-encapsulated scaffolds and their degradation products.  
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Figure 43. The elastic modulus of CNP encapsulated nanocomposite scaffolds (as prepared and 
after 3-week hVIC culture) by uniaxial tensile tests.  
# indicates p<0.05 as compared to as prepared 0% CNP group. 
* indicates p<0.05 as compared between “as prepared” and “3 week culture” of each group of 
samples (n=4, Two-way ANOVA, Tukey’s Post-hoc test). 
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7.3.5 In vitro calcification of electrospun scaffolds 
We further hypothesized that CNP-encapsulated scaffolds with ROS scavenging properties could 
diminish oxidative stress-induced hVIC calcification. To test this hypothesis, we first 
demonstrated calcification promoting ability of oxidative stress in hVICs cultured on the fibrous 
scaffolds. We used H2O2 (100 µM) to induce oxidative stress. The hVICs were cultured on APS-
25PEG/PCL scaffold with or without additional H2O2 (100 µM) for 7 days. Compared to the 
hVICs cultured without H2O2, hVICs cultured with H2O2 showed increased degree of 
calcification as demonstrated by the increase in intracellular calcium content (Fig. 44a) and 
mRNA expression of RUNX-2 and OPN (VIC osteogenic differentiation markers) and α-SMA 
and COL-1 (VIC myofibroblast activation and fibrosis markers) (Fig. 44b). These results are in 
accordance to the previous hVIC calcification study conducted on 2D cell culture [248]. 
Therefore, we continued to examine whether hVICs cultured on CNP-encapsulated scaffolds 
would mitigate calcification when challenged by oxidative stress (in the form of H2O2). Herein, 
we selected 1% rod CNP-encapsulated scaffolds based on their cytocompatibility and ROS 
scavenging properties (Fig. 41 and 42). At the end of the 7-day calcification study, hVICs 
cultured on 1% rod CNP-encapsulated scaffolds demonstrated reduced intracellular calcium 
content compared to 0% CNP scaffold (Fig. 44c). Furthermore, to elucidate the phenotypic 
changes in hVICs seeded on scaffolds with and without CNPs, mRNA expression of various 
markers including were quantified out by qRT-PCR. The hVICs cultured on 1% rod CNP 
encapsulated scaffold exhibited reduced mRNA expression of osteogenic related (RUNX-2 and 
OPN) and fibrosis related (α-SMA and COL-1) gene (Fig. 44d). These results provided 
preliminary evidence that CNP-encapsulated scaffolds could mitigate hVIC calcification. It also 
suggested the beneficial roles of CNP under oxidative stress in reducing both, the osteogenic and 
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myofibroblastic differentiation of hVICs, which are two major mechanisms in directing valvular 
calcification [274].  
 
Figure 44. Oxidative stress-induced in vitro hVIC calcification on fibrous scaffolds. 
The effect of oxidative stress (H2O2) on (a) intracellular calcium content; and (b) the fibrosis and 
osteogenic related gene expression of hVIC; (c) Encapsulation of CNP mitigated intracellular 
calcium deposition; and (d) the effect of CNP encapsulation on the fibrosis and osteogenic 
related gene expression of hVICs. *indicates p<0.05 (Unpaired t-Test). 
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7.3.6 Summary 
In conclusion, we have demonstrated the feasibility of fabricating CNP-encapsulated 
nanocomposite scaffolds using different CNP shapes and concentrations. CNP encapsulation 
enhanced the ROS scavenging properties of the scaffolds compared to those without CNPs. In 
addition, CNP encapsulation could be used to maintain (via sphere CNP encapsulation) or 
increase (via sphere CNP encapsulation) the scaffold stiffness. At the concentrations tested (0.5 
and 1% w/w), no significant cytotoxicity was observed for CNP-encapsulated scaffolds. Most 
importantly, in an oxidative stress-induced hVIC calcification model, CNP-encapsulated 
scaffolds demonstrated diminished calcification tendency as compared to those without CNPs. 
We envision that encapsulation of CNPs into the fibrous scaffolds represent a promising strategy 
to tackle the calcification issue of the most tissue-engineered heart valve constructs.   
 
 
 
 
 174 
8.0  CONCLUSIONS AND FUTURE PERSPECTIVES 
8.1 MAJOR CONCLUSIONS 
Tissue engineering-based technology stands as a promising enabling strategy to serve the clinical 
unmet needs in treating valvular heart diseases. Pioneered by leaders such as Langer and Vacanti 
back in the early 1990s, the past decades have witnessed the exponential growth of studies to 
understand and apply the principles of tissue engineering for recreating various tissues and 
organs, either alone or in combination. To this end, one of the central dogmas that have been 
repeatedly practiced and proven is to create ECM-mimetic biocompatible tissue-engineered 
construct.  
Engineering heart valves are of immense interests due to 1) the increasing patient 
number; 2) the limited choices of treatment; and 3) the significant drawbacks of these treatments. 
However, the unique function and architecture of the heart valve pose huge challenges in 
recreating valve replacement faithfully. Prior studies have identified several key aspects when 
engineering heart valves. Specifically, a tissue-engineered valve needs to withstand the dynamic 
in vivo environment while being mechanically compliable for valve opening and closing. It also 
needs to be anisotropic in its geometry and mechanical properties to guide the regeneration and 
carry out the essential opening and closing movement. Due to its vital position (inside the heart) 
and blood-contacting nature, the biocompatibility of the tissue-engineered valve needs to be 
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carefully scrutinized. Unfortunately, these critical features have been rarely studied in 
combination.  
I approached this scientific problem by designing and applying novel materials and 
scaffolds using micro-/nanotechnology. In Chapter 3 and 4, I reported the synthesis, fabrication, 
and characterization of a novel series of biodegradable and biocompatible elastomers named 
APS-co-PEG. It was demonstrated that the scaffolds made from these elastomers had widely 
tunable elasticity and less thrombogenicity compared to the un-PEGylated prototype polymer. In 
Chapter 5, I described a novel optimization of electrospinning process to fabricate anisotropic 
scaffolds, which emulate the anisotropic architecture and mechanical properties of native valves. 
It was further demonstrated that the mechanical properties of scaffolds could be tuned by 
polymer formulation. In chapter 6, I tested antioxidant CNPs as novel therapeutic agents to 
prevent valvular calcification. It was demonstrated that CNPs scavenged intracellular oxidative 
stress and consequently mitigated calcification. Lastly, in chapter 7, I combined the two micro-
/nanotechnologies to fabricate CNP encapsulated anisotropic fibrous scaffolds as a proof-of-
concept prototype of tissue-engineered heart valve. Overall, the work presented in this 
dissertation demonstrated the feasibility and effectiveness to incorporate multiple design criteria 
when constructing tissue-engineered valves. Additionally, the technologies developed herein 
allow the fabrication of scaffolds with widely tunable properties and can be re-purposed for other 
soft tissue engineering applications.  
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8.2 STUDY LIMITATIONS 
The current studies are not without limitations. This section will present the main limitations in 
my studies from three aspects and provide insights to overcome these limitations.  
 First of all, although we have recreated anisotropic fibrous scaffolds (chapter 5), which 
mimic the anisotropic mechanical properties of the native valve, the tri-layered structure of 
native valve ECM (as described in section 1.3.1) has not been recapitulated in this study. It has 
been reported that the three layers of the valve ECM work in an orchestrated manner to maintain 
the normal valve opening and closing cycles. In this dissertation, the middle proteoglycan-rich 
spongiosa layer was not taken into the design of tissue-engineered heart valve scaffold. Although 
being a relatively thin layer as compared to the fibrosa, the spongiosa layer provides excellent 
shock-absorbing properties to reduce the friction, dampen vibrations, and resist delamination. 
Potential strategy to overcome this limitation and further improve the overall scaffold design 
could be the fabrication of elastomeric fiber-hydrogel composite scaffolds to recapitulate this 
important structural feature.  
 Secondly, although we were able to achieve anisotropic fiber alignment, and degree of 
anisotropy and linear modulus similar to the native valves (chapter 5), I would like to 
acknowledge that the polymeric scaffolds and native valve tissue were not identical in their 
biaxial mechanical behaviors. As shown in the equibiaxial stress-strain plots (Fig. 24), native 
valves displayed non-linear mechanical behavior with two distinct linear regions. The initial toe 
region is attributed to the stretching of coiled collagen fibers which is followed by a second stage 
where further elongation of the straightened collagen fibers results in a steep rise in tensile stress 
until the tissue attains maximum extensibility. On the other hand, the polymeric scaffolds, in 
general, have relatively linear mechanical behaviors. It was suspected that such difference in the 
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biaxial mechanical properties could be attributed to the structural differences such as the lack of 
the gel-like spongiosa layer in our fibrous scaffolds to provide shock-absorbing properties.  
 Last but not the least, in a proof-of-concept study (chapter 7), the feasibility of CNP 
encapsulation in elastomeric fibrous scaffold as one approach to mitigate valve calcification was 
demonstrated. However, the encouraging preliminary results also raise more important yet 
unanswered questions with regard to the functionality of this nanocomposite scaffold. For 
example, how will CNPs exert their effects after encapsulation? Will CNPs be released? If yes, 
how will the polymer formulation affect the release profile? Additionally, in terms of its long-
term effect, whether and how will CNPs be eliminated in vivo? How will CNP encapsulation 
modulate the local redox balance, which is crucial for the immune infiltration and subsequent 
tissue regeneration?  
 Overall, the study limitations identified here will guide the future studies to improve the 
scaffold design and understand the mechanisms of action of nanocomposite scaffolds.  
8.3 FUTURE DIRECTIONS 
It is believed that the work presented in this dissertation opens up to more sophisticated 
investigations to facilitate the development of tissue-engineered heart valve therapy. This section 
will first discuss the immediate research directions on the continuation of the current work and 
then discuss some long-term research goals for the successful clinical translation of this therapy.   
 First, the scaffold design can be further improved to achieve a better mimicry of the 
mechanical properties of native valve. As mentioned in section 8.2, strategy such as a fiber-
hydrogel composite scaffold may enable the non-linear biaxial tensile behaviors. Next, the 
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functionality (continuous opening and closing) of the scaffold needs to be assessed in a 
physiologically relevant bioreactor, which can provide the proper flow conditions. The structural 
integrity and degradation of the scaffold, de novo ECM synthesis, and cellular phenotypic 
changes during this dynamic culture system need to be further investigated. Moreover, prior to 
the implantation in the valve position in vivo, the suitability of the scaffolds to be sutured or for 
minimally invasive transcatheter technology needs to be studied and validated.  
Looking forward, the field of tissue-engineered heart valve is still in its infancy. There 
remain huge challenges and opportunities to facilitate its clinical translation in terms of the 
mechanistic understanding of tissue regeneration process and product development of tissue-
engineered valve.  
In terms of the mechanistic understanding, there is little knowledge available regarding 
the immune response to tissue-engineered valves and more profound investigations are required. 
Upon implantation, almost all biomaterials initiate host responses with immune cell infiltration 
and cytokine secretion. Such host responses to biomaterials are often necessary and beneficial in 
removing cellular debris due to injury and deterring the progression of infection. However, 
sustained and uncontrolled immune responses will eventually result in chronic inflammation and 
tissue fibrosis. Although little is known on valve regeneration, prior studies on skeletal muscle 
and vascular tissue engineering have suggested that the differentiation of monocytes towards the 
alternative macrophage phenotype (M2) in the early regeneration process would be beneficial in 
creating suitable conditions for tissue formation. Therefore, scaffolds that can harness the innate 
immune response by skewing the macrophage differentiation and/or selective recruitment of 
immune cells to facilitate tissue regeneration will be advantageous. This goal can be achieved by 
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the encapsulation or grafting of biological molecules such as cytokines and growth factors or via 
the biophysical cues such as roughness, matrix stiffness, and micro-/nano-architecture.  
A successful medical product/device needs to be amenable to large scale manufacturing 
and should have a long shelf life as well as a straightforward regulatory process to be appealing 
to the biomedical industry and patients. Conventional tissue engineering strategy involves the in 
vitro culture of cell-seeded scaffold until its maturation followed by implantation. Such strategy 
is often lengthy and costly in its process and may hit multiple regulatory hurdles due to the 
complex components. Therefore, scaffolds designed for in situ tissue engineering which offer the 
off-the-shelf availability may be more promising in terms of the clinical translation of tissue 
engineering technology. Recently, encouraging results from Baaijens and Bouten groups have 
demonstrated the feasibility and functionality of an in situ tissue engineered heart valve made 
from electrospun polycarbonate scaffold [136]. In a 12-month study in the sheep model, tissue 
engineered valves maintained hemodynamic performance where a native-like, layered ECM 
structure slowly formed and replaced the graft. Also, moving forward, more preclinical studies, 
which can elucidate the underlying principles and mechanisms of scaffold design, neo-tissue 
formation, and host responses of in situ tissue engineering are warranted. Moreover, the issue of 
scale-up manufacturing of such scaffolds needs to be addressed. Electrospinning technology has 
been investigated for the large-scale industrial manufacturing. Flat electrospun mat can be 
fabricated at around 200 g of fibers/h using free surface electrospinning technology where 
numerous electrospinning jets emerge simultaneously to produce a large sheet of fibers collected 
on a negatively charged parallel electrode. However, fabricating electrospun scaffolds with a 
unique shape and geometry remains largely unexplored and presents new challenges that need to 
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be addressed such as 1) manufacturing in large quantity; 2) reproducibility during fabrication; 
and 3) safety and environmental control of electrospinning.  
In conclusion, the results of the present work contributed to the current knowledge of 
design, synthesis, fabrication, and characterization of functional and biocompatible tissue-
engineered heart valve. To facilitate its clinical translation, a strong collaboration among material 
scientists, biomedical engineers, pharmacists, clinicians, and industrial engineers is essential to 
provide new insights and progress towards mending a diseased heart valve.  
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